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Oh, the depth oj the riches 
oj the wisdom 
and knowledge oj God! 
How unsearchable 
his judgements, 
and his paths 
beyond tracing out! 
"Who has known 
the mind oJ the Lord? 
Or who has been 
his counsellor?" 
"Who has ever given to God, 
that God should repay him?" 
For from him and through him 
and to him are all things 
To him be the glory Jor ever! 
Amen 
Romans 11: 33-36 
ABSTRACT 
The mammalian pineal gland is mainly innervated by the sympathetic nervous system which 
modulates the activity of indole pathway enzymes and the secretion of pineal hormones. Recently 
researchers have demonstrated and characterized the presence of muscarinic cholinergic receptors 
in the pineal gland. However the role of these receptors remains unclear. In an attempt to 
investigate the role of cholinergic receptors in the pineal gland, a number of studies were carried 
out on the various steps in the indole metabolic pathway, using various agents which act on the 
cholinergic system. 
Investigations using pineal organ cultures showed that stimulation of these muscarinic cholinergic 
receptor sites with a parasympathomimetic agent, a rise in levels of aHT occurred without a 
concomitant increase in aMT levels. Further organ culture experiments using the cholinergic 
agonist acetylcholine and anticholinesterase agent physostigmine, produced a similar rise in aHT 
without altering aMT levels. This acetylcholine-induced rise in aHT levels were not altered by the 
ganglion blocking agent hexamethonium whilst the antimuscarinic agent atropine prevented the 
acetylcholine-induced rise in aHT levels. Thesefindings suggest that cholinergic agents may play 
a role in regulating indoleamine synthesis in the pineal gland. 
Cyclic-AMP assay studies showed that acetylcholine increases pineal cAMP levels significantly and 
does not influence the isoproterenol-induced cAMP rise in the pineal gland. The cAMP regulator 
cAMP-phosphodiesterase (cAMP-PDE) was found to increase significantly in the presence of the 
anticholinesterase agent physostigmine. NAT enzyme studies revealed that physostigmine does not 
affect NAT enzyme levels significantly and HIOMT studies showed that this agent does not inhibit 
HIOMT activity. The mechanism by which acetylcholine and physostigmine are able to cause a 
increase in aHT and not aMT levels needs to be researched further. 
Acetylcholinesterase enzyme assay studies revealed that the AChE enzyme undergoes a diurnal 
rhythm in the pineal gland with activity being higher during the day and lower at night. 
ii 
Investigations using the drug reserpine showed that this rhythm is not under the control of the 
sympathetic nervous system. Further research needs to be done however, in determining whether 
or not this enzyme is present in the pineal gland to regulate the levels of acetylcholine interacting 
with muscarinic receptors in the gland, or for some other reason. 
Choline acetyltransferase studies demonstrate the presence of the enzyme in the rat brain cerebral 
cortex as well as showing that melatonin increases ChAT enzyme activity in this tissue. This 
suggests that melatonin plays a role in cholinergic transmission there. ChAT activity could not be 
measured in the pineal gland however. Muscarinic receptor binding studies also carried out on 
rat brain cerebral cortex show that melatonin enhances cholinergic receptor affinity and receptor 
number in this tissue. 
In summary, data presented herein concur with proposals that: 
i) the cholinergic system affects the indole metabolic pathway by causing a rise in 
aRT but not aMT levels. 
ii) cholinergic agonist acetylcholine causes cAMP levels to rise with a concomitant 
increase in cAMP-PDE levels. 
iii) the enzyme acetylcholinesterase undergoes a diurnal rhythm in the pineal gland 
which is not under the control of the sympathetic nervous system. 
iv) the activity of the enzyme choline acetyltransferase is increased by melatonin in the 
rat brain cerebral cortex suggesting that melatonin facilitates cholinergic 
transmission in this tissue. 
v) melatonin enhances cholinergic receptor affinity and receptor number in the 
cerebral cortex of rat brain. 
iii 
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1.1 Introduction 
CHAPTER 1 
LITERA TURE REVIEW 
1 
Pineal research has proceeded with ever increasing speed and investigators have had the advantage 
of being able to draw upon a substantial body of information. Researchers representing a variety 
of different disciplines have become involved in pineal studies, and this field has developed into 
an acknowledged area of the neurosciences. Although the existence of the mammalian pineal gland 
has been recognized for many centuries it was only thirty years ago that it was considered to be 
more than a "vestigial organ of little functional importance". The expansion of neuroscientific 
research has witnessed the pineal gland attain the status of one of the most important participants 
in the regulation of various physiological and behavioral processes. 
The mammalian pineal gland enjoys a large measure of protection by virtue of its location and yet 
it is directly exposed to the vascular system, providing an ideal environment in which to monitor 
homeostasis. The pineal also exhibits other unique features such as a) receiving both peripheral and 
central innervations, b) being part of the brain, yet existing outside the blood brain barrier, and c) 
especially exhibiting an astonishing and often bewildering species-directed variation in their 
innervations and biochemical properties (See Korf and Moiler, 1984; and Ebadi and Govitrapong, 
1986a for reviews and references). 
The pineal gland is also considered to be an active neuroendocrine transducer (Wurtrnan and 
Axelrod, 1965) converting neural input, namely a neurotransmitter released at a synapse, to a 
hormonal output ie. methoxyindoles of melatonin and polypeptides. In addition it appears that the 
pineal may itself be subjected to other hormonal signals suggesting endocrine-endocline and 
endocrine-neural transduction mechanisms (Cardinali and Vacas, 1978). It was only subsequent to 
the isolation and characterization of melatonin - a secretion of the pineal gland, by Lerner and his 
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coworkers in 1958 (Lerner et ai., 1958) that a lot of the functional significance of this enigmatic 
gland has begun to be unravelled. 
The cyclic nature of the gland's activity earned it the title of a 'biological clock', a switching 
mechanism regulating the activity of the sex glands in response to the changing seasons and 
exposure to light and dark. The pineal gland in all mammals produces melatonin in a rhythmic 
manner with peak levels occurring at night irrespective of whether the animal is nocturnal or diurnal 
in its behaviour pattern. The major functions of pineal melatonin appears to synchronize the 
seasonal and circadian rhythms of a variety of physiological events (Armstrong, 1989). These 
include effects on reproduction, coat growth, temperature regulation and locomotor activity in 
species where seasonal cycles depend on photoperiod (Reiter, 1980; Tamarkin et ai., 1985; 
Armstrong, 1989). 
The pineal gland has inspired novel avenues of research due to its unique nature and its discrete 
association with the sympathetic nervous system. The idea that the pineal might respond when 
challenged by certain agents lent a new tool for biochemists and pharmacologists involved with this 
type of study and extensive investigation into the effects of administered substances on the pineal 
gland has been performed. Increased emphasis has been placed on the pineal gland in recent years, 
being chemically associated with the functions of other organs, and is perhaps appropriately labelled 
as the 'last great frontier' in the study of physiology. 
The rat pineal gland was used in this study for a variety of reasons. It is situated outside the blood 
brain barrier and is thus accessible to drugs administered peripherally. It also has the ability to 
maintain its metabolic functions in organ culture, which enables investigations on the effects of 
various drugs on the gland. Pineal metabolites such as melatonin and its precursor N-
acetylserotonin, as well as associated enzymes can be conveniently assayed using rat pineal gland. 
In this way important information on the effects of various cholinergic agents on the internal 
metabolism of the pinealocyte may be derived. 
3 
The pineal has a modulatory effect, changing the timing, amplitude or intensity of the response 
rather than a primary effect of initiating such responses. It is no longer a matter of what organs or 
organ systems the pineal and melatonin influences but rather it is a question of whether any escape 
its influence (Reiter, 1988). 
Govitrapong et ai., (l989b) have recently identified and characterized the presence of muscarinic 
cholinergic receptors in the pineal glands of cow and swamp buffalo by using quinuclidinyl 
benzilate binding studies. The pineal gland is innervated almost exclusively by sympathetic nerves 
from the superior cervical ganglia and although recently muscarinic receptors have been found in 
the pineal glands, their function still remains a mystery. This study serves to explore the use of the 
rat pineal gland as a model for the investigation into cholinergic interactions in the pineal gland as 
well as to determine the role that these muscarinic cholinergic receptors play in this gland. A 
number of cholinergic agents will be used and their effect on pineal function and metabolic 
pathways examined. 
1.2 History of Pineal Research 
The discovery of the human pineal has generally been ascribed to Herophilos (325 to 280 BC), the 
"father of anatomy". During the medieval period around 400 BC when Galen and Hippocrates were 
the medical authorities, Galen coined the term "konareion" for the pineal gland because of its 'pine-
cone'-like shape in man (refer to Ariens-Kappers, 1981 for references). The Renaissance heralded 
a more personal approach to the study of the pineal. Berangario de Carpi (1470-1530) was the first 
to examine the pineal gland of man more carefully from which Andreas Vesalius (1514-1564) in 
the famous paper 'De Humani Corporis F abrica Libri Septem' described the topography and 
consistency of the gland but little in terms of a suggested function was proposed. 
Rene Descartes (1596-1650) is widely cited as stating that the pineal gland is the seat of the soul. 
At this time the problem of the localization of the soul was very much in the mind of both 
philosophers and scientists. Descartes reasoned that the soul, in principle, cannot be localized in any 
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precise region of the body because it is related with all of its parts, according to the doctrine of 
Aristotle. He however suggested that the soul would be more expressed in the pineal, the only 
unpaired part of the brain. According to Descartes, an optical image can pass from the retina to the 
pineal thereby inducing the pineal to transmit its spirits by moving in different directions to 
different motor nerves. The seat of the soul and ancient theories on the spiritus haunted 
neuroscience research for more than twenty centuries before new concepts cleaved a path for more 
useful research. 
Interest in the pineal was revived in the latter nineteenth century after the discovery of endocrine 
glands by Oaude Bernard (1818-1878) and Brown-Sequard (1817-1894). The medical profession 
continued to believe that the pineal was of no functional significance, and that its only medical 
value was to the neuro-radiologists who made use of the radio opaqueness of the acervuli as a 
welcome reference point (refer to Ariens-Kappers, 1981 for references). However the mammalian 
pineal gland was being considered as a serious candidate for hormone production as interest by 
physiologists and clinicians became more intense. 
Heubner (1898) first described a boy suffering from a pinealoma and showing signs of precocious 
puberty. According to Marburg, the human pineal is an endocrine gland which in youth exerts an 
inhibitory effect on hypothalamic function. Berblinger (1920) and Engel (1936) were convinced that 
the pineal gland inhibits gonadal development being of the opinion that its extract was 
antigonadotropic. Bargman (1943) stressed the necessity of investigations on the influence of light 
on the pineal and Kitay and Altschule (1954) edited a book on pineal physiology and suggested 
future lines of research in this field. 
1.3 Anatomy 
1.3.1 Location and Characteristics 
The pineal gland or the epiphysis cerebri is located between the cerebral cortex and the cerebellum. 
In the rat brain it is situated between the two cerebral hemispheres just forward of the cerebellum 
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(Figure lola and LIb). It is covered by the confluence of the superior sagittal and transverse 
sinuses. It is connected to the commissural region of the brain by a pineal stalk (Kappers, 1965). 
Topographically the stalk can be divided into three parts namely a proximal part, midpart and dorsal 
part. The proximal part lies between the habenulae and caudal commissures. The midpart is 
extremely thin and the distal part is the largest of the three structures, situated between the rostral 
and caudal collicles (Kappers, 1965). The gland consists of two parenchymal cell types, 
pinealocytes and intestinal cells (Wartenberg and Gusek, 1965) both of neuroectodermal origin. The 
pinealocytes are the neurosecretory cells of the gland. 
The pineal gland is considered to lie outside the blood brain barrier, with its own arterial blood 
supply of up 10 four branches of the posterior cerebral artery (Hodde, 1979) and posterior choroidal 
artery (Gladstone and Wakely, 1940). Drainage consists of some sixteen veins into the great 
cerebral vein which leads to the systematic circulation via the confluens sinuum (Hodde, 1979). The 
pineal is thus sensitive to stimuli from the periphery, including hormones and those drugs not 
entering the brain (Axelrod, 1974; Tamarkin et al., 1985). A profuse blood supply reaches the 
pineal gland at a rate of 4ml/min/g surpassed only by the kidney (Reiter, 1981). This blood supply 
is greater at night than during the day (Quay, 1972; Rollag et al., 1977). 
1.3.2 Pineal Innervation 
From initial detailed studies of rat pineal gland innervation, which were carried out by Kappers 
(1960, 1965), it appears that innervation of the pineal gland is critical to its activity and function. 
Datta and King (1980) discovered sympathetic innervation destruction of the gland, destroying the 
ability of the gland to synthesize pineal hormones and the pineal is rendered non-functional by all 
currently measured parameters (Reiter, 1989). Pinealopetal orthosympathetic and pinealopetal 
parasympathetic fibres innervate the pineal gland. The function of the parasympathetic fibres is 
unclear, reaching the pineal gland by way of the facial and greater superficial petrosal nerves. 
Although the existence of central pinealopetal fibres which enter the gland via its stalk (Korf and 
Moller, 1984) has been well defined, their function also remains an enigma (Reiter, 1989). The 
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existence of a parasympathetic innelVation was demonstrated in certain mammals (Kenny, 1961; 
Romijn, 1973; Romijn, 1975b). Both postganglionic noradrenergic sympathetic and postganglionic 
acetylcholinergic parasympathetic fibres do not form true synaptic contacts with the pinealocytes, 
ending either in the parenchyma or in the peri capillary spaces. 
Wurnnan et ai., (1963b) describes the pineal gland as a 'neuroendocrine transducer' whose 
hormonal output depends upon, or is mediated by, the light message reaching the pineal through 
its nelVe supply. Although it appears that the major driving force of the pineal gland occurs due 
to the activity of the afferent sympathetic neurons, the gland can receive other hormonal effects 
through its blood supply. The hormonal effects have been found however to be subsidiary to, and 
modulated by, the sympathetic neuronal effects (Cardinali, 1981; Datta and King, 1980). Hence 
noradrenaline (NA) released from sympathetic nelVes regulates the daily rhythms in enzyme activity 
and melatonin synthesis that occur in response to environmental lighting. 
1.3.3 The Neural Pathway 
In the rat pineal gland the neural pathways by which photosensory information reaches the pineal 
is well established. Unlike a number of other endocrine organs, the pineal relies heavily on its 
innelVation for its endocrine activity (Reiter, 1989). In particular, sensory information perceived by 
the eyes is essential in determining the production of pineal melatonin (Figure 1.2). The first stage 
of the pathway is a monosynaptic projection from the retina to the hypothalamic suprachiasmatic 
nucleus (SCN) (Moore, 1983). Using radio-labelled amino acids, Moore (1973) was able to prove 
unequivocally the existence of this retina hypothalamic pathway. Moore also found that after 
transduction into a neural signal in the photo receptors of the retina, the message is sent to the 
hypothalamus via ganglion cell axons which form part of the retinohypothalamic tract (Moore, 
1978). At the level of the optic chiasma these fibres diverge from the classic optic system and 
terminate in the suprachiasmatic nuclei of the anterior hypothalamus (Sonofriew and Weindl, 1982). 
After synapsing in this location, fibres project possibly to the paraventricular nuclei of the 
hypothalamus (Bittman, 1984). Long descending axons then supposedly carry the neural message 
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into the intermediolateral cell column of the upper thoracic spinal cord (Swanson and Sawchenki, 
1983). The axons of these preganglionic perikarya leave the spinal cord and pass up the sympathetic 
trunk to synapse on postganglionic fibres entering the skull and among other organs, terminate 
within the pineal gland (Kappers, 1965). 
The SCN contains elements of the circadian timing system which generates pineal and other 
rhythms. Although the SCN can function in a cyclical manner autonomously, environmental lighting 
has strong effects on the clock. 
There is a general agreement that the fibres do not form distinct synapses with the pinealocytes 
(Kappers, 1976) but end on the perivascular spaces and that the neurotransmitter simply diffuses 
to the surface of the pineal cells. A few processes might terminate between the perikarya of the 
pinealocytes (Matsushima et aI., 1981). Apart from the delivery of NA, the sympathetic nerves can 
also act as a sponge, taking up and concentrating catecholamines from the perivascular space 
(Kvetnansky et at., 1979). This protective effect has been demonstrated when stressful treatments, 
known to elevate catecholamine levels have had little effect on the pineal or plasma melatonin 
levels (Vaughan et ai., 1982). This is true, provided that the uptake process is not blocked (Parfitt 
and Klein, 1976). 
The sympathetic neural connections between the SCN and the pineal gland must remain intact in 
order for the pineal to function in its normal capacity. Interruption of the neural connection caudal 
to the SCN in either the central or peripheral nervous system interferes with the cyclic production 
of melatonin as well as with the endocrine capability of the pineal gland (Kneisley and Moskowitz, 
1978). 
1.3.4 Other Possible Pathways Modulating Neural Control of Pineal Function 
Attention has been drawn recently to prostaglandins (PO's) as possible modulators of melatonin 
synthesis and release. Prostaglandins are produced and released by the pineal gland and by 
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stimulation of pineal a-adrenoreceptors, resulting in the activation of phospholipase A2 (Ho and 
Klein, 1987) and enhancing the release of arachidonic acid and PGE2. PG~ added in vitro 
increased rat pineal cAMP levels, NAT activity and melatonin release, while the addition of cyclo-
oxygenase inhibitors decreased NA-induced melatonin release (Cardinali and Ritta, 1983). 
Vasoactive intestinal polypeptide (VIP) is localized in nelVe endings of the pineal gland and is one 
of several neuropeptides which have been reported to affect pineal melatonin biosynthesis (Moller 
and Mikkelsen, 1989). A rapid increase in pineal cAMP accumulation and NAT activity is induced 
when VIP interacts with specific receptor sites (Yuwiler, 1983; Kaku et a/., 1985,1986). VIP has 
an effect which has been shown to be potentiated by a-adrenoceptor activation by the same 
mechanism which potentiates /3-adrenergic stimulation (Chik et ai., 1988). 
Another neuropeptide, neuropeptide Y (NPY) has been found in pineal glands (Shiotani et al., 
1986) and may be located in nelVe fibres together with noradrenaline. The use of 
immunohistochemical techniques have allowed the detection of NPY (Schon et ai., 1985; Schroder, 
1986). The NPY have been shown to exert a dual effect in the pineal by enhancing the postsynaptic 
effects of NA at low concentrations whilst inhibiting sympathetic neurotransmission at high 
concentrations. It may even playa role in the transfer of light information as administration of NPY 
to the SCN area causes phase shifts in the circadian rhythm (Harrington and Eicberg, 1983). Vacas 
et ai. (1987) showed that NPY enhanced the noradrenergic induced stimulation of melatonin 
production in the pineal and imparts the K+ induced release of eH]-noradrenaline. 
Substance P has been detected in the pineal glands of mammals. The characterization of receptors 
for substance P has occurred in bovine pineals but not in rat pineals (Govitrapong and Ebadi, 1986). 
The substance P plays a key role as a neurotransmitter or as a neuromodulator in the peripheral and 
central nelVOUS system (for reviews see Euler and Pernow, 1977; Leeman et ai., 1977; Porter and 
O'Connor, 1982; Pernow, 1983; JesseU, 1983; Jordan and Oehme, 1985). Euler and Gaddum (1931) 
identified in the brain a hypotensive and spasmogenic factor which to a certain extent resembled 
acetylcholine in its action, but whose effects could not be blocked by atropine, a muscarinic 
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cholinergic receptor blocking agent. The factor was called substance P. 
There are many other candidate neurotransmitters and neuropeptides for which binding sites in the 
pineal have been reported and they include glutamate (Govitrapong et ai., 1986), dopamine (D:J 
(Govitrapong et al., 1984), acetylcholine (muscarinic) (Govitrapong et at., 1986; Laitinen et ai., 
1989a), substance P (Govitrapong and Ebadi, 1986) and peptide histidine isoleucine (PHI) 
(Tsuchiya et ai., 1987; Moller and Mikkelsen, 1989). However for many of these, an effect on 
pineal melatonin synthesis and release is yet to be demonstrated. 
There is a peptide transmitter found in discrete populations in central synapses called delta sleep 
inducing peptide (DSIP) (Graf and Kastin, 1986). This peptide has been reported to have various 
effects on sleep as well as other physiological functions (Schoenenberger, 1984; Graf and Kastin, 
1984). DSIP has been proposed as a "programming substance for circadian rhythms" (Graf et at., 
1982). It has been known to reduce the nocturnal rise in rat pineal NAT as well as reducing the 
stimulation of NAT in the presence of u- and /3- adrenergic agonists both in vivo and in vitro (Graf 
and Schoenenberger, 1986). The enhancement of the effect of NA on NAT through a 
adrenoreceptor mechanism occurs through DSIP (Graf and Schoenenberger, 1987). 
1.4 Circadian Rhythm 
In mammals the circadian clock is a powerful device. Buried deep in the brain it tells us when to 
wake and when to sleep as well as regulating the temperature of our bodies. The body rhythms it 
sets is a puzzle that has kept a branch of physiology known as 'chronobiology' in business for more 
than two decades. Only now are researchers getting to grips with its most important environmental 
time keeper: daylight. 
Left to its own devices the body clock completes its cycle over a period of about, but not exactly, 
24 hours - hence the term circadian (circa-about; diem-day). In this free running state all that drives 
the clock is the activity of its constituent nerve cells. In everyday life, we never experience the 
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rhythms of this state because the clock is always entrained by time cues in the environment. These 
cues which chronobiologists call "zeitgebers" (the German word meaning 'time-givers') synchronize 
the clock with the daily solar cycle. Enviromental lighting has the effect of resetting and keeping 
the clock entrained to the light cycle (Reiter, 1991b). 
The hormonal and biochemical rhythm that has been studied most intensely is that of melatonin 
production (Binkley, 1981; Klein, 1985). Melatonin may be speculated to hold the key to unlocking 
the location of the circadian clock since it is the best known hormone whose release is timed by 
it. Melatonin acts as a chemical time-keeper, being released by the pineal gland in darkness it sets 
both daily and annual hormonal rhythms. 
The components of this circadian system in the rat and other mammals are anatomically distinct 
with a multi synaptic pathway connecting these components. The photoreceptors are the retina, the 
pacemaker is in the suprachiasmatic nucleus of the hypothalamus (Moore, 1983) and the chemical 
time-keeper melatonin is synthesized in the pineal gland. The rat pineal gland is neither rhythmic 
nor photosensitive in vitro but can be stimulated to make melatonin (Zatz, 1982; Klein, 1985). 
1.4.1 Light· A Pineal Zeitgeber 
The melatonin rhythm of the rat pineal gland is influenced largely by light. Light causes an acute 
reduction of amplitude (synthesis and output) of the melatonin rhythm and influences the carrying 
of the underlying pacemaker as revealed by changes in period or phase (Erlich and Apuzzo, 1985). 
A precipitous decline in pineal melatonin synthesis and release occurs due to acute exposure of 
animals or humans to light at night. The reduction to daytime levels requires only 20 to 30 minutes. 
Exposing the pineal gland to light at night suppresses melatonin production in the pineal of all 
animals tested, but the brightness (irradiance) of light required to achieve this result varies greatly 
among mammals (Reiter, 1985). An illustration as to how these species differ, the albino rat pineal 
gland can respond to as little as 0,0005pW/cm2 of white light at night whereas the Richardson's 
ground squirrel requires light of about 1850pW/cm2• The human pineal is intermediate between 
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these two extremes responding to about 150pW/cm2 of white light at night. Normal room light 
averages 50-lOOpW/cm2 while on a clear day the sunlight at noon can be as bright as 25 000 to 
50000 pW/cm2 (Reiter, 1988). 
Melatonin synthesis is not only suppressed by the brightness of the light but also due to its 
wavelength. Brainard (1985) found that light in the blue range 500-51OA seems to be most 
suppressive of pineal melatonin production. This includes light in the yellow-green range as 
reported by Wurtman and Moskowitz (1977). 
Light controls the amplitude and length of melatonin production cycle and although it is the 
primary input in controlling the cycle, it appears that the levels of other hormones such as 
oestrogen, progesterone, glucocorticoids and prostaglandins are also important in the full expression 
of the final response (Cardinali and Vacas, 1987). 
Melatonin synthesis may be activated by stress and hypog1ycaemia (Lynch et ai., 1973; Sampson, 
1975) demonstrating that environmental stimuli other than light may also be involved in the 
regulation of pineal melatonin synthesis. The effect of ambient temperature also has an effect on 
melatonin synthesis leading to a suggestion that the pineal gland may be involved in 
thermoregulation (Ralph et ai., 1979). 
1.5 The Role of ~- and a- Adrenergic Mechanisms in Melatonin Production 
The most abundant neurotransmitter released from the nerve-endings is noradrenaline (pellegrino 
de lraldi and Zieher, 1966). Noradrenaline exhibits a circadian rhythm in the rat pineal gland 
(Wurtman and Axelrod, 1966) and when released, acts on adrenoreceptors present on the pineal 
gland. The cascade of events leading to the biosynthesis and release of melatonin together with 
other indoles and polypeptide compounds is then initiated. 
The (X- and ~- receptors exhibit 24 hour rhythms in their density (panger1 et aI., 1990). Such 
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fluctuations are generally believed to be detenuined by NA itself which following its release, causes 
desensitization or the internalization of the receptors (Romero et aZ., 1975; Gonzalez-Brito et aZ., 
1988; Pangerl et at., 1989). The involvement ofthese two receptors in the regulation of intracellular 
cAMP is a feature common to many cells (Reiter, 1991a). Cyclic-AMP is the essential intracellular 
second messenger required for the rise in nocturnal melatonin production (Axelrod, 1974; Klein et 
aI., 1981a; Santana et ai., 1988). 
Beta-adrenergic stimulation of the pinealocyte causes a rise in intracellular accumulation of cAMP 
due to its ability to increase the activity of adenyl ate cyclase (O'Dea and Zatz, 1976). Activation 
of /3-adrenergic receptors alone induces up to 10-fold increase in cAMP in the pineal gland. 
Conversely stimulation of a-adrenergic receptors alone is without any effect on cyclic nucleotide 
accumulation (Vanacek et ai., 1985). However, when combined stimulation of both /3- and a-
adrenergic receptors by NA occurs, the rat pineal response in tenus of cAMP is greatly potentiated 
with nucleotide content increasing up to 100-fold (Klein, 1985). These findings are consistent with 
the view that, in the pinealocyte, /3-receptor activation is a requirement for cAMP accumulation 
with the a-receptor stimulation amplifying the response. The dual receptor regulation of cAMP in 
the pineal gland also translates into a similar stimulation (by /3-adrenergic receptors) and 
augmentation (by a-adrenergic receptors) of the activity of the rate-limiting enzyme in melatonin 
production, N-acetyltransferase (Klein et ai., 1981a) as well as of melatonin itself (Santana et ai., 
1988). 
Noradrenaline released at night acts on the pinealocyte membrane to stimulate /3-adrenoceptors. 
Beta-adrenoceptors have been identified in rat pinealocytes (Auerbach et ai., 1981) and in sheep 
and hamster pineal membranes (Foldes et al., 1983; Craft et aI., 1985) using radioligand binding 
studies. Stimulation of these receptors results in the activation of the enzyme adenyl ate cyclase and 
in so doing causes cAMP synthesis. The increase in cAMP mediates the activation of a cAMP-
dependent protein kinase, protein kinase A, which initiates the transcription of mRNA required for 
new synthesis of enzymes in the melatonin pathway (Axelrod, 1983; Ebadi, 1984). Thus an increase 
in cAMP mediates an increase in activity of serotonin N-acetyltransferase (NAT). This rate limiting 
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enzyme catalyses the conversion of serotonin to N-acety1serotonin which is a precursor for 
melatonin. Similarly the activity of the enzyme that converts N-acety1serotonin to melatonin, 
HIOMT, is also increased by cAMP. 
By observing the fact that ribosy1ation of the G-protein by cholera toxin can substitute for /3-
adrenergic receptor activation (Sugden, 1989) it is believed that a G-protein is involved in /3-
receptor mediated stimulation of adenyl ate cyclase. 
Activation of rat pineal a-adrenoceptor triggers the hydrolysis of phosphatidylinosito1 (PI) to yield 
diacylglycerol and inositol phosphates (mainly inositol monophosphates). In addition, a-
adrenoreceptor stimulation produces an increase in intracellular Ca2+, presumably by opening a 
ligand-dependent channel (Sugden et ai., 1987). Diacylglycerol is a potent activator of calcium and 
phospholipid dependent enzyme, protein kinase C (PKC). Activation of PKC mediates the 
amplification of the cAMP and NAT response. 
1.6. Pineal Indole Biosynthesis and Metabolism 
1.6.1 Synthesis of Melatonin 
The biosynthesis of melatonin commences with the uptake of circulating tryptophan by the 
parenchymal cells of the pineal gland (Figure 1.3). A major portion of this is converted to 5-
hydroxy tryptophan. This conversion is catalysed by tryptophan hydroxylase (Lovenberg etai., 1967; 
Jequier et ai., 1969) which may differ from the one in the brain (Nakamura et ai., 1965). It requires 
the presence of oxygen pervious irons and a reduced pteridine cofactor (Lovenberg et al., 1962; 
Snyder and Axelrod, 1964b). 
The 5-hydroxytryptophan is then decarboxylated to form serotonin (Lovenberg etal., 1962; Snyder 
and Axelrod, 1964b), which is found in very high concentrations in the pineal (Giarman and Day, 
1959). The enzyme involved here is the pyridoxal dependent aromatic L-amino acid decarboxylase 
(Snyder and Axelrod, 1964b). This enzyme has a concentration in the pineal greater than in any 
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other tissues examined (Snyder and Axelrod, 1964b). 
The next step involves the acetylation of serotonin to fonn N-acetylserotonin by the enzyme NAT, 
acetyl CoA being the donor of the acetyl group (Weissbach et al., 1960). Finally, the N-
acetyl serotonin is converted to melatonin by O-methylation in the 5-position. This step is catalysed 
by the enzyme, HIOMT (Axelrod and Weissbach, 1960,1961; Cardinali and Wurtman, 1972). 
1.6.2 Synthesis of Other Pineal Indoles 
Serotonin is also oxidized to 5-hydroxyindole acetaldehyde by monoamine oxidase (Axelrod et al., 
1969). Some of this is then converted to 5-hydroxyindoleacetic acid by aldehyde dehydrogenase 
(Wurtman and Larin, 1968; Lerner and Case, 1960). This is then O-methylated in the 5-position 
by HIOMT to fonn 5-methoxyindole acetic acid (Wurtman and Axelrod, 1967). Some of the 5-
hydroxyindole acetaldehyde is also converted to 5-hydroxytryptophol by alcohol dehydrogenase 
(McIsaac and Page, 1959) and is then methoxylated by HIOMT to fonn 5-methoxytryptophol 
(Wurtman and Axelrod, 1967). Serotonin can also be methoxylated by HIOMT to fonn 5-
methoxytryptamine. 
In addition to the pineal, several other organs have the capacity to produce melatonin. Most of the 
tissues that produce melatonin seem somehow to be related to the visual system, the pineal gland 
itself being an end organ of the visual system. Melatonin is produced in the retina (Pang and Allen, 
1986), harderian gland (Bubenik et ai.. 1976) and the extra-orbital lacrimal glands (Mhatre et al., 
1988). It appears that these organs lack the ability to secrete melatonin. Thus under nonnal 
circumstances the blood melatonin concentration almost exclusively reflects that of the pineal 
(Cardinali, 1981; Reiter, 1989). 
Whereas melatonin's actions on mammals are no longer debated, the diversity and mechanisms of 
melatonin's effects are still being uncovered. Clearly, the consequences of the pinea1 and melatonin 
are extremely widespread, perhaps influencing every organ system in the body (Reiter, 1980; 
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Vriend, 1983; Heidmaier and Lynch, 1986; Watson-Whitmyre and Stetson, 1988; Maestroni et at., 
1989). 
1.6.3 
1.6.3.1 
Pineal Enzymes Involved in Serotonin Metabolism 
Monoamine Oxidase 
Monoamine oxidase activity has been reported to be high in the pineal (Snyder et al., 1965), the 
enzyme being mainly confined to the mitochondria. The principle function of this enzyme is to 
counterbalance amine production and to maintain a constant level of amine. 
1.6.3.2 Alcobol debydrogenase 
This enzyme, alcohol dehydrogenase, transforms aldehydes into acids and requires an oxidized 
pyridine cofactor (Feldstein and Williamson, 1968) for its mechanism. 
1.6.3.3 Serotonin N-acetyltransferase (NAT) 
Serotonin N-acetyltransferase undergoes large daily changes (Axelrod, 1974). Rat NAT adversely 
is 30-70 fold higher during the night than during the day. Pineal NAT is found entirely in the 
cytoplasm, and acts to transfer an acetyl group from the cofactor acetyl CoA to acceptor amines 
(Weissbach et ai., 1961). The main acetyl group acceptor is considered to be serotonin, although 
5-methoxytryptamine can also be N-acetylated. It has been speculated that a physiological 
disulphide in the pinealocyte is involved in NAT regulation. Pineal NAT activity is regulated by 
an adrenergic-cAMP mechanism (Klein et ai., 1978). Inhibition of cAMP destruction by drugs or 
cAMP analogs results in an increase in NAT activity (Klein et al., 1970). 
Cycloheximide and actinomycin D block these effects, indicating that the increase in NAT requires 
the synthesis of new RNA hyperpolarization is necessary for NAT stimulation. An additional 
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important piece of evidence concerning the role of cAMP is that propanolol treatment reduces the 
amount of cAMP in the cell as well as NAT (Klein et at., 1978). 
The amount of cAMP in the cell is a function of its rate of production, which is under adrenergic 
control. Pineal NAT activity is hence regulated by this second messenger cAMP, the production 
of which is controlled by a beta-adrenergic receptor associated with adenylate cyclase in the 
membrane of the pinealocyte. 
Environmental factors known to regulate pineal NAT activity are drugs, light and stress. An analogy 
of noradrenaline, isoproterenol, is a drug commonly used in vivo to induce an increase in NAT 
activity. Environmental lighting exercises a marked effect on pineal NAT activity. During the day, 
when NAT activity is diminished, exposure to darkness does not induce an increase in NAT 
activity. 
Stress has also been shown to induce small increases in NAT activity (Lynch et ai., 1973). It is 
important thus, for these factors to be strictly controlled during experimental procedures which 
directly or indirectly involve NAT. NAT activity is generally considered to be rate limiting in the 
production of melatonin (Klein, 1985). Thus the pineal melatonin content typically rises parallel to 
NAT levels. There are however notable exceptions where a large melatonin peak is present without 
a large increase in NAT activity (Menendez-Palaez et ai., 1990). 
1.6.3.4 HydroxindoJe-O-Methyltransferase (HIOMT) 
In the pineal gland hydroxyindole-o-methyltransferase (HIOMT) catalyses the conversion of N-
acetylserotonin to melatonin and to a lesser degree converts 5-hydroxyindole acetic acid to 
methoxyindole acetic acid, hydroxytryptamine and hydroxytryphophol to methoxytryptophol 
(Axelrod and Weissbach, 1961). The enzyme is located almost entirely in the cytosol of the 
pinealocyte. 
20 
HIOMT is regulated by a neural mechanism modulated by light and circulating steroids. Pineal 
HIOMT activity alters slowly over a period of days in response to changes in environmental 
lighting conditions (Axelrod and Wurtman, 1978). During exposure to constant darkness there is 
a gradual increase in HIOMT activity, and in constant light there is a gradual decrease in HIOMT 
activity. It is generally accepted that the signals generated endogenously on a circadian basis in the 
suprachiasmatic nucleus stimulates the release of transmitter in the pineal gland, resulting in an 
increase in HIOMT activity. 
Light appears to block transmission of signals to the pineal gland although intracellular mechanisms 
involved in HIOMT regulation have not been entirely elucidated. No direct evidence implicating 
NA release in the stimulation of HIOMT exists. Attempts to stimulate HIOMT activity in organ 
culture with NA and cAMP have been unsuccessful (Berg and Klein, 1971). The increment in 
HIOMT activity observed in constant darkness is due to an increase in the number of HIOMT 
molecules (Yang and Neff, 1975). 
N-acetylserotonin appears to occupy the role of a "fulcrum" in terms of melatonin production. At 
night, when NAT levels are high, and when saturating amounts of N-acetylserotonin are produced, 
it would appear that HIOMT would function as the rate limiting enzyme. During the day, however, 
when N-acetylserotonin levels are low, NAT would probably assume dominance in this role. 
Several forms of HIOMT exist in pineal tissue (Jackson and Lovenberg, 1971) and unlike the 
enzyme NAT, it is restricted to only a few other organs. It is found in the retina (Cardinali and 
Rossier, 1971), the harderian gland (Vlahakes and Wurtman, 1972) and in the erythrocytes 
(Rosengarten et ai., 1972). Monoclonal antibodies to bovine HIOMT show a high degree of 
structural similarity with HIOMT from other species and have allowed the immunocytochemical 
cytosolic localization of this enzyme (Deguchi et ai., 1987). 
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1.7 Melatonin - a neuroendocrine modulator 
Of all the pineal substances studied, melatonin is probably the most investigated substance. The 
importance of the pineal gland and melatonin as possible neuroendocrine modulators becomes 
apparent when studying their various physiological effects. In 1917 MCord and Allen obselVed a 
lightening of the skin of amphibians fed with bovine pineal extracts. Lerner et aI., (1958) first 
isolated and identified the pineal substance responsible for this effect, and called it melatonin (5-
methoxy-N-acetyltryptamine). Melatonin is synthesized and secreted by the pineal gland of all the 
vertebrate species examined. As far as can be determined melatonin is not stored within the pineal 
gland in any appropriate quantity. Shortly after being synthesized it is released into circulation 
(Kennaway et al., 1977). In some cases melatonin may even be released into the cerebral spinal 
fluid (Reppert et aI., 1988) and blood levels in the cerebrospinal fluid (CSF) follow those of the 
pineal gland. 
Melatonin appears to be secreted by the pineal gland by simple diffusion. Although it is generally 
accepted that the blood of the pineal capillaries rather than the cerebro-spinal fluid (CSF) is the 
primary site of melatonin secretion (Cardinali et aI., 1983). Melatonin has a half life of about 20 
minutes in the blood of rats (Gibbs and Vriend, 1981). A major portion of melatonin in blood is 
bound to plasma protein (partridge and Mietus, 1980). The primary site for the metabolism of 
melatonin in experimental animals is the liver (Wurtman et aI., 1968). After being secreted into the 
blood, melatonin is loosely bound to plasma albumin and passes through the liver where it is 
rapidly conjugated with glucuronide (5%) and sulphate (70-80%) by hepatic microsomes and the 
metabolites are then excreted in the urine (see Kveder and McIsaac, 1961 and Reiter, 1989 for 
reviews and references). 
N-acetylserotonin has been recently identified as a melatonin metabolite in the urine (Yang and 
Neff, 1975) suggesting that melatonin is demethylated back to its precursor and implying the 
existence of a complex feedback mechanism controlling melatonin synthesis. One of the metabolites 
in the urine, 6-hydroxy-melatonin-sulphate is sometimes measured to monitor pineal melatonin 
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production, and may serve to provide a simple, rapid, non-invasive technique of assessing melatonin 
levels in clinical situations (Aldous and Arendt, 1988). This technique would not however be able 
to pick up rapid changes of short duration. 
1.7.1 Site and Mechanism of Action of Melatonin 
There are many potential functions of the pineal gland and melatonin which have been suggested 
but possibly the most extensively documented effects of the pineal gland are those on the 
reproductive system. Reiter and colleagues (1988) were one of the first to observe an involution 
of the gonads and accessory sex organs of both male and female hamsters on exposure to constant 
light providing convincing data that the pineal gland is an organ of internal secretion. 
Although the principle locus of melatonin activity is still a matter of controversy, most investigators 
agree that the central nervous system is probably the major site of melatonin action (Anton Tay, 
1974; Cardinali, 1981; Sugden, 1983; Smith, 1985). The high density of melatonin binding sites 
in the suprachiasmatic nuclei (SCN) (Vanacek et ai., 1987; Reppert et ai., 1988) suggests that 
melatonin may affect circadian rhythms via this structure. It has recently been shown that lesions 
of the SCN disrupt locomotor activity and drinking rhythms and inhibit the effect of administered 
melatonin (Bartness and Goldman, 1989). Zisapel et aI., (1988) demonstrated a distinct diurnal 
variation in binding site density in the hypothalamus but not in the striatum. The diurnal variations 
in the density of melatonin binding sites at specific brain regions underlie the physiological 
response of the neuroendocrine system to melatonin. 
It has been suggested that melatonin assists the entry into sleep and perhaps maintains undisturbed 
sleep throughout the night (Armstrong, 1989). Anton Tay et al., (1971) noted an increase in REM 
sleep and a slowing down of the EEG rhythm in patients treated with melatonin. In humans a 
circadian secretory pattern is well established, with low daytime and high nighttime blood 
concentrations. An age related disease on nocturnal melatonin concentration has been observed 
(Touitou et al., 1984; Carini et ai., 1987). The relation of secretory episodes to sleep stage cycles 
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remains controversial. Vaughan et ai., (1979) and Weinberg et ai., (1979) reported that nocturnal 
plasma melatonin levels exhibit an episodic pattern with no apparent relation to sleep stages. 
Spontaneous waking episodes are significantly correlated to the occurrence of melatonin peaks but 
not with other sleep stages. 
Many reports suggest that the pineal gland may be involved in the modulation of epileptic seizures 
with melatonin being the principle anticonvulsant agent exerting its action possibly by reducing the 
ability of excited epileptic neurons to maintain activity (Pang et ai., 1976). An increase in the 
convulsive threshold in epileptic patients and an improvement in the clinical picture of Parkinsonian 
patients (Anton Tay et ai., 1971) was noted. 
1.7.2 Influence of melatonin on man 
Melatonin has been implicated in the immune reaction. Interleukin-2 cells inhibit pineal melatonin 
production in vivo (Eposti et ai., 1988) and melatonin may stimulate natural killer cell activity in 
humans and enhance humoral and cellular immune responses in mice (Fraschini et ai., 1988). 
The pineal has been suggested to influence the spread and growth of malignant tumours (Tapp, 
1980). Patients dying of breast cancer often have enlarged pineals (Tapp, 1982; Blask, 1984) while 
those dying of disseminated forms of cancer invariably have high HIOMT levels and less Ca2+ 
deposits in their pineals (Kerenyi et ai., 1977). In studies done on female rats, melatonin has 
emerged as a particularly important anti-neoplastic agent especially with respect to growth of breast 
cancer. Lissoni et ai., (1988) have suggested that an increase in plasma melatonin concentrations 
can be used as a prediction of the objective response of cancer patients' chemotherapy. These 
investigations have suggested that the anti-neoplastic effect of cytotoxic drugs may require the 
participation of the pineal gland. In rats pinealectomy generally promotes the growth of cancer 
tissue while melatonin administration does the opposite. 
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The therapeutic potential of melatonin in jet-lagged travellers who have passed through eight or 
more time zones is well established (Arendt et ai., 1987; Arendt and Aldous, 1988; Armstrong and 
Chesworth, 1987). The timed administration of melatonin to these individuals improves mood and 
synchronizes endogenous melatonin and cortisol rhythms. The most recent demonstration of 
melatonin receptors in the SCN of human brains (Reppert and Weaver, 1988) encourages the view 
that exogenous melatonin acts on this structure to synchronize disrupted circadian rhythms. By the 
administration of the drug triazolam, phase shifts or "jet-lag" caused by changes in environmental 
light input into the "clock" may be adjusted (Turek, 1987). The drug flumazenil, a specific 
benzodiazepine antagonist, may block this effect. Turek (1987) discovered this finding useful since 
it could shorten the time of readjustment to the circadian rhythm and thus altering the sleep wake 
cycle. 
Due to exhaustive investigations done to determine the effect of blindness on the biological clock, 
studies done on blind patients suggest that melatonin may affect circadian systems. Sach et at., 
(1987) found in a controlled study that the timed daily administration of melatonin to two blind 
subjects was found to phase advance the free running endogenous melatonin rhythm. In another 
study (Arendt et a!., 1988) involving a blind subject with a severely disrupted and possibly free 
running sleep wake rhythm, melatonin administration was found to synchronize the endogenous 
melatonin rhythm and improve synchronization of sleep onset. 
Ageing has been related to a relative melatonin deficiency, a result of a gradual failure of the pineal 
gland. The hypothesis proposes that the persistence of serotonin in the midst of the melatonin 
decline results in the chain of neuro-endocrine and peripheral events which promote ageing 
(Rozencwaig et ai., 1987). Hasegawa et ai., (1987) described pineal decline and the presence of 
calcifications in the pineal. This study found however that although there existed a correlation 
between pineal weight and the degree of calcification, some pineals in patients over 90 years old 
showed no calcification and were indistinguishable from the ones of younger subjects. This 
suggested that the pineals of humans do not necessarily degenerate after involution. 
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Melatonin may be the most investigated substance in the pineal. It is unwise to assume that it is 
the only pineal factor with physiological consequences. Many other known or yet undiscovered 
pineal substances may prove to have roles equally as, or perhaps even more important than 
melatonin. For instance, melatonin free pineal extracts were observed to exert anti gonadotropic 
effects (Damian et at., 1981) which raises the possibility of other factors other than the 
methoxyindoles such as pteridines and pterins exerting an effect (Ebels, 1979). Pineal factors other 
than melatonin such as 5-methoxytryptophol and 5-methoxytryptamine (McIsaac et at., 1964) also 
exert anti gonadotropic effects even in the absence of an intact pineal gland (Pevet et at., 1981). 
To exhaustively review the vast literature available on the pineal gland would exceed the scope of 
this study. Newly discovered possible physiological functions for the pineal gland and its factors 
are constantly being suggested. Indeed pineal research is a dynamic field of study and certainly 
the wide range of data being collected from both animal and human sources indicates much interest 
in the pineal gland and its possible roles, very different from the lack of enthusiasm for the gland 
in the past. 
1.8 The Autonomic Nervous System and the Pineal Gland 
1.8.1 Introduction 
A brief background into the autonomic nervous system, its characteristics as well as 
neurotransmission needs to be reviewed in order to put into perspective the role that the cholinergic 
system and its receptors play in the pineal gland. 
The autonomic nervous system (ANS) supplies innervation to smooth muscles, glands and visceral 
organs. Termed the "involuntary nervous system" because of its control of physiological reaction 
not under conscious regulation, this communications network maintains homeostasis and facilitates 
appropriate bodily responses to environmental influences. The integrating action of the autonomic 
nervous system is of vital importance for the well-being of the organism. As Claude Bernard 
(1818-1879) and Cannon (1829-1932) have emphasized, that the constancy of the internal 
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environment of the organism is to a large extent controlled by the negative or autonomic nervous 
system. 
1.8.2 Anatomy and Physiology of the Autonomic Nervous System (ANS) 
The autonomic (or involuntary) nervous system is separated into two divisions based upon anatomic 
and physiological criteria: the parasympathetic and sympathetic nervous systems. Both ANS 
divisions innervate many organs. The dual autonomic innervation of the heart and intestines are 
important because of the opposing action of these two divisions. Effector cells in these organ 
systems may be activated to either elevate or suppress the characteristic inherent activity of the 
heart and intestines. 
Changes in the organ system activity result from the interplay between the sympathetic and 
parasympathetic divisions. Drugs that affect the ANS may mimic the activity of one of the systems 
thereby eliciting a pharmacologic effect by an "active" mechanism. Conversely a "passive" mimetic 
effect on one of the divisions may result from blocking the influence of the opposing division. 
1.8.3 Characteristics of the Autonomic Nervous System 
The central nervous system (CNS) functions in concert with the ANS in both the maintenance of 
homeostasis and the body's reaction to environmental or internal stresses. Thus, centres in the 
medulla oblongata influence the integration of blood pressure control and respiration (Miller, 1978). 
Ganglia and plexuses are distinguishing factors in the ANS. Chemical mediators transmit 
information (nerve action potential) across gaps or spaces in the autonomic neuron pathways 
(Bullock and Hagiwara, 1957). These interruptions in physical communication are represented by 
autonomic ganglia in which a synaptic cleft separates the preganglionic fibres from postganglionic 
fibres and by the neuro-effector junction in which the autonomic postganglionic fibres do not 
physically attach to effector cells or receptor sites on smooth muscles and visceral organs. After 
release into the autonomic synapse or neuro-effector junction upon passage of a nerve action 
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potential, these chemicals (transmitters or neurohonnones) attach to receptor sites on postganglionic 
membranes or effector cells on smooth muscles, glands and visceral organs. Combining a chemical 
transmitter with a receptor site initiates biochemical events that culminate in a physiological effect 
or response (Schmitt et aI., 1976). 
Acetylcholine ACh is the chemical neurotransmitter at the following: all autonomic ganglia; the 
neuro-effector junction of postganglionic parasympathetic fibres and effector cells on smooth 
muscle, glands and visceral organs; the junction of autonomic fibres and the adrenal medulla; and 
the autonomic nerve-effector cell union on sweat glands and vasodilator vessels. Thus, these fibres 
are designated as cholinergic - as a consequence of a specific chemical (ACh) released from their 
endings upon passage of a nerve action potential. Various regions of the CNS differ markedly in 
their ability to synthesize ACh (Hebb, 1963). 
Noradrenaline is the neurotransmitter released from postganglionic sympathetic nerves that innervate 
smooth muscles, glands and visceral organs. Thus, these fibres are tenned "adrenergic fibres", 
indicating the chemical transmitter released from these sympathetic nerve endings. 
1.9 Drug Action on ANS Neurotransmission 
Upon the passage of a nerve impulse, neurotransmitters such as acetylcholine and noradrenaline are 
released from presynaptic sites and nerve tenninals. Phannacological agents alter neurotransmitter 
events at one or more sites on the neurotransmission sequence. Most drugs owe their activity to 
an effect on the synaptic or neuro-effector environment and act either directly or indirectly on the 
"breaks" or "gaps" in the neuron pathway by altering neurotransmitter influence at receptor sites 
on effector cells. A direct agonist or antagonist attaches to a receptor site to either elicit or block 
a neurotransmitter response, respectively. For example, isoproterenol is a direct acting beta-
adrenergic receptor agonist that mimics the action of the neurotransmitter noradrenaline. A direct 
cholinergic receptor antagonist, ego atropine, blocks cholinergic receptors to prevent the attachment 
of the neurotransmitter ACh. 
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1.10 Cholinergic Transmission 
Acetylcholine is synthesized from acetyl coenzyme A (CoA) and choline by the action of choline 
acetyltransferase. The source of acetyl CoA is citrate, an intermediate in oxidative carbohydrate 
metabolism. Choline is either obtained from exogenous sources or "recycled" following synaptic 
hydrolysis of acetylcholine by active transport into the cholinergic nerve terminals (Figure 1.4). 
Choline acetyltransferase is found in the cytoplasm of nerve ending particles. The enzyme 
originates in the perikaryon and travels to the nerve terminal where it catalyses acetylcholine 
synthesis. Choline acetyltransferase (ChAT) has been partially purified from cell free extracts of 
the organ of the Amazonian electric eel by Nachrnahnsohn and associates, playing a major role in 
elucidating its properties (Nachrnahnsohn, 1959). Choline is the limiting factor in the synthesis of 
ACh and about 50% of the choline produced by cholinesterase activity is reutilized to synthesise 
new ACh. Choline acetyltransferase catalyses the final step in the synthesis of ACh i.e. the 
acetylation of choline with acetyl coenzyme A (Hebb, 1972; Collier et al., 1976; Rossier, 1977). 
1.10.1 The Mechanism of Cholinergic Transmission 
After ACh synthesis, the neurotransmitter is stored in vesicles. The vesicles that house the newly 
synthesized ACh are one of the most consistent ultrastructural features of junctional tissues. In 
cholinergic nerve endings, the synaptic vesicles range in diameter from 200 - 400 A units. These 
neurohumoral containers migrate toward the nerve terminal synaptic membrane during nerve 
stimulation and disgorge their ACh contents by exocytosis (Figure 1.5). Thus, the vesicle and 
synaptic membrane essentially fuse prior to the exocytotic emptying of ACh into the synaptic cleft. 
Acetylcholine reversibly attaches to the postsynaptic membrane receptor and induces changes in the 
membrane character. The role of dissociation of the neurotransmitter-receptor union occurs rapidly 
to activate neuron activity with succeeding impulses. Upon release from cholinergic nerve endings, 
ACh is inactivated by several means. Enzymatic degradation of ACh is accomplished by 
cholinesterase, including true or specific cholinesterase. This enzyme, associated with and present 
Figure '1.4 
29 
j'osI111.1h,d mechanisms of s"lll1ll''-.is, <;\lll,lgl' illld rp!easl' III dtdrklllllilH' .1I1d 
lIlt' In )'t'ling of vesirles in I h(llilll'lgit Ill'rH' l'ndillgs (1l11\\111.111 .11ld ](.llld, 
]ti}\ll), 
) ..L----- CIlOLItlEHGIC AXON 
------- NEURONAL CYTOPLASM 
sytMPTIC VESICLE 
CON TAINING ACE TYlCHOl.lNE 
-4----- PRESYNAPTIC MEMBRANE 
EXOCYTOSIS 
OF ACETYLCHOLINE 
.... ---------- SYNAPTIC CLEFT 
,----. ----. 
/~::~~_~-=-:=-----\.~----- _ ACE T YLCIJOl.lNF. 
A llACIIED TO REeF f' lOllS 
-- -pus TSYNAPnC MEM8HAliE 
FFFECTOIl CELL OR 
~--.--
PUSTSYNAPTIC NFl1flOrl 
C holi )wrgk lr,lIlsJ11 iss in)). 
31 
at the surface of post-junctional membranes (Davis and Koelle, 1967; Couteaux, 1972), is 
preferential in its catabolism of ACh. Other sites containing true or specific cholinesterase 
(acetylcholinesterase) include the red blood cells and the placenta. Nonspecific cholinesterase 
catalyses the hydrolysis of other choline esters, especially butyrylcholine. For ACh to serve as the 
neurohumoral agent in peripheral junctional transmission, the ester must be removed or inactivated 
within the time limits imposed by the response characteristics of visceral neuro-effector junctions, 
motor end plate and various types of neurons (Dale, 1914). 
Plasma, liver and glial cells contain the nonspecific cholinesterase. Non-enzymatic means of ACh 
inactivation involve binding to nonreceptor sites, diffusion away from the neuron receptor site and 
dilution in extracellular fluids. 
1.11 The Acetylcholine Receptor 
The acetylcholine receptor translates acetylcholine binding into changes in ionic permeability of the 
post-synaptic membrane. Membrane-bound, the ACh receptor is concentrated mainly at synaptic 
sites. The isolation and characterization of the ACh receptor was accomplished by using materials 
with a high ACh receptor concentration, such as the intact electroplax of the electric eel 
(Electrophorus electricus) and frog skeletal muscle (Colquhoun, 1975; Rang, 1973). 
Isolation by subcellular fractionation techniques purifies the receptor material five to ten fold. 
Certain snake neurotoxins, such as bungarotoxin, bind specifically to post-synaptic ACh receptors. 
ACh receptor affinity labels (such as "bungarotoxin") are introduced in situ to irreversibly bind to 
the membrane-bound ACh receptor. By using iontophoresis or by radioligand receptor-displacement 
assays it was found that ACh binds to a mixture of nicotinic and muscarinic cholinergic receptors 
on the synaptic membranes (Appelt and Appelt, 1988 for reviews). 
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1.11.1 Nicotinic Acetylcholine Receptor 
Three points of attraction exist between acetylcholine and the nicotinic acetylcholine receptor. The 
affinity triad on the ACh molecule consists of the quaternary nitrogen (1), the atom bridge 
separating the quaternary nitrogen from the carbonyl oxygen (2) and the carbonyl function (3). 
An anionic function on the receptor surface attracts the quaternary nitrogen of the ACh molecule. 
The anionic receptor function is probably the carboxylate anions of aspartic or glutamic acids. 
These dicarboxylic amino acids are negatively charged at physiological pH and are strong 
candidates as the anionic affinity source on the ACh receptor. Two of the methyl groups on the 
quaternary nitrogen apparently add stability by enhancing the receptor cavity fit and binding 
through van der Waals forces. 
The distance between the quaternary nitrogen on the methonium compounds (R3-N+-(CH2)n-R3)' as 
determined by the number of the methylene groups (CH0, differentiates between nicotinic receptors 
at autonomic ganglia and neuromuscular junctions. A four to eight group carbon separation in the 
quaternary nitrogen functions produces compounds that are primarily autonomic ganglia blockers. 
Dale (1914) suggests that the two nicotinic receptor anionic sites at the neuromuscular junctions 
are located further apart. Thus, a separation of (CH~lO is the preferred distance for blocking 
nicotinic receptors at the neuromuscular junction. 
The biological translation of the acetylcholine-receptor combination is initially evidenced by a rapid 
influx of sodium ions and efflux of potassium ions through channels in the synaptic membrane. 
Depolarization of the synaptic membrane results from the ion flux and a specific physiological 
event occurs. 
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1.11.2 Muscarinic Acetylcholine Receptor 
Physiological responses to muscarinic receptor activation usually occurs more slowly and less 
dramatically than with nicotinic stimulation. Studies on the structure-activity relation of muscarinic 
receptor blocking drugs, such as atropine sulphate, have demonstrated certain features of the 
muscarinic receptor. The distance between the nitrogen atom and the carbonyl oxygen of the ester 
portion of atropine approaches the separation distance of these functional groups in the ACh 
molecule. Consequently the positively charged nitrogen on ACh agonists or antagonists forms an 
ionic bond with an anionic subsite on the muscarinic receptor. Hydrogen bonding occurs between 
the carbonyl function of ACh agonists and antagonists and a cavity located at the esteratic subsite 
on the receptor substance. 
Muscarinic receptors are divided into M} and M2 designations. M} receptors are present on 
intemeurons in autonomic ganglia and in certain regions of the central nervous system, whereas M2 
receptors are primarily present in cardiac tissue and gastro-intestinal smooth muscle. 
Biochemical changes at postsynaptic sites are noted upon muscarinic agonist attachment to the 
receptor substance. M2 receptors may be linked to carbonyl cyclase, in which inhibition of this 
enzyme occurs when these receptors are activated. M2 receptor interaction with a guanine 
nucleotide-binding regulatory protein that binds guanosine triphosphate (GTP) may explain the 
adenyl cyclase inhibition. Another related theory hypothesizes that the combination of ACh (or 
other cholinergic agonists) with the M2 receptor activates guanylate cyclase, which forms guanosine 
3' ,5' -monophosphate (cyclic GMP). Muscarinic receptor activation is also characterized by calcium 
ion influx across synaptic membranes. M} receptors probably regulate Ca++ fluxes and the synthesis 
of phosphorylated derivatives of inositol. 
Understanding of the events associated with activation of the muscarinic receptor remains small. 
Accumulation of cyclic guanosine 3',5'-monophosphate (cyclic GMP) (George et ai., 1970), 
enhanced permeability of monovalent cations (Burgen and Spero, 1968) and increased turnover of 
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phosphoinositol (JaffeIji and Michell, 1976) have each been implicated in the sequence of steps that 
follows occupation of the receptor. 
1.12 Cholinergic Drugs 
Cholinergic drugs elicit their pharmacological responses by activating cholinergic receptors. These 
ACh receptors are classified as either muscarinic or nicotinic and their agonist activity is classically 
defined in terms of pharmacological response. Cholinergic drugs act on the ANS by either a direct 
action on ACh receptors or by an indirect effect that increases endogenous ACh concentration at 
synaptic and neuro-effector junctions. A variety of cholinergic drugs such as the direct and indirect 
acting cholinergic drugs, the anticholinesterase agents as well as cholinergic receptor blocking 
agents have been used in this study. A brief overview of their characteristics, structural features 
and mode of action are carried out in the sections which follow. 
1.12.1 Direct acting cholinergic drugs 
These direct acting cholinergic drugs are agonists at muscarinic and nicotinic receptor sites. ACh 
is an example of this type of cholinergic drug and is also an endogenous neurotransmitter at 
cholinergic synapses. Rapid hydrolysis by plasma cholinesterase causes the transient and fleeting 
action of ACh. ACh directly stimulates both muscarinic and nicotinic receptors depending on 
accessibility to the receptor site and dosage. This drug produces rapid and complete miosis by 
intracellular administration. 
Carbachol is another direct acting cholinergic drug and is an ester of carbamic acid (rather than 
acetic acid as in the case of ACh) and choline. Carbachol is a potent muscarinic agonist that is not 
readil y hydrolysed by acetylcholinesterase or non-specific choline esterase (because of the resistance 
of the carbamoyl group to degradation). The release of endogenous ACh from cholinergic nerve 
terminals contributes to the cholinergic response. 
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1.12.2 Anticholinesterase Drugs (Indirect Acting Cholinergic Drugs) 
Anticholinesterase drugs block the enzymatic degradation of acetylcholine and causes its 
accumulation at cholinergic receptor sites. Several of the anticholinesterase drugs are toxic agents 
employed as insecticides or promoted as potential "nerve gases" in chemical warfare. However, 
some of these agents (including physostigmine, neostigmine and pyridostigmine) are useful as 
therapeutic agents because of their indirect cholinergic action. 
The active centre of acetylcholinesterase consists of anionic and esteratic subsites. The anionic 
subsite on AChE combines with the positive nitrogen charge of choline by means of electrostatic 
or ionic bonding, comprising one of the attachment sites of ACh to the enzyme. At the esteratic 
subsite, a covalent bond forms with the carbonyl group of the acetate portion of ACh. The 
attachment of ACh to AChE in this manner orients the ACh molecule so that nucleophilic attack 
on the acyl carbon occurs. Thus, acetylation of the enzyme is followed by rupture of the ester 
linkage of acetylcholine and the elimination of choline. The acetylated enzyme then reacts with 
water to form regenerated active enzyme that has the capacity to hydrolyse 3 x 105 ACh molecules 
per enzyme molecule per minute. 
1.12.3 Acetylcholinesterase Inhibition 
Reversible inhibitors of AChE combine with the active anionic subsite or with a peripheral anionic 
subsite that is spatially removed from the active centre of the enzyme. Quaternary reversible AChE 
inhibitors interact by means of the quaternary nitrogen with the anionic subsite on the active site 
and by hydrogen bonding to the nitrogen at the esteratic subsite. Reversible acetylcholinesterase 
inhibitors that contain a carbamyl ester grouping, such as physostigmine and neostigmine, attach 
to the anionic subsite because of their quaternary (neostigmine) or tertiary (physostigmine) nitrogen. 
A carbamylated enzyme forms by the bonding at the esteratic subsite of AChE. The carbamylated 
intermediate is stable and its formation precludes the rapid enzymatic hydrolysis of ACh for a 
period of time. The interaction of a reversible inhibitor (substrate) with AChE (enzyme) depends 
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upon the anionic site attraction and the nature of the esteratic site interaction. Subsequent rapid 
reversibility of binding (edrophonium) or the fonnation of a stable carbarnylated intennediate 
(physostigmine and neostigmine) characterise the reversible inhibitor-AChE interaction. 
Irreversible inhibitors of AChE, the organophosphates, do not routinely interact with the anionic 
subsite at the active centre of AChE. Rather, the organophosphates fonn a stable complex by 
phosphorylating the enzyme. 
1.12.4 Reversible Anticholinesterase Agents 
Reversible anticholinesterase drugs inhibit the degradation of acetylcholine and penn it its 
accumulation at muscarinic and nicotinic receptor sites. 
1.12.4.1 Physostigmine (Eserine): Physostigmine is a naturally occurring alkaloid obtained 
from the Calabar bean and is a reversible inhibitor of acetylcholinesterase that fonns a carbarnylated 
intennediate with the enzyme. Physostigmine reacts primarily with AChE. The carbamylated 
intennediate of the enzyme so fonned prevents the ACh-AChE interaction and spares endogenous 
ACh from enzymatic hydrolysis. The accumulation of ACh at autonomic ganglia and cholinergic 
neuro-effector junctions causes the pharmacological responses to physostigmine. The predominant 
effects that occur in therapeutic doses of physostigmine are muscarinic in nature. 
Physostigmine contains a tertiary amine and because it is lipid soluble it readily passes the blood 
brain barrier. Consequently it possesses both peripheral and central cholinergic activity. 
1.12.4.2 Neostigmine: A reversible cholinesterase inhibitor, neostigmine contains a quaternary 
nitrogen. This structural feature limits its passage into the CNS and imparts a direct action on 
peripheral cholinergic receptor sites. Neostigmine inhibits the hydrolysis of ACh by competing 
with ACh for attachment sites on AChE. By fonning a carbarnylated intennediate with AChE, 
neostigmine elicits anticholinesterase activity. Additionally, neostigmine has a direct action at the 
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motor end plate on skeletal muscle. This direct cholinomimetic activity sets the drug apart from 
physostigmine and makes the neuromuscular actions of neostigmine more pronounced than those 
of physostigmine. As well as augmenting gastric secretions, neostigmine also increases the motor 
activity of the gastro-intestinal tract. 
1.12.5 Muscarinic Receptor Blocking Agents 
Antimuscarinic drugs exert their pharmacological effects by competitive blockade of ACh receptors 
at the neuro-effector junction of postganglionic parasympathetic fibres and effector cells on smooth 
muscle, glands and visceral organs. The classical antimuscarinic drug is atropine, an alkaloid 
obtained by extraction from the plant Atropa belladonna (Deadly Nightshade). Atropine inhibits 
the action of ACh on smooth muscles, glands and visceral organs by blocking muscarinic receptors. 
Due to its structural similarity to ACh, atropine binds to muscarinic receptors, but does not elicit 
the response noted when ACh-receptor interaction occurs. The atropine-receptor combination 
prevents access of ACh to receptor sites, which produces an effective muscarinic block. The degree 
of muscarinic block depends upon the relative concentrations of atropine and ACh present in the 
receptor vicinity and represents a classic example of competitive inhibition in drug mechanisms. 
The atropine molecule does not produce the identical conformational changes in the muscarinic 
receptor substance that ACh elicits. Rather, atropine produces molecular perturbations in the 
receptor substance that are sufficiently different from ACh so that the typical pharmacological 
response is absent. In summary, atropine is structurally similar enough to ACh to bind to 
muscarinic receptors, but the receptor fit is not as "tight" and does not produce the response noted 
with the ACh-receptor interaction. The bulky substituent group connected to the carbonyl function 
in the atropine molecule apparently prevents a "proper" fit in the receptor substance cavity that 
accepts this molecular portion of muscarinic agonists and antagonists. 
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1.12.6 Drugs blocking Nicotinic Receptors 
Drugs that block nicotinic receptors including nicotine, lobeline and succinylcholine, usually 
produce a transient stimulation at these sites. Nicotinic blocking drugs either prevent the 
depolarizing action of ACh or produce a persistent depolarization of the postsynaptic membrane 
receptor substance. Some drugs (such as nicotine) produce an initial stimulation of ganglioniC 
nicotinic receptors before effecting a final blockade of these same receptors. 
1.12.6.1 Hexamethonium: Hexamethonium is the prototype C6 compound that led to the 
development of newer ganglionic blocking drugs. The drug acts as a competitive inhibitor of ACh 
at nicotinic receptor sites in autonomic ganglia. They produce a ganglionic blockage by occupying 
receptor sites and by stabilizing the postsynaptic membranes against the actions of ACh liberated 
from presynaptic nerve endings. 
1.13 A Summary of Recent Studies Based on the Cholinergic System in the Pineal 
Gland 
The innervation of the mammalian pineal gland is mainly sympathetic and modulates the activity 
of indole pathway enzymes and secretion of pineal honnones (Cardinali 1981). This fact arose 
from the classical studies of Ariens-Kappers (1965) who proposed the sympathetic nature of the 
innervation of the mammalian pineal gland, originating from the superior cervical ganglion and 
entering the pineal gland via the conarian nerve. Furthennore, the main neurotransmitter released 
from these sympathetic fibres was noradrenaline (Wurtrnan and Moskowitz, 1977), which interacted 
with pineal B-adrenergic receptor sites. 
In addition to these receptors, recent studies have shown that the pineal glands also contain 
GABAergic receptors (Ebadi et ai., 1989), benzodiazepine receptors (Lowenstein and Cardinali, 
1983), glutamatergic receptors (Govitrapong et ai., 1986), D2-dopaminergic receptors (Govitrapong 
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et al., 1984) and substance Preceptors (Govipatrong and Ebadi, 1986). Furthennore, it has been 
shown that in addition to its sympathetic innervation, the mammalian pineal glands also receive a 
distinct central pinealopetal innervation (Korf and Moller, 1984). The possible existence of 
cholinergic pineal innervation in various species is controversial. 
Cholinergic neurons are distributed widely in the autonomic nervous system. For examples, the 
preganglionic neurons of both sympathetic and parasympathetic nervous systems are cholinergic. 
Furthennore, the postganglionic parasympathetic neurons are mainly cholinergic. In addition while 
the majority of postganglionic sympathetic fibres are adrenergic, the fibres supplying the sweat 
glands, vessels of skeletal muscles in some species and vessels of tongue muscles are all cholinergic 
in nature (Dale, 1937; Gabella, 1976). The development and use of immunohistochemical methods 
for measuring both cholinesterase and choline acetyltransferase have provided excellent tools for 
the localization of cholinergic neurons in various areas of CNS (Butcher and Woolf, 1984; Nitecka 
and Frotsher, 1989). 
The origin of cholinergic fibres innervating the bovine pineal gland, which may involve the 
habenula, needs to be studied and delineated carefully. Nevertheless, there is evidence that in 
addition to serotonin and noradrenaline, sympathetic fibres containing acetylcholinesterase do exist 
in the rat pineal gland (Eranko et aI., 1970; Eranko and Eranko, 1971). Moreover, 
neurohistological studies involving silver impregnation technique using mammalian pineal glands 
including those of humans (Scharenberg and Liss, 1965) have shown that nerve fibres passing via 
the habenula or posterior commissure may intenningle and associate functionally with pineal 
parenchyma. In addition, recent immunohistochemical studies have demonstrated that choline 
acetyltransferase immunoreactive cells are indeed present in the habenula (Vincent et ai., 1986). 
The functions of ACh and cholinergic receptors in the pineal gland are not known. However 
fragmentary evidences gathered thus far denote that ACh does influence pineal functions. For 
examples: 
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(i) The injection of melatonin or ACh into the cisterna magna of rabbits increases the 
concentration of 3'5'cyclic guanosine monophosphate (cGMP) (Rudman, 1976). 
(ii) The intraventricular injection of carbachol, a cholinergic receptor agonist, causes a rapid 
reduction in the activity of serotonin N-acetyltransferase. Furthermore, mimicking the 
effects of light exposure, carbachol also causes a shift to the right on the temporal patterns 
of NAT (Zatz and Brownstein, 1979). 
(iii) Atropine methy1bromide, a cholinergic receptor antagonist, inhibits the activity of HIOMT 
in constant darkness, whereas oxotremorine oxalate, a cholinergic receptor agonist, restores 
it (Wartman et ai., 1969). 
(iv) Studies involving micro-electrophoretic ally applied melatonin, NA and ACh indicated that 
the responses of pinealocytes to these agents were non-uniform in nature (Semm and 
Vollrath, 1981) suggesting that pinealocytes may possess the biochemical mechanisms to 
respond uniquely and differently to various neurotransmitters. 
(v) ACh is able to lighten some frogskins (Moller and Lerner, 1966; Goldman and Hadley, 
1968), and atropine, the cholinergic receptor antagonist, causes melanosome dispersion 
(Tercafs, 1966). 
(vi) In rat pineal glands in culture, ACh (10.6 M) stimulated the release of arginine vasotocin 
(Sartin et ai., 1979). 
Schrier and Klein (1974) were unable to identify choline acetyltransferase (ChAT) activity in 
pineals of rat or rabbit, whereas Rodriguez de Lores Arnaiz and Pellegrino de Iraldi (1972) showed 
that the presence of ChAT activity in the rat pineal gland can be detected even after bilateral 
superior cervical ganglionectomy (SCGX). This suggests that the presence of cholinergic terminals 
do not originate in these ganglia. In addition, Moller and Korf (1983) and Romijn (1973) reported 
finding pineal nerve terminals containing small clear vesicles that stained intensely for AChE. 
These structures did not disappear after SCGX and were considered as cholinergic vesicles. 
In fact, muscarinic binding sites found in the pineal gland were not distinguishable from those 
identified as muscarinic receptors in other tissues (Taylor et al., 1980). The number of sites did 
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not decrease after SCGX, indicating that muscarinic receptors were not exclusively located in 
sympathetic terminals (Taylor et ai., 1980). The first positive evidence for the existence of 
functional muscarinic receptors in the pineal gland, however, was the demonstration of an 
acetylcholine-stimulated increase in the turnover rate of phosphatidylinositol (Basinka et al., 1973). 
Laitinen et aI., (1989b) suggested that the activation of the muscarinic Mt-receptor by carbachol 
produced an accumulation of inositol monophosphates, a finding that confirms and extends the 
report by Basinka et al., (1973). 
Indirect evidences supporting the presence of cholinergic fibres (Labella and Shin, 1968; Eranko 
et ai., 1970; Eranko and Eranko, 1971; Trueman and Herbert, 1970; Rodriguez de Lores Arnaiz and 
Pellegrino de Iraldi, 1972; Romijn, 1973, 1975a; David and Herbert, 1973; David and Kumar, 1978; 
Matsushima and Reiter, 1978; Burt and Taylor, 1980) or the absence of cholinergic fibres (Schrier 
and Klein, 1974) in the pineal gland have appeared in the literature. 
In addition to the large number of terminals containing NA and serotonin, other neurotransmitters 
such as gamma-aminobutyric acid, taurine, octopamine and dopamine have been found in the pineal 
gland (Ebadi, 1984). Only terminals containing small dense cored vesicles, catecholaminergic in 
nature, disappear with SCGX, while those containing mostly large dense-cored vesicles, probably 
peptidergic, and small clear vesicles, probably cholinergic, remained unaffected (Cardinali et al., 
1987). These observations imply a complex neuronal regulation of pineal activity. Furthermore, 
ChAT activity was detected in pineal homogenates, suggesting that the neurotransmitter could be 
synthesized in situ. 
A necessary requirement for neurotransmitter-mediated effects on a target tissue is the presence of 
specific receptors. Accordingly, Finocchiaro et ai., (1989) found that [3H]QNB-binding sites in the 
pineal membranes showed similar properties to muscarinic receptors in other tissues confirming a 
previous report by Taylor et ai., (1980). [3H]QNB binding sites in the pineal described above are 
so similar to those identified as muscarinic receptors in other tissues ego heart (Fields et ai., 1978), 
brain (Yamamura and Snyder, 1974b), ileum (Yamamura and Snyder, 1974a), parotid (Talamo et 
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ai., 1979) and pituitary (Burt and Taylor, 1980), that there can be little doubt that they represent 
muscarinic receptors. There is, however, virtually an absence of corroborating functional data. 
Indeed only the possible existence of ACh-stimulated increase in the turnover in 
phosphatidylinositol (Basinka et ai., 1973) regularly found to accompany muscarinic receptor 
activation in other tissues (Heilbronn and Bartfai, 1978) may be taken as positive functional 
evidence for muscarinic receptors in the pineal. Even here there is a counterbalancing negative 
report (Eichberg et ai., 1973) as well as a similar negative report for effects of ACh on pineal 
cyclic GMP content (Sharma and BaneIjee, 1978). 
Although pineal muscarinic receptors were found in relatively low concentrations, they have a 
definite functional activity. Their existence raises interesting questions about the possible location 
and functional role of the muscarinic receptors in the pineal. The likelihood remains that an 
appreciable portion of them are on sympathetic terminals where their activation may stimulate the 
release of noradrenaline, as demonstrated in the hypothalamus (Engberg and Stevensson, 1980) and 
septal area where ACh liberates serotonin through a mechanism mediated by NA (Pirola et ai., 
1987). A postsynaptic action of the muscarinic agonist (Finocchiaro et ai., 1989) may be suggested 
since the number of muscarinic binding sites are not decreased after SCGX (Moller and Korf, 
1983). 
The study done by Finocchiaro et ai., (1989) rules out any action due to muscarinic receptors 
located in pineal vessels, as suggested in the case of muscarinic effects on blood flow associated 
with secretory stimuli in the posterior pituitary (Sooriyamoorthy and Livingston, 1972). Hence 
some of these receptors might therefore be located in pineal neurons or pinealocytes. 
1.13.1 Muscarinic AcetylchoHne Receptor Genes 
Muscarinic receptors mediate many of the actions of ACh in the central and peripheral nervous 
systems (Nathanson, 1987). Two pharmacologically distinct classes of such receptors, M} and M z, 
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have been defined on the basis of their affinities, high and low respectively, for the antagonist 
pirenzepine (Hammer et ai., 1980). However a variety of heterogeneous properties of muscarinic 
receptors have not always correlated well with this classification which suggests that there may be 
other classes. It has been unclear whether the apparently different receptors represent modifications 
of a single receptor or whether they are different proteins. Recently a porcine brain muscarinic 
receptor complementary DNA (cDNA) was cloned and expressed in Xenopus oocytes to produce 
functional receptors (Kubo et al., 1986). The presence of related messenger RNA (mRNA) in 
tissues rich in Ml receptors and its absence in tissues rich in M2 receptors suggested that there are 
more than one muscarinic ACh receptor gene. 
Muscarinic receptors are members of a large class of neurotransmitter hormone and light receptor 
which act through binding to and activation of guanosine 5' -triphosphate (G) binding proteins. The 
activated G proteins can stimulate or inhibit adenylate cyclase, stimulate phosphatidylinositol 
turnover and directly regulate ion channels thereby affecting a variety of cellular responses (Gilman, 
1984; Stryer and Bourne, 1986; Spiegel, 1987). 
1.13.2 Cholinergic Stimulation of Phosphoinositol Hydrolysis 
Muscarinic receptors transduce agonist signals by activating G proteins to regulate ion channel 
activity and to generate second messengers. It has been reported that four different genes code for 
muscarinic receptors (Kerslavage et ai., 1987). Studies on second messenger coupling of 
muscarinic receptor SUbtypes (Ml - MJ suggest that the expression of rat muscarinic Ml and human 
Ml and M4 receptor genes in cells lacking endogenous muscarinic receptors can lead to a complete 
appearance of the phosphoinositol (PI) signalling pathway and that the magnitude of the signal 
produced is proportional to the level of gene expression for these receptors (Dudley et ai., 1988; 
Peralta et al., 1988). Expression of human Ml and M3 subtypes in embryonic kidney cells was 
coupled to PI hydrolysis to a lesser extent (peralta et al., 1988). 
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Laitinen et at., (1989b) suggest the presence of a functional ACh receptor in the rat pineal which 
are coupled to the PI signalling pathway. Furthennore, the relative potency of muscarinic 
antagonists to block the PI accumulation suggests that these receptors are of Ml subtype. These 
receptors, as judged by the PI response, were not affected by the removal of the sympathetic 
innervation to the gland. 
In line with this, Taylor et at., (1980) reported no changes in [3H] quinuclidinyl benzylate 
(eH]QNB) binding in rat pineals after bilateral ganglionectomy. On the other hand, 
ganglionectomy resulted in enhanced adrenergic stimulation of pineal PI turnover. In other studies, 
both the PI response to NA (Zatz, 1985) and the density (but not the affinity) of a-adrenoreceptors 
(Sugden and Klein, 1985) have been shown to double after bilateral SCGX. All these results 
indicate supersensitivity of the rat pineal to adrenergic stimulus after removal of the sympathetic 
innervation. 
Although the muscarinic receptor density in rat pineals (Taylor et ai., 1980) seems to be only a 
fraction of that reported for a-adreno receptors in the gland (Sugden and Klein, 1985), the PI 
response for submillimolar concentrations of both muscarinic acid and adrenergic agonists was very 
similar (Laitinen et at., 1989b). The reason for this is unclear at the moment. Taken together, the 
results of the study done by Laitinen et ai., (1989b) suggest that ACh could modulate pineal 
function through the stimulation of PI turnover. 
2.1 Introduction 
CHAPTER 2 
ORGAN CULTURE STUDIES 
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The pineal gland is one of the most highly perfused organs in the body and is highly vascularized 
second only to the kidney (Kappers, 1976). Various drugs are capable of affecting pineal indole 
synthesis and metabolism. Ideally, a technique is required that is sensitive enough to determine the 
normal functioning of the gland as well as to detect changes in activity upon drug manipulation in 
vitro. 
Strangeways and Fell (1926) were amongst the first workers to employ the organ culture technique. 
At the time, the method was used chiefly for the culture of embryonic rudiments. More recently, 
refinements in biochemical techniques have led to an increase in the use of organ culture systems 
for the study of physiological and biochemical properties of living tissue. Trowell (1959) 
successfully employed a technique that allowed a number of fully differentiated organs, or parts 
thereof, to be kept viable in vitro without either growth or dedifferentiation, thus paving the way 
for many experimental studies. 
Many researchers have successfully developed organ culture techniques for the pineal gland (Alphs 
et ai., 1980; Klein and Notides, 1969; Axelrod et al., 1969; Shein and Wurtman, 1969). The 
technique of pineal gland organ culture is rendered suitable by virtue of its favourable size and 
accessibility (Trowell, 1959). It is also a useful technique since it eliminates the complexities of 
organ interaction and allows for direct pharmacological manipulation. Rat pineal glands cultured 
in our adequately aerated medium and incubated at 37°C have been shown 10 be viable for at least 
6 days (Klein, 1969). 
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2.2 Theory of Assay 
The pineal gland in culture is able to utilize an exogenous radioactive precursor (tryptophan, 5-
hydroxy tryptophan or serotonin) to synthesize various indole metabolites associated with pineal 
metabolism. It has been shown that approximately 95% of the synthesized radioactive indoles are 
secreted into the culture medium during the incubation period. It is usual to incubate rat pineal 
glands for 24 hours after which incubation is terminated by the removal of the gland from the 
medium (Klein and Rowe, 1970; Skene, 1985). The radioactive indoles are then separated, most 
commonly using bidimensional thin layer chromatography (TLC) (Klein and Notides, 1969; 
Balemans et al., 1978; Daya and Potgieter, 1982) and quantitated with the aid of radiospectrometry. 
In the following sections, the procedures for pineal organ culture, TLC separation of radioactive 
indole metabolites and quantification of labelled indoles using radio spectrometry are described. The 
pineal glands take up the radioactive precursor and incorporates it as part of its normal biosynthetic 
pathway, synthesizing radioactive metabolites and releasing them into the culture medium. The 
metabolites are then separated and quantitated using among other methods, bidimensional thin layer 
chromatography and liquid scintillometry. This method provides a more quantitative picture of 
pineal indole metabolism and has been shown to be sensitive to pharmacological manipulations 
(Klein and Rowe, 1970; Balemans et ai., 1983; Voisin et al., 1983; Daya and Potgieter, 1985) as 
well as adequately detecting changes in pineal indole metabolism (Daya and Fata, 1986). 
2.3 
2.3.1 
2.3.1.1 
ORGAN CULTURE TECHNIQUE 
Materials and Methods 
Chemicals, drugs and reagents 
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5 Hydroxy (side-chain-2)4C) tryptamine creatine sulphate (specific activity 56 mCi/mmol) was 
purchased from Amersham, England; aluminium TLC plates coated with silica gel 60 F254 (0.20mm) 
from Merck, Gennany; and BGJb culture medium (Fitton-Jackson modification) from Gibco, 
Europe. Beckman Ready-Solv mUltipurpose premixed liquid scintillation solution was obtained from 
Beckman RIlC Ltd, Scotland. The antibiotics benzyl penicillin and streptomycin were purchased 
from Hoechst, SA; and amphotericin B from Squibb Laboratories, SA. All standard indoleamines, 
melatonin (aMT), N-acetyl serotonin (aHT) and hydroxy and methoxy indoles were purchased from 
Sigma Chemical Co, USA. All other chemicals and reagents were obtained from local commercial 
sources. 
2.3.1.2 Animals 
Inbred adult male albino rats of the Wi star strain were used throughout this study. Female rats were 
not included in the experiments because of the variation in the rt4C] serotonin metabolism noted 
in female rats in different stages of the estrus cycle (Daya, 1982). Variation was reported in the 
HIOMT sensitivity to oestradiol during the estrus cycle of female rats (Cardinali, 1981; Daya and 
Potgieter, 1982). All animals were maintained under artificial illumination with a daily photoperiod 
of 12 hours (lights on at 06hOO). The light intensity during the light phase was approximately 
30OpWatts/cm2 provided by cool white fluorescent tubes. As far as possible, the temperature of the 
living quarters was kept constant (20-24°C) and an extractor fan ensured the constant removal of 
stale air. All animals were housed in groups of 4 or 5 in opaque white plastic cages. A metal grid 
served as a floor in each cage. Animals were maintained on a diet of standard rat pellets ad libitum 
and tap water and weighed between 200-300g at the time of sacrifice. 
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Rats were killed swiftly by celVical dislocation and decapitation. Using a pair of scissors an incision 
was made through the bone from the foramen magnum to near the orbit. A clean, sterile dissecting 
forceps was inserted into this incision and the skull and adhering brain was lifted and folded back. 
The brain was gently peeled away from the dura and the skull, exposing the pineal gland. The small 
pearl white structure was often found adhering to the skull. Rarely, when this did not occur, the 
pineal gland could be found in the groove between the cerebral hemispheres, anterior and cephalic 
to the colliculi. Forceps were inserted into this groove and the pineal gland was easily removed, 
placed on a cold stainless steel spatula and dissected free of the pineal stalk and any adhering 
tissue. Once perfected this procedure could easily be accomplished within 30 seconds. Pineals were 
then placed in organ culture tubes as described in [2.3.1.3]. 
2.3.1.3 Organ Culture of Pineal Glands 
Following decapitation, the rat pineal glands were exposed and removed as described in [2.3.1.2]. 
The glands were transferred to sterile (borosilicate 75xlOmm) culture tubes containing 52p1 culture 
medium. The culture medium consisted of BGJb medium (Filton-Jackson modification), 
supplemented with benzylpenicillin sodium, streptomycin sulphate and amphotericin B. The 
components of the culture medium and their respective concentrations are listed in Table 2.1. Each 
culture tube thus contained one pineal which floated just below the surface of the medium. To this, 
8p1 of the substrate e4C] serotonin (0.4 pCi) was added. The air in the tube was displaced with 
carbogen (95%O/5%C02), and once the atmosphere was saturated the tubes were tightly sealed 
with parafilm. The culture tubes were placed in a Fonna Scientific model 3028 incubator and the 
pineals were incubated in the dark at 37°C for 24 hours. 
In experiments involving drug addition to the culture medium, 10pl of the drug was added to 52p1 
of the culture medium containing the pineal gland prior to the addition of the 8pl aliquot of e4C] 
serotonin. Where basal pineal e4C] serotonin metabolite levels had to be detennined, 10p1 of 
vehicle was substituted for the drug. After the 24 hour incubation period the reaction was stopped 
by the removal of the pineal glands from the culture medium. 
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TABLE 2.1 Constituents o(BGJb culture medium (Fitton-Jackson moditicationj 
CONTENTS 
Amino Acids 
L-Alanine 
L-Arginine 
L-Aspartic acid 
L-Cysteine HCl 
L-Glutamine 
Glycine 
L-Histidine 
L-Isoleucine 
L-Leucine 
L-Lysine HCl 
L-Methionine 
L-Phenylalanine 
L-Proline 
L-Serine 
L-Threonine 
L-Tryptophane 
L-Tyrosine 
DL-Valine 
Inorganic Salts 
Dihydrogen sodium ortho phosphate 
Magnesium sulphate 7H20 
Potassium chloride 
Potassium dihydrogen phosphate 
Sodium bicarbonate 
Sodium chloride 
CONCENTRATION (mgll) 
250.00 
175.00 
150.00 
90.00 
200.00 
800.00 
150.00 
30.00 
50.00 
240.00 
50.00 
50.00 
400.00 
200.00 
75.00 
40.00 
40.00 
65.00 
90.00 
200.00 
400.00 
160.00 
3 500.00 
5 300.00 
Continued on next page '" 
CONTENTS 
Vitamins 
a-Tocopherol phosphate 
Ascorbic acid 
Biotin 
Calcium pantothenate 
Choline chloride 
Folic acid 
Inositol 
Nicotinamide 
Para aminobenzoic acid 
Pyridoxal phosphate 
Riboflavin 
Thiamine HCl 
Vitamin B12 
Other Components 
Calcium lactate 
Glucose 
Phenol red 
Sodium acetate 
CONCENTRATION (mg/l) 
1. 00 
50.00 
0.20 
0.20 
50.00 
0.20 
0.20 
20.00 
2.00 
0.20 
0.20 
4.00 
0.04 
555.00 
10 000.00 
20.00 
50.00 
50 
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2.3.1.4 Thin Layer Chromatography Separation of the Indoles 
The technique employed was a minor modification of the method of Klein and Notides (1969). To 
measure the relative amounts of e4C] indoles present, a IOpl aliquot of culture medium was spotted 
on a 10cm x lOcm TLC plate (SiHca gel 60, Type F254 0.25mm x 20cm x 20cm aluminium plates 
cut to lOcm x lOcm from Merck, Gennany). 
Following this, a solution containing synthetic unlabelled standards of all the pineal indoles to be 
measured was spotted on top of the culture medium spot. A total of lOp} of a solution containing 
2pg of each standard was spotted. The indole standard solution was prepared as follows: 1mg of 
each standard indole amine was dissolved together in a test tube containing 2.5ml of 95% ethanol. 
To this, 2.5ml of a solution of 1 % ascorbic acid in O.IN HCl was added. The ascorbic acid was 
included by Klein and Notides (1969) to protect indoles against oxidation. The solution was stored 
in darkness at -20°C. Monon (1987) reponed no difference between plates spotted and run in 
normal light as opposed to those spotted and run in the dark (as suggested by the original method). 
In all instances the TLC plates were spotted in subdued light and a gentle stream of nitrogen was 
used to dry the spots which were no larger than 0.5cm to prevent atmospheric oxidation of the 
indole metabolites. 
Each spotted plate was then placed in a TLC tank and developed twice in the same direction in a 
solvent containing chloroform: methanol: acetic acid (93:7:1). The total front movement allowed 
during each development was 9cm. Once the solvent had reached this point (±2Smin) the plates 
were taken out of the TLC tanks and the position of the solvent front was marked. These were dried 
under nitrogen, then placed back into some solvent and run once again in the same direction up to 
the mark. Following this, the plate was developed once in ethyl acetate at right angles to the first 
direction and with a total front movement of 7cm. The plate was then dried under nitrogen 
evaporating off the ethyl acetate sprayed with Van Urk's reagent (lg of 4-dimethylamino 
benzaldehyde dissolved in 50ml of 2S% HCl, followed by the addition of SOml of 9S% ethanol) 
and dried in an oven at 60°C for 20min to allow for development of the spots. 
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The spots were then cut out and placed into plastic scintillation vials. One millilitre of absolute 
ethanol was added to the vials together with 3ml scintillation cocktail fluid (Beckman Ready-Solv 
HP-B) and shaken on a Vortex Rotor-mixer Deluxe for 30 seconds. The radioactivity was 
quantitated at a counting efficiency of 79.58% in a Beckman LS 2800 scintillation counter and each 
vial was counted for a total of 5 minutes. 
2.3.2 Results 
A typical bidimensional thin layer chromatogram of the indole metabolites are presented in Figure 
2.1. Adequate separation of all the indoles was achieved. Nomenclature for the pineal indoles 
follows the system suggested for international adoption by Smith (1982). A list of indoles together 
with abbreviations is presented in Figure 2.1. 
2.3.3 Discussion 
Using TLC the ability to separate N-acetylserotonin (aHT) , melatonin (aMT) , 5-hydroxyindole 
acetic acid (HA). 5-hydroxytryptophol (HL). 5-methoxyindole acetic acid (MA) and 5-
methoxytryptophol (ML) was confinned. This system has recently been validated by Skene (1985). 
This author was able to confinn that the removal of aliquots of medium present an accurate picture 
of the indole synthesis within the isolated pineal gland, as well as detennining that the radioactivity 
on the TLC plates was present within the area of the standard spots. Skene was also able to 
demonstrate a recovery from the medium of expected metabolites in excess of 90%. Although 
Morton (1987) does not include acetic acid in solvent A, it was found that acetic acid was essential 
for good separation of the ML and MA indoles. Hence acetic acid was included in solvent A. 
ngure 2.1 
MA HA 
ML 0 
o 
o 
aMT 
o 
aHT 
liT I M T SECOND DIRECT 1011 
ETHYL ACE1~TE 
rlRST DlnECTION (x2) 
CHLOROFonM : 1.1E I HAlIOL : ACETIC ACID 
( 98 : 7 : 1 ) 
liT - Serotonin 
MT - 5-McthoxjlryptLlminc 
aliT - N-AcctylscTotonin 
aMT - Melatonin 
IlA - 5-Hydroxyindole acetic acid 
ilL - 5-Hydroxytryplophol 
MA - 5-Mcthoxyindolc acclic acid 
I\1L - 5-Mcthoxytryplllphlll 
;\ II.ICP of TLC plntp showing Ihc dirl'clion in whkh Ihl' S{ll\Tllh \\l'll' 11111 
i1nd 1111' subsequent location of the pinl'al indule IlWI,111ll1 i It'..,. N{lllH'll1 1,11111(' 
,1<; III ~;ll1ilh (IYRn 
54 
2.4 Experiment 1 : THE EFFECT OF CARBACHOL ON PINEAL 
INDOLE METABOLISM. 
2.4.1 Introduction 
Innervation of the mammalian pineal gland is mainly sympathetic and this modulates the activity 
of the indole pathway enzymes and secretion of pineal hormones (Cardinali, 1981). Noradrenaline 
is released from sympathetic nerves inducing the production of the pineal hormone melatonin 
through the rate limiting enzyme N-acetyltransferase (NAT). The diurnal rhythm in melatonin 
synthesis by the pineal is under direct control of this system (Cardinali, 1981). By using tritiated 
muscarinic receptor antagonist quinuclidinyl benzilate (eH] QNB) as a ligand, Govitrapong et aI., 
(1989b) identified and characterized muscarinic cholinergic receptors in the pineal glands of cattle. 
The aim of this experiment was to ascertain the effect of carbachol in the rat pineal gland using 
organ culture techniques, confirming the presence of these receptors in the pineal. 
2.4.2 
2.4.2.1 
Materials and Methods 
Materials 
Carbachol was purchased from Sigma Chemical Co., USA; and noradrenaline was bought from 
Merck, Germany. All other chemicals and reagents were obtained from previously acknowledged 
sources I2.3.1.1]. 
2.4.2.2 Animals 
Adult male Wi star rats (250-280 g.b.wt) were used for this series of experiments and were housed 
in groups of 4 to 5 animals per cage as described in I2.3.1.2]. The rats were killed by cervical 
dislocation and decapitation and their pineal glands removed. 
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2.4.2.3 Methods 
The technique of pineal organ culture and the analysis oflabelled indoles was perfonned as outlined 
in f2.3.1.3]. Fifteen pineal glands were rapidly collected and cultured individually in the BGJb 
culture medium containing 0.4 pCi of e4C] serotonin. Five pineal glands were cultured in the 
presence of carbachol (1O-5M) alone, another five pineal glands in the presence of a combination 
of carbachol (10-5) and noradrenaline (1O-5M) and a further five pineal glands were incubated in the 
absence of drug to act as a control group. The pineal glands were cultured at 37°C with a relative 
humidity of 95% and in an atmosphere of 5%C02:95%02' Aliquots of culture medium was 
removed after 24 hours of incubation. The [14C] indoles in the samples were isolated using 
bidimensional TLC and quantitated with the aid of liquid scintillometry as described in [2.3.1.4]. 
2.4.2.4 Data Analysis and Statistics 
When using the pineal as an experimental tool it would seem logical to use the two indole 
metabolites aHT and aMT, as biological markers of pineal activity. These two metabolites represent 
the two products of two primary enzymes, NAT and HIOMT, in indole metabolic pathways. Skene 
(1985) suggested that an overall gauge of pineal activity could be the sum of the N-acetylated 
product (ie aHT and aMT). The results are therefore primarily analysed using these values. 
However it would not be fair to ignore the other indoles produced, especially the hydroxyindoles 
HA and HL which are produced in such great quantity. As these two hydroxyindoles are further 
methylated by HIOMT, to MA and ML, respectively, any correlations evident here could be used 
as a possible indicator of HIOMT activity. 
Data are expressed as dpm/10pl medium/pineal gland calculated as the mean ± SEM(n=5). Owing 
to the multiple combinations of treatment within a single experiment a One-Way ANOVA followed 
by Neuman-Keuls Multiple Range test was applied for comparison of groups. 
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2.4.3 Results 
The results are presented in Table 2.2 showing all the metabolites separated by TLC, with the 
exception of the starting spot which contains both HT and MT. The muscarinic agonist carbachol 
increased aHT levels significantly (p<O.05) whilst aMT levels remained unaltered. 
The presence of carbachol did not have any influence on the noradrenaline-induced rise in 
melatonin (p<O.Ol). 
2.4.4 Discussion 
Carbachol is a parasympathomimetic agent causing muscarinic cholinergic receptor stimulation. The 
drug caused a rise in the indole aHT and left aMT levels unaltered. The drug did not affect the 
adrenergic system with reference to melatonin synthesis. A daily rhythm in circulating melatonin 
occurs in all mammals (Klein, 1979). In the rat this is generated by a large rhythm in the activity 
of pineal arylamine N-acetyltransferase (Klein, 1979; Klein and Weller, 1970; Klein and Berg, 
1970; Klein and Weller, 1973), the enzyme that converts serotonin to the intermediate precursor 
of melatonin, N-acetylserotonin. The activity of N-acetyltransferase is regulated by a neural circuit 
that stimulates the nocturnal release of noradrenaline from sympathetic nerves in the pineal gland 
(Klein et aI., 1971; Moore and Klein, 1974; Klein and Moore, 1979; Brownstein and Axelrod, 
1974). Noradrenaline acts through an adrenergic mechanism to increase intracellular cAMP (Strada 
et aI., 1972; Deguchi and Axelrod, 1973) which induces and activates N-acety1 transferase (Klein 
and Berg, 1970; Klein and Weller, 1973) leading to an increase in melatonin production (Klein et 
al., 1970; Shein and Wurtman 1969). The parasympathomimetic, carbachol was unable to affect this 
noradrenergic increase in melatonin production suggesting some other functional role for cholinergic 
receptors in the pineal gland. Laitinen et aI., (1989a) suggested that activation of the muscarinic 
Mt-receptor by carbachol produced an accumulation of inositol monophosphates, a finding that 
confirms and extends a previous report by Basinka et ai., (1973). 
TABLE 2.2 The effect of carbachol (10-5 • and a combination of carbachol and noradrenaline (CAR+NA) (1 0-5• on [l4C} serotonin 
metabolism in rat pineal glands. 
-------
Metabolites Control CAR Significance CAR + NA Significance 
ML 662 ± 325,76 477,25 ± 145,25 NS 179,20 ± 62,28 NS 
MA 388,25 ± 130,61 224,50 ± 37,82 NS 174,20 ± 41,29 NS 
aMT 1 619,25 ± 250,79 1 203,50 ± 365,21 NS 3 855,00 ± 777,20 (a) p<O.OI 
HL 8 594,50 ± 2 644,22 14 844,25 ± 2 534,51 NS 10 346,40 ± 3 368,85 NS 
HA 27 663,75 ± 4 083,01 27 035,00 ± 4 437,87 NS 21 745,60 ± 3 408,38 NS 
aHT 990,00 ± 207,67 4 477,75 ± 1 667,78 (a) p<0.05 3 504,00 ± 612,54 NS 
5HT/5MT 67 020,00 ± 5 624,13 54 090,50 ± 4 287,82 NS 65 126,00 ± 8 951,35 NS 
1 Dill aliquots of medium were chromatographed by TLC. Results are expressed as dpm/ pineal gland (mean ± SEM; n=5 individually cultured 
pineal glands per group). Significance is computed using One-Way ANOVAfollowed by Neuman-Keuls Multiple Range test. 
a) Significantly increased w.r.t vehicle control. 
2.5 
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Experiment 2: THE EFFECT OF ACETYLCHOLINE AND 
HEXAMETHONIUM ON PINEAL INDOLE METABOLISM. 
2.5.1 Introduction 
Identification of neurotransmitter receptor sites by chemical measurements of direct binding has 
been reported for nicotinic cholinergic receptors in the mammalian neuromuscular junction (Berg 
et at., 1972; Fambrough and Hartzell, 1972; Hartzell and Fambrough, 1972; Miledi and Potter, 
1971), and central nervous system (Bosman 1972; De Robertis, 1971; De Robertis et ai., 1969; 
E1defrawi and O'Brien, 1970) and for the glycine receptor in the mammalian central nervous system 
(Young and Snyder, 1973). 
The aim of this experiment was to determine whether the rise in the indole aHT induced by 
carbachol was indeed caused by muscarinic receptor stimulation and not through nicotinic receptors. 
Acetylcholine is a general agonist of the muscarinic and nicotinic receptors whilst the drug 
hexamethonium is a ganglion blocking agent inhibiting the transmission of the nicotinic receptor. 
By using these two drugs individually and in combination it is possible to investigate their effects 
on the pineal indole metabolic pathway. 
2.5.2 Materials and Methods 
2.5.2.1 Materials 
Acetylcholine chloride as well as hexamethonium was purchased from Sigma Chemical Co., USA. 
All other chemicals and reagents were obtained from previously acknowledged sources [2.3.1.1]. 
2.5.2.2 Animals 
Adult male Wistar rats (250-280g.b.wt) were used and maintained under an automatically regulated 
lighting cycle of LD12: 12. Their living environment is described in detail in [2.3.1.2]. 
59 
2.5.2.3 Methods 
The technique of pineal organ culture and the analysis oflabelled indoles was performed as outlined 
in [2.3.1.3]. Fifteen pineal glands were rapidly collected and cultured individually in BGJb culture 
medium containing O.4pCi of e4C] serotonin. Five pineal glands were cultured in the presence of 
acetylcholine (lO-5M), another five with a combination of hexamethonium (lO-5M) and acetylcholine 
(lO-sM) and a further five pineal glands were incubated in the absence of drug to act as a control 
group. The pineal glands were cultured at 37°C with a relative humidity of 95% and in an 
atmosphere of 5%C02:95%02' Aliquots of culture medium was removed after 24 hours of 
incubation. The [14C] indoles in the samples were isolated using bidimensional TLC and quantitated 
with the aid of liquid scintillometry as described in [2.3.1.4]. The significantly different groups 
were identified using a One-Way ANOVA followed by Neuman-Keuls Multiple-Range test. 
2.5.3 Results 
The results are presented in Table 2.3 showing all the metabolites separated by TLC with the 
exception of the starting spot which contains both HT and MT. Acetylcholine induced a rise in aHT 
production (p<O.OOl) whilst aMT levels remained unaltered. Hexamethonium does not alter the 
acetylcholine induced rise in aHT (p<O.025). 
2.5.4 Discussion 
The drug acetylcholine resulted in increased aHT levels whilst aMT levels remained unaltered. 
Hexamethonium did not alter this effect of acetylcholine and aHT levels still rose after applying 
the ganglion blocking agent. It may be suggested that the aHT increase is not induced at the 
nicotinic receptors. If the nicotinic receptors had played a role in the aHT increase, the 
hexamethonium would have suppressed any rise by acetylcholine. These results lead to a 
speculation that the rise in aHT occurred through muscarinic receptors. Acetylcholine may also be 
speculated to act on the enzyme NAT, inducing activation, and on the enzyme HIOMT to lower 
its activity thus reducing the conversion of aHT to aMT. 
TABLE 2.3 The effect of acetylcholine (ACh](10·sM) and a combination of hexamethonium and acetylcholine (HEX + ACh] (10·sM) 
on [14Cl-serotonin metabolism in rat pineal glands. 
Metabolites Control ACh Significance HEX + ACh Significance 
ML 909,83 ± 139,28 426,33 ± 88,24 (a) p<0,005 323,5 ± 94,84 (a) p<0,005 
MA 288,33 ± 29,38 202,67 ± 18,79 NS 179,4 ± 50,06 NS 
aMT 1 615,00 ± 543,01 3 053,67 ± 615,36 NS 2 707,33 ± 578,79 NS 
HL 15 482,50 ± 1 742,81 9 563,83 ± 1 316,93 (a) p<O,Ol 9 402,00 ± 1 424,40 (a) p<0,025 
HA 24 372,83 ± 2 270,62 19 271,00 ± 2 520,89 NS 15 917,00 ± 2 161,84 (a) p<0,05 
aHT 1 077,00 ± 187,51 3 278,00 ± 500,46 (b) p<O,OOl 1 932,50 ± 429,48 (b) p<0,025 
5HT/5MT 57 062,67 ± 6 895,55 58 296,33 ± 4 723,89 (b) p<0,05 74 677,00 ± 5 816,60 (b) p<0,05 
lDJll aliquots oj medium were chromatographed by TLC. Results are expressed as dpm/ pineal gland (mean ± SEM; n=5 individually 
cultured glands per group). Significance is computed using a One-Way ANOVAJollowed by Neuman-Keuls Multiple Range test. 
(a) Significantly decreased w.r.t vehicle control 
(b) Significantly increased w.r.t vehicle control 
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2.6 Experiment 3: THE EFFECT OF A TROPINE ON PINEAL INDOLE 
METABOLISM. 
2.6.1 Introduction 
Antimuscarinic agents are competitive inhibitors of the action of acetylcholine at the muscarinic 
receptors of autonomic effector sites innervated by parasympathetic nerves as well as being 
inhibitors to some extent of the action of acetylcholine on smooth muscles lacking cholinergic 
innervation. Atropine is an antimuscarinic agent which competitively inhibits the action of 
acetylcholine at the muscarinic receptors, in so doing it may be possible to determine whether the 
rise in aHT occurred through the muscarinic receptor or not. 
2.6.2 Materials and Methods 
2.6.2.1 Materials 
Atropine was purchased from BDH Chemicals Ltd, England. All other chemicals and reagents were 
obtained from previously acknowledged sources [2.3.1.1]. 
2.6.2.2 Animals 
Adult male Wi star rats (250-280g.b.wt) were used and maintained under an automatically regulated 
lighting cycle of LD12:12. Their living environment is described in detail in [2.3.1.2]. All the 
animals were sacrificed at IlhOO. 
2.6.2.3 Methods 
The technique of pineal organ culture and the analysis of labelled indoles was performed as outlined 
in [2.3.1.3]. Ten pineal glands were aseptically removed and individually cultured in the presence 
of OApCi e4C] serotonin. Five pineals were cultured in the presence of 1O-5M atropine and another 
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five with a combination of atropine and acetylcholine (lO-5M) and a further five in the absence of 
the drug to act as a control group, at 37°C with a relative humidity of 95% and in an atmosphere 
of 5%C02:95%02- Aliquots of culture medium was removed after 24 hours of incubation and the 
rt4C] indoles in the samples were isolated using bidimensional TLC and quantitated with the aid 
of liquid scintillometry as described in [2.3.1.4]. Statistical comparisons were made using a One-
Way ANOVA followed by Neuman-Keuls Multiple Range test. 
2.6.3 Ites~ts 
The results are presented in Table 2.4 showing all the metabolites separated by TLC with the 
exception of the starting spot which contains both HT and MT. Atropine was found to block the 
rise in aHT induced by acetylcholine. 
2.6.4 Discussion 
The antimuscarinic agent atropine antagonizes the muscarinic actions of acetylcholine, in so doing 
preventing the operation of the muscarinic cholinergic system. The results show that atropine 
blocked the aHT rise induced by acetylcholine, implying that acetylcholine acts on the pineal 
muscarinic receptor. eH] Quinuclidinyl benzilate (eH] QNB) binding sites in the rat pineal glands 
were found to show similar properties to cholinergic muscarinic receptors in other tissues (Sharma 
and Banerjee, 1978; Pirola et ai., 1986). Functionality of these receptors was demonstrated as in 
vitro muscarinic activation by pilocarpine increased the pineal metabolic production of the 
hydroxyindole derivatives 5-hydroxytryptophan and serotonin, with a slight effect on melatonin 
biosynthesis (Finocchiaro et aI., 1989). Electric field stimulation of pineal slices caused similar 
metabolic effects with the probable release of acetylcholine on excitation. These effects were 
inhibited by muscarinic blockade with atropine. 
These results [2.6.3] suggest that acetylcholine plays a role in the pineal and that cholinergic 
activity may therefore regulate indole metabolism in the pineal gland. The mechanism by which 
this regulation occurs needs to be further examined. 
TABLE 2.4 The effect of acetylcholine (ACh') 0·5M) and a combination of atropine and acetylcholine (ATR + ACh) 11 0·5M) on (14C) 
serotonin metabolism in rat pineal glands. 
Metabolites Control ACh Significance ATR + ACh Significance 
ML 324,09 ± 100,46 285,26 ± 209,20 NS 707,82 ± 195,48 NS 
MA 31 009,53 ± 6 798,64 34 563,97 ± 5 323,86 NS 40 436,54 ± 3 777,13 NS 
aMT 1 090,18 ± 327,75 1 666,67 ± 79,97 NS 612,74 ± 158,80 NS 
HL 10 301,89 ± 51,85 4 383,22 ± 52,01 a) p<0.01 9 783,48 ± 50,44 NS 
HA 2 309,08 ± 433,15 2 154,30 ± 587,47 NS 1 834,48 ± 280,34 NS 
aHT 2 012,27 ± 1 630,69 4 288,11 ± 741,27 b) p<O.OOI 2 363,60 ± 870,21 NS 
5HT/5MT 22 899,33 ± 5 383,02 29 752,53 ± 2 450,31 NS 29 285,36 ± 3 803,19 NS 
10J.1l aliquots of medium were chromatographed by TLC. Results are expressed as dpm/ pineal (mean ± SEM; n=5 individually cultured glands 
per group). Significance is computed using One-Way ANOVAfollowed by Neuman-Keuls Multiple Range test. 
a) Significantly decreased w.r.t. vehicle control 
b) Significantly increased w.r.t. vehicle control 
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2.7 Experiment 4 : THE EFFECT OF NEOSTIGMINE ON PINEAL 
INDOLE METABOLISM. 
2.7.1 Introduction 
Anticholinesterase drugs block the enzymatic degradation of acetylcholine and cause its 
accumulation at cholinergic receptor sites. Several anticholinesterase drugs are toxic agents 
employed as insecticides or used as 'nerve-gases' in chemical warfare. Reversibly acting agents 
such as physostigmine and neostigmine are useful in therapeutics because of their indirect 
cholinergic action. The aim of this experiment was to investigate the effect of an anticholinesterase 
agent neostigmine on indole metabolism in the pineal. 
2.7.2 Materials and Methods 
2.7.2.1 Materials 
Neostigmine bromide was purchased from Sigma Chemical Co., USA. All other chemicals and 
reagents were obtained from previously acknowledged sources [2.3.1.1]. 
2.7.2.2 Methods 
The technique of pineal organ culture and the analysis of labelled indoles was performed as outlined 
in [2.3.1.3]. Ten pineal glands were aseptically removed and individually cultured in the presence 
of O.4pCi e4C] serotonin. Five pineals were cultured in the presence of 10-5M neostigmine and 
another five in the absence of drug to act as a control group, at 37°C with a relative humidity of 
95% and in an atmosphere of 5%C02:95%02. Aliquots of culture medium was removed after 24 
hours of incubation. The e4C] indoles in the samples were isolated using bidimensional TLC and 
quantitated with the aid of liquid scintillometry as described in [2.3.1.4]. Statistical comparison 
made using Student's t-test. 
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2.7.3 Results 
The results are presented in Table 2.5 showing all the metabolites separated by TLC with the 
exception of the starting spot which contains both aHT and aMT. Neostigmine did not cause any 
significant changes in aMT and aHT levels. 
2.7.4 Discussion 
Neostigmine is a reversible cholinesterase inhibitor which contains a quaternary nitrogen. This 
structural feature limits its passage into the CNS and imparts a direct action on peripheral 
cholinergic receptor sites and at the motor end plate on skeletal muscle. 
In general, compounds such as neostigmine which contain a quaternary ammonium group do not 
penetrate cell membranes readily. Hence anticholinesterase agents in this category are poorly 
absorbed from the gastrointestinal tract and are excluded by the blood brain barrier from exerting 
significant action on the CNS (Goodman and Gilrnon, 1980). 
The results show that neostigmine did not influence the pineal indoles in any significant way. 
Finocchiaro et al., (1989) demonstrated the functionality of cholinergic muscarinic 
receptors in the rat pineal gland. These authors showed neostigmine to enhance the action of 
acetylcholine released by electric field stimulation resulting in a rise in 5-hydroxytryptophan and 
serotonin levels. However, 5-hydroxyindole 3-acetic acid (HA), N-acetylserotonin (aHT) and 
melatonin (aMT) showed no additional increase when compared with the electrically stimulated 
controls confinning our organ culture results above [2.7.3]. 
Although the effects of muscarinic activation may be due to increased tryptophan uptake or the 
activation of tryptophan hydroxylase, additional experiments are required to detennine the 
mechanism involved and as to the reason why activation of indoles such as aHT and aMT do not 
occur. 
TABLE 2.5 The effect of neostigmine (10·sMJ on (14C]wserotonin metabolism in rat pineal glands. 
Metabolites Control Neostigmine Significance 
ML 1 241,71 ± 207,30 568,07 ± 79,77 a) p<O,Ol 
MA 488,27 ± 54,05 404,26 ± 64,76 NS 
aMT 843,69 ± 295,31 1 616,72 ± 309,03 NS 
HL 8 740,34 ± 1 269,89 6 460,66 ± 718,45 NS 
HA 23 436,72 ± 1 368,34 26 103,68 ± 4 322,48 NS 
aHT 370,57 ± 135,99 638,04 ± 145,29 NS 
5HT/5MT 20 834,75 ± 2 357,67 33 085,69 ± 5 351,78 NS 
10Jll aliquots oj medium were chromatographed by TLC. Results are expressed as dpm/ pineal gland (mean ± SEM; n=5 individually cultured 
glands per group). Significance is computed using the Student's t-test. 
a) Significantly decreased w.r.t. vehicle control- Student's t-test. 
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Table 2.5 shows 5-methoxytryptophol levels to decline significantly when compared to control 
groups. Neostigmine could be speculated to influence methoxytryptophol levels by possibly 
inhibiting the HIOMT enzyme activity in some manner and in so doing limit the conversion of 5-
hydroxytryptophol to 5-methoxytryptophol. 
2.8 Experiment 5 : THE EFFECT OF PHYSOSTIGMINE ON PINEAL 
INDOLE METABOLISM 
2.8.1 Introduction 
The drug physostigmine is a reversible inhibitor of acetylcholinesterase that forms a carbamylated 
intermediate with the enzyme. Physostigmine reacts primarily with the true acetylcholinesterases. 
The carbamylated intermediate of the enzyme so formed prevents the acetylcholine-
acetylcholinesterase interaction and spares endogenous acetylcholine from enzymatic hydrolysis. The 
accumulation of acetylcholine at autonomic ganglia and cholinergic neuroeffector junctions causes 
the pharmacologic responses to physostigmine. Physostigmine is a lipid-soluble agent possessing 
a tertiary amine and having a ubiquitous effect on central cholinergic receptor sites (Goodman and 
Gilman, 1980). 
The aim of this experiment was to investigate the effects of a cholinesterase substrate inhibitor 
physostigmine on pineal indole metabolism. 
2.8.2 Materials and Methods 
2.8.2.1 Materials 
Physostigmine was purchased from Merck, Germany. All other chemicals and reagents were 
obtained from previously acknowledged sources [2.3.1.1]. 
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2.8.2.2 Animals 
Adult male Wistar rats (250-280g.b.wt) were used for this series of experiments and were 
maintained under an automatically regulated lighting cycle of LDI2:12. Their living environment 
is described in detail in [2.3.1.2]. All the animals were sacrificed at IlhOO. 
2.8.2.3 Methods 
The technique of pineal organ culture and the analysis of labelled indoles was performed as outlined 
in [2.3.1.3]. Ten pineal glands were aseptically removed and individually cultured in the presence 
of O,4pCi e4C] serotonin. Five pineals were cultured in the presence of 1O-5M physostigmine and 
another five in the absence of drug to act as a control group, at 37°C with a relative humidity of 
95% and in an atmosphere of 5%C02:95%02' Aliquots of culture medium was removed after 24 
hours of incubation. The e4C] indoles in the samples were isolated using bidimensional TLC and 
quantitated with the aid of liquid scintillometry as described in [2.3.1.4]. Statistical comparisons 
were made using Student's t-test. 
2.8.3 Results 
The results are presented in Table 2.6 showing all the metabolites separated by TLC with the 
exception of the starting spot which contains serotonin (HT) and 5-methoxytryptamine (MT) 
respectively. Physostigmine was found to cause a significant rise in aHT (p<O.005) but not aMT. 
2.8.4 Discussion 
Our investigation found that the cholinesterase inhibitor physostigmine increased aHT levels 
significantly but not aMT. Physostigmine is a lipid-soluble drug containing a tertiary amine and 
readily passes the blood brain barrier. Consequently it has effects at both peripheral and central 
TABLE 2.6 The effect of physostigmine l1U5M] on C14C]-serotonin metabolism in rat pineal glands. 
Metabolites Control Physostigmine Significance 
ML 1 275,62 ± 303,09 1 194,07 ± 71,74 NS 
MA 883,94 ± 118,57 578,25 ± 96,14 a) p<0,05 
aMT 450,24 ± 162,08 479,87 ± 165,77 NS 
HL 9 961,65 ± 1 823,21 26 991,58 ± 4 758,53 b) p<0,005 
I 
HA 61 112,07 ± 1 307,56 58 285,04 ± 3 628,51 NS 
aHT 460,02 ± 92,78 1 256,98 ± 177,04 b) p<0,005 
5HT/5MT 18 030,61 ± 1 678,27 17 277,03 ± 2 280,59 NS 
lOlll aliquots oJmedium were chromatographed by TLC. Results are expressed as dpm/pinealgland (mean ± SEM; n=5 
individually cultured glands per group). Significance is computed using the Student's t-test. 
a) Significantly decreased w.r.t vehicle control 
b) Significantly increased w.r.t vehicle control 
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cholinergic receptor sites. Although both neostigmine and physostigmine are anticholinesterases, 
neostigmine contains a quaternary nitrogen (Goodman and Gilman, 1980). This structural feature 
limits neostigmine's passage into the eNS and hence it imparts a direct action on peripheral 
cholinergic receptor sites only and not on central cholinergic receptor sites. This may be a reason 
why physostigmine causes aHT levels to rise significantly whilst neostigmine is unable to do so. 
By being lipid-soluble physostigmine is able to pass through the blood brain barrier and influence 
central cholinergic receptor sites in the pineal gland. These results further confirm the presence of 
cholinergic muscarinic receptors in the pineal gland. The physiological significance and mechanism 
behind the acetylcholine and physostigmine-induced rise in aHT without influencing aMT levels 
remains to be elucidated. 
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CHAPTER 3 
CYCLIC AMP DETERMINATION TECHNIQUE 
3.1 Introduction 
Adenosine 3'5' cyclic monophosphate (cyclic AMP) has been identified in almost all forms of life, 
where it mediates intracellular responses to external stimuli (Fried, 1972). After receptor activation 
by an agonist, hormone receptor interaction occurs on the external cell surface. The membrane 
associated event usually triggers a secondary cascade of responses inside the cell to affect internal 
metabolic processes. In many cases the primary effect of the hormone receptor interaction is to 
cause a change in the level of some "second messenger" inside the cell (Fried, 1972; Yamamura 
and Enna, 1981). The second messenger can then directly or through a further cascade process 
affect the activity of appropriate metabolic enzymes or the expression of particular genes. Such a 
process appears to operate at all beta-adrenoreceptors and at some dopamine receptors. At these 
receptors, the enzyme adenylate cyclase is activated by the process of neurotransmitter receptor 
combination (Kruk and Pycock, 1979). 
Various researchers have, at different times, employed a variety of techniques to measure cAMP 
levels. Early attempts, in this regard, were essentially indirect and involved determining the activity 
of the enzyme adenylate cyclase as an index of cAMP levels (Krishna et ai., 1968). This method 
involved measuring the rate of formation of cAMP from its radioactive precursor, e4C] ATP. The 
cAMP thus formed was isolated by ion exchange chromatography followed by precipitation of all 
the nucleotides and inorganic phosphates. The radioactivity of the cAMP left in the supernatant was 
then measured. 
A direct cAMP assay, using a purified protein from bovine muscle as the specific binding protein, 
was developed by Gilman (1970). Various workers have used this technique to measure rat pineal 
cAMP levels. Generally, the method involves prior trichloroacetic acid precipitation and ether 
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extraction before measuring cAMP levels. Deguchi (1973) found no difference in the amount of 
cAMP between purified and unpurified pineal tissue using the method of Gilman (1970). 
Brown and co-workers (1971) have developed a saturation assay for cAMP using purified bovine 
adrenal protein as the specific binding protein. The assay was similar to the Gilman assay (1970), 
also involving trichloroacetic acid precipitation and ether extraction prior to measurement of cAMP 
levels. Although the two assays had similar sensitivity and specificity characteristics, the assay of 
Brown and co-workers (1971) was considerably simpler and less time-consuming. 
More recently radioimmunoassays (RIAs) have been developed to measure rat pineal cAMP levels 
(Moyer et al., 1979; Heydom et al., 1980). The cAMP concentration is measured using e25I] 
antigen and antiserum available commercially. The cAMP RIAs, although expensive, they have a 
high degree of specificity and sensitivity. In addition, these assays are rapid and simple to use. 
The assay developed by Brown et al., (1971) was chosen to measure pineal cAMP levels for the 
purposes of this study. The assay is sensitive, specific, easy to use and relatively inexpensive. The 
following section describes the preparation of the adrenal binding protein as well as the cAMP 
assay, adapted for the pineal gland. 
3.1.1 Methods for the Determination of Cyclic AMP 
Although several very sensitive radioimmunoassays for the determination of cAMP are available, 
their cost was prohibitive. Since the action of cAMP in all tissues involves its binding to some type 
of protein (Oye, 1973), several techniques have been devised which make use of a natural binding 
protein coupled to a radio isotope type of dilution assay, thereby giving greater sensitivity. The 
methods of Gilman (1970) and Brown et al., (1971) are two well known examples of these so-
called saturation binding assays. 
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Cyclic AMP assay kits are commercially available but the method by Brown et ai., (1971) was 
favoured by our laboratory. Modipane et al., (1985) compared the efficiency, cost and working time 
between the commercial cAMP kit and the published laboratory method. The authors found the 
method by Brown et al., (1971) had far greater advantages compared to the commercial kit, 
particularly with regard to cost since it was adaptable to tissues other than the pineal gland. Hence 
because of ever-increasing costs of biochemicals and the price of commercially available cyclic 
AMP kits, the method of Brown et ai., (1971) was used. 
3.1.2 Theory of the Assay 
The assay is based on the competition between unlabelled cAMP and a fixed quantity of the tritium 
labelled compound for binding to a protein which has a high specificity and affinity for cAMP. The 
amount of eH]-cAMP bound to this protein is inversely related to the amount of cAMP present in 
the assay sample. The amount of unlabelled cAMP in the sample is calculated by measurement of 
the protein-bound radioactivity. Separation of the protein-bound cAMP from the unbound nucleotide 
is achieved by centrifugation. The supernatant (which contains the protein-bound complex) is added 
to scintillation cocktail and its activity determined by liquid scintillometry. The concentration of 
unlabelled cAMP in the sample is then determined from a linear standard curve. 
3.2 
3.2.1 
3.2.1.1 
CYCLIC-AMP DETERMINATION TECHNIQUE 
Materials and Methods 
Chemicals, Drugs and Reagents 
[3H] Adenosine 3'5 '-cyclic phosphate, ammonium salt (specific activity 30 Ci/mmol) was purchased 
from Amersham, England; and the activated charcoal from Merck, Germany. Theophylline, bovine 
serum albumin, cyclic AMP and phosphodiesterase were obtained from Sigma Chemical Co., USA. 
The chemicals used in buffers were of analytical grade from commercial sources. 
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3.2.1.2 Animals 
Male Wi star rats (200-250g.b.wt) were housed five per cage in a temperature controlled room under 
a fixed lighting cycle of LD12:12 (lights on 06hOO) with food and water ad libitum. The rats were 
sacrificed between 10h30 and 11h30, maintaining uniformity with previous studies. 
Male rats were chosen for the cAMP studies because they tended to be less anxious when handled, 
than the female rats. It was therefore felt that their cAMP levels would more accurately reflect the 
drug treatment, rather than exogenous stress influences. Skene (1985) has reported higher basal 
cAMP levels in female rats, which she ascribed to their more anxious nature. 
3.2.1.3 Pineal Glands 
The pineal glands were rapidly removed and transferred to prewarmed (37°C) BGJb culture medium 
(Fitton-Jackson modification). 
3.2.1.4 
3.2.1.4 
Assay of cAMP in Rat Pineal Glands 
(0 Collection and Preparation of Binding Protein 
Bovine adrenals glands were collected from the local abattoir as soon after slaughter as possible 
and transported to the laboratory on ice. The cortices were separated from the medullas, chopped 
and homogenized in a glass homogenizer using 1.5 volumes of an ice-cold medium comprising of 
0.25M sucrose; 50mM Tris Hel buffer, pH7.4; 25mM potassium chloride and 5mM magnesium 
chloride. The homogenate was centrifuged in a Hettich Universal 25 centrifuge at 2000 x g for 10 
minutes at 4°C. The pellet was discarded and the supernatant respun at 5000g for 15 minutes at 
4°C. The resulting supernatant was stored in 1ml eppendorf tubes at -20°C. A negligible loss of 
binding activity was found after at least 3 months of storage. The preparation, which contains a 
binding protein (protein kinase), was thawed and diluted as required with 50mM Tris-HO buffer, 
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pH7.4 containing 8mM theophylline and 6mM 2-mercaptoethanol. This buffer was used for all 
subsequent procedures. The stored protein remained stable for the duration of this study. 
3.2.1.4 (ij) Dilution of the Binding Protein 
In order to determine the optimum dilution of the stock binding protein for the cAMP assay, 
aliquots of binding protein was thawed and diluted with an appropriate volume of cyclic AMP 
protein diluting buffer. Serial dilutions of binding protein in buffer were assayed for radioactivity 
by following the zero dose column in Table 3.1 of the scheme for the cAMP assay of Brown et 
al., (1971) and adding dilutions of binding protein. A protein dilution curve Figure 3.1, thus 
obtained shows that a 1:3 dilution provides optimum binding (85%) and radioactivity counts. This 
dilution factor was thus used in all subsequent cAMP assays with this particular batch of stock 
protein. Each time a new batch of binding protein was prepared a new dilution curve was 
determined. However a 1:3 dilution was found to be appropriate for all batches tested in this way. 
The method of Lowry et al., (1951) for determination of protein in biological samples was used. 
A simple protocol for this method using bovine serum albumin as a standard is outlined in Table 
3.2. Figure 3.2 shows the protein standard curve obtained by this Folin Lowry method. 
Briefly, a series of tubes were prepared for the Folin Lowry method which included: (1) a blank 
containing 1.0ml H20; (2) a set of standard tubes each containing appropriate aliquots of water and 
a protein standard solution (eg. Img BSAjml) that will yield separate tubes containing 50, 100, 150, 
200, 250 and 300 pg of protein, all in final volumes of 1.0ml, and (3) a set of assay tubes 
containing water and appropriate dilutions of the protein solution of unknown concentration (eg. 
0.025 and O.OSml of the unknown) plus water up to 102ml. Separately prepare 100mI of fresh 
alkaline copper reagent by mixing, in order, Iml of 1 % CuS04 05H20, Iml of 2% sodium tartrate 
and 98ml of 2% N~C03 in O.lN NaOH. Add, and immediately mix in , 6ml of alkaline copper 
reagent to each tube. After 10 minutes at room temperature add, and immediately mix in, 0.3ml of 
Folin-Ciocalteu reagent to each tube. After 30 more minutes, read the absorbance of the standard 
and assay tubes at 500nm against the blank. 
76 
TABLE 3.1 Scheme of the cyclic AMP assay (Brown et at. 1971) 
cAMP standards Blank 0 0.25 0.5 1.0 2.0 4.0 8.0 Sample 
(pmol) 
Buffer * O.l.l) 250 150 150 150 150 150 150 150 150 
III Standard - - 12,5 25 50 - - - -
(1:10) 
III Standard - - - - - 10 20 40 -
(as is) 
Sample (Ill) - - - - - - - - 50 
Distilled 50 50 37,S 25 - 40 30 10 -
water (Ill) 
[3H ] -cAMP (Ill) 50 50 50 50 50 50 50 50 50 
Vortex briefly 
III diluted - 100 100 100 100 100 100 100 100 
protein 
Mix gently to avoid frothing 
Incubate on ice for 100 minutes or in a cold room at 4°C 
Charcoal (Ill) 1100 1100 1100 1100 1100 1100 1100 1100 1100 
Vortex briefly 
Centrifuge at 1200 x g for 15 minutes at 4°C 
Supernatant 100 100 100 100 100 100 100 100 100 
(Ill) 
Carefully remove 100 III of the supernatant. 
Add supernatant to 3ml scintillation fluid and count radioactivity 
.. Tris HeI (50 mM, pH 7.4) containing 8 mM theophylline and 6 mM 2-mercapto ethanol. 
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Figure 3.1: A typical protein dilution curve obtained in these experiments_ Each point represents the mean 
of duplicate determinations. 
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TABLE 3.2 Scheme for the determination of protein (LoWry et at. 1951) 
* 
Protein 
Concentration Blank 50 100 150 200 250 
<!-lg/ml) 
Protein 
Volume 0 0,05 0,1 0,15 0,2 0,25 
(ml) 
Distilled 
Water (ml) 1 0,95 0,9 0,85 0,8 0,75 
Alkaline * 
Copper 6 6 6 6 6 6 
reagent 
(ml) 
Stand : 10 minutes at room temperature 
Folin- 0,3 0,3 0,3 0,3 0,3 0,3 
Ciocalteu 
reagent (ml) 
Total (ml) 7,3 7,3 7,3 7,3 7,3 7,3 
Stand: 30 min at room temperature 
Read absorbance oj the standard and assay 
tubes at 500 nm against the blank. 
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Figure 3.2: Protein standard curve (Folin Lowry method). Each point represents the mean of duplicate 
determinations. 
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3.2.1.5 Preparation of Pineal Tissue and Incubation Procedure 
Pineal glands were rapidly removed and immediately placed in ice-cold physiological saline (0.9%). 
Pineals were then dissected free of adhering connective tissue. The pineals were then placed in 2ml 
of fresh prewarmed BGJb incubation culture medium (Filton-Jackson modification, Gibco (Europe) 
[2.3.1.2] and incubated at 37°C for 20 minutes. Following incubation the pineals were removed 
from the medium and homogenized in 100p1 ice-cold cAMP protein diluting buffer. Duplicate 
aliquots (50pl) of pineal homogenate was transferred to reaction tubes and was used in the cAMP 
assay. 
3.2.1.6 Cyclic AMP Assay 
A simplified schematic representation of the saturation binding method of Brown et al., (1971) is 
presented in Table 3.1. Each reaction tube contained SOpl of either a known amount (0-8pmol) of 
cAMP standard (Boehringer Mannheim) or of an unknown sample, 50p1 of eH] cAMP (8nCi), 
1000).11 of diluted (1:3) binding protein and buffer (50mM Tlis-HCl, pH7.4 containing 8mM 
theophylline and 6mM 2-mercaptoethanol) to a final volume of 350pl. The reaction tubes were 
placed on ice and incubated at 4°C for 100 minutes. Following incubation, 100pl of a 10% w/v 
suspension of charcoal in buffer containing 2% w/v of bovine serum albumin was added to each 
retention tube and the tubes were vortexed for 10 seconds, each on a Rotamixer Deluxe. 
The charcoal was prepared by dissolving 400mg Bovine Serum Albumin (BSA) in 20ml of protein 
diluting buffer together with 2g of activated charcoal. After centrifugation at 1200 x g for 15 
minutes at 4°C, a lOOpl aliquot of the supernatant was added to plastic scintillation vials containing 
3ml Ready-Solv HP (Beckman USA) scintillation fluid. The vials were briefly agitated on a Griffith 
flask shaker for 15 minutes and the radioactivity quantitated in a Beckman LS 2800 liquid 
scintillation counter at an efficiency of 61.12%. 
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3.2.1.7 Statistical Analysis 
Cyclic AMP levels - the mean of duplicate detenninations - were detennined from the cAMP 
standard curve and expressed as pmol/pineal ± SEM. For each drug group the cAMP levels in those 
glands were compared to those of the control. The significance was evaluated using a One-Way 
ANOVA followed by Neuman-Keuls Multiple Range test. 
3.2.2 Results 
3.2.2.1 Calibration Curve 
A calibration curve was set up for each assay and were plotted using the data obtained from the 
standard amounts of cAMP added to the tubes as outlined in Table 3.1. The amounts of unknown 
cAMP in samples were detennined by reference to such curves. A typical cAMP calibration 
standard curve is given in Figure 3.3. The calibration curve was calculated in tenns of the ratio 
Co/Cx against the concentration (pmoles/tube) of standard nucleotide. The Co/Cx ratio was obtained 
by dividing the radioactivity (cpm) of the zero standard (Co) by the radioactivity of the higher 
standards (Cx) after subtraction of blank values. 
Co = mean cpmzero standard - mean cpmBlank 
or for samples 
Cx = mean cpmstandard 
Cx = mean cpmsarnple 
3.2.2.2 Validation of Results 
- mean cpmBlank 
- mean cpmB1ank 
(i) After addition of tracer quantities of eH]-cAMP, BSA coated activated charcoal was added 
to the tubes. Assay of the supernatant showed all tracer had been removed. 
5~-------------------------------------------------------. 
4 
3 
2 
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Figure 3.3: A typical cAMP calibration standard curve. Each point represents the mean of duplicate 
determinations. 
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(ii) Known quantities of standard cAMP were added to the tubes containing zero added cAMP. 
These were placed among the normal assay tubes, and the results from these were tested 
to determine whether they agreed with the calibration CUlVe. 
3.2.3 Discussion 
The results presented indicate that the assay procedure described above is sufficiently sensitive and 
specific to measure cAMP levels in rat pineal tissue. In addition, the assay is considerably simpler 
than the method of Brown et ai., (1971) since it allows for the direct quantification of cAMP levels 
in pineal homogenates without prior trichloroacetic acid precipitation and ether extraction. The assay 
was therefore suitable for use in subsequent studies. 
3.2.4 Problems Encountered with cAMP Assay 
A series of problems were experienced when carrying out the cAMP assay by saturation binding 
method of Brown et ai., (1971). Adrenals were collected from the abattoir on two occasions, Batch 
1 was collected three months earlier than Batch 2. It was disturbing to note the low counts per 
minute and the narrow range of the standard calibration CUlVe for both batches. This reduces the 
sensitivity of the assay and diminishes the accuracy in reading the results off the CUlVe. 
To establish the cause of the low counts per minute the following avenues were investigated: 
(i) The possibility that in separating out the cortices, some adrenal medulla remained, 
contaminating the cortices by releasing an unknown factor which disrupts and interferes 
with the binding protein. Careful removal of adrenal medulla took place on both occasions 
so the possibility of this being a factor was discarded. 
(ii) Another possibility was that the binding protein was defective or damaged in some way 
resulting in inefficient binding of radiolabelled cAMP. This too would explain some of the 
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low counts per minute. Calibration curves done on Batch 1 and 2 indicate similar ranges 
and counts suggesting some other factor acting on the protein could possibly be the cause. 
(iii) Another possibility is that the chemicals used in the assay were defective. The charcoal for 
example is required to strip extracellular proteins and unbound radiolabelled and non 
radiolabelled cAMP from the homogenate which leaves the binding protein with the cAMP 
attached to it in the supernatant. This process is essential in removing unbound 
radiolabelled cAMP which would otherwise interfere with scintillation readings. For this 
purpose activated charcoal from Merck, Germany is needed, not the neutral type which 
would be unable to bind the protein. The type of Bovine Serum Albumin (BSA) used is 
also important. BSA is used to saturate the assay homogenate medium in order to prevent 
charcoal from removing the binding protein. Whole BSA obtained from Sigma in 
crystallized form is used, not BSA Fraction V since it does not bind to the charcoal 
properly. The chemicals used were double-checked and found to be all correct and in so 
doing removed the possibility of it being the contributing factor to the low counts obtained. 
(iv) The possibility of high endogenous cAMP in the protein homogenate was then suspected 
which would shift the equilibrium of the radiolabelled and non radiolabelled cAMP binding 
to the protein. More non-radiolabelled cAMP could be present due to circulating 
endogenous cAMP, displacing the radioactive cAMP from the binding protein resulting in 
low cpm's. In an attempt to remove endogenous cAMP a purification step was carried out 
in order to remove it. Protein homogenate and charcoal were mixed together in a ratio of 
1:1 in Eppendorftubes and vortexed. Centrifugation occurred at 1200g for 15 minutes. The 
'purified' supernatant was then subsequently removed and used in the cAMP standard curve 
assay. The supernatant was diluted 1:3 and lOOpl of the dilution was removed and used in 
the assay. 
The purification step using charcoal produced a marked increase in binding. This provides strong 
evidence that endogenous cAMP was the possible factor contributing to the low binding. Batch 1 
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protein was compared with Batch 2 using the purification step and it was found that the counts 
were similar as well as being relatively high with a much wider range than before. 
Thus in modifying the cAMP assay of Brown et ai., (1971), a unique relationship may be 
speculated to occur between endogenous cAMP and the physiological state of the animal. It is well 
known that during stress, catecholamines such as noradrenaline and adrenaline are released from 
the adrenal medulla. These possibly stimulate beta receptors in the adrenal cortex activating the 
enzyme adenylate cyclase which in turn causes an increase in the synthesis of cAMP from ATP. 
Hence high endogenous cAMP may be associated with the method of slaughter where it appears 
that the animal undergoes a great deal of stress resulting in increased levels of endogenous cAMP. 
3.3 Experiment TO DETERMINE THE EFFECT OF 
ACETYLCHOLINE ON PINEAL cAMP 
3.3.1 Introduction 
The possibility exists that the cholinergic system may influence cAMP levels without acting through 
the adrenergic system resulting in NAT enzyme activation and an increase in aHT levels. The aim 
of the experiment is to establish whether the cholinergic agonist acetylcholine is able to influence 
cAMP levels in any way. 
3.3.2 Materials and Methods 
3.3.2.1 Materials 
All reagents used were of analytical grade from commercial sources. Isoproterenol and acetylcholine 
chloride were obtained from Sigma Chemical Co., USA. Sources of all other materials have been 
recorded in [3.2.1.1]. 
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3.3.2.2 Method 
A cAMP standard curve was constructed, and calibration curves were plotted Co/Cx against 
standard cAMP pmol/tube. Five rat pineals were exposed to isoproterenol (ISO){1O-4M), another 
five to acetylcholine (ACh)(l0-4M), and a further five pineals to a combination of isoproterenol 
(l0-4M) and acetylcholine (l0-4M) (ISO+ACh) with a 20 minute incubation time period. The cAMP 
saturation binding assay of Brown et ai., (1971) with modifications, was used [3.2.1.4]. The 
significance was evaluated using a One-Way ANOVA followed by Neuman-Keuls Multiple Range 
test. 
3.3.3 Results 
The average cpm for each of the three treatment groups is shown in Table 3.3 The pineals treated 
with acetylcholine (lO-4M) showed a significant increase when compared to the controls (p<O.OOOl). 
Acetylcholine was also found not to influence ~e isoproterenol induced rise in cAMP levels 
(p<O.OOOl) (Figure 3.4). 
3.3.4 Discussion 
The organ culture results [2.5.3] show that acetylcholine causes a significant rise in aHT levels 
without altering aMT levels significantly. By using hexamethonium, a ganglion blocking agent, the 
nicotinic receptor sites were blocked and this resulted in aHT levels still rising. When an 
antimuscarinic agent atropine was used, the rise in aHT was successfully blocked suggesting the 
presence of muscarinic cholinergic receptors in the pineal gland. 
The results shown from Table 3.3 of the cAMP assay reveal that the presence of acetylcholine 
caused a significant increase in cAMP levels in the pineal glands (p<O.OOOl). The rise in cAMP 
levels caused by isoproterenol was not affected in any way by the presence of acetylcholine. Hence 
the cholinomimetic agent, acetylcholine, influences the sympathetic pathway in a significant manner 
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Table 3.3 Cyclic AMP formed per rat pineal gland in the presence of 
vehicle or when stimulated with acetylcholine (ACh) (lO·4M), 
isoproterenol aSO) (lO·4MJ. and a combination of the two drugs tACh + 
ISO) (1 U4M) (mean :t: SEM; n=5 glands per group). 
Treatment cAMP formed 
(pmol/20min/pineal gland) 
Control 1,815 ± 0,136 
ISO 3,387 ± 0,138 * 
ACh 2,667 ± 0,153 * 
ISO + ACh 3,516 ± 0,388 * 
In comparison with respect to vehicle control p<"O,OOOl (One-Way ANOVA 
followed by a Neuman-Keuls Multiple Range test) 
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Figure 3.4 Cyclic AMP formed per rat pineal gland in the presence of vehicle or when stimulated with 
acetylcholine (ACh)(10-4M), isoproterenol (ISO)(1O-4l\/!) and a combination of the two drugs (ACh + ISO) 
(10-4) (mean ± SEM; n=5 glands per group; p<*O.OOOl with respect to vehicle control: One-Way ANOVA 
followed by a Neuman-Keuls Multiple Range test). 
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with regard to cAMP. Noradrenaline is known to act by increasing intracellular cAMP in the pineal 
(Strada et al., 1972; Deguchi and Axelrod, 1973) which in tum induces and activates the enzyme 
N-acetyltransferase (Klein and Berg, 1970; Klein and Weller, 1973). The rise in aHT (a precursor 
of aMT) due to the presence of acetylcholine in the organ culture studies [2.5.3] could be 
speculated to be caused by the stimulation of the adrenergic beta receptors resulting in the 
conversion of A TP to cAMP. 
Another hypothesis that could be examined is the supply of acetate for acetylation of serotonin to 
melatonin. In the acetylation of serotonin to N-acetylserotonin, acetyl CoA is utilized. The 
adrenergic-cAMP mechanism regulates the activity of the pineal enzyme NAT. Cyclic-AMP 
stimulates the synthesis of specific new macromolecules, RNA and protein required for the 
stimulation of NAT (Klein and Weller, 1970). The NAT enzyme mainly acts in transferring an 
acetyl group from the co-factor acetyl CoA to acceptor amines and is responsible for the formation 
of N-acetylserotonin in the melatonin biosynthetic pathway (Axelrod, 1974). The possibility does 
exsist that acetylcholine could provide the acetate necessary for acetyl CoA formation, hence 
increasing acetyl group transfer and raising NAT activity. This could be another possible 
mechanism by which acetycholine increases aHT levels. The activity of the enzyme H10MT would 
hence not increase to produce a rise in melatonin levels since the enzyme is only able to transfer 
methyl groups from cofactor S-adensyl methionine to acceptor S-hydroxyindole molecules for 
conversion of aHT to aMT. 
4.1 Introduction 
CHAPTER 4 
cAMP-PHOSPHODIESTERASE STUDIES 
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The regulation of many biological functions are under the control of cyclic nucleotides (Robison 
et al., 1968) and their intracellular concentrations are delicately controlled (Teo et ai., 1973). The 
generation and quenching of the signal in any informational system must be considered equal. The 
biological actions of these cyclic nucleotides are terminated by the hydrolytic cleavage ofthe cyclic 
nucleotides to their corresponding 5'-nucleotides. This is the only mechanism by which termination 
of the biological actions of these nucleotides occur and they are catalysed by one or more types of 
phophodiesterase. Hence these cyclic nucleotides, which play a primary role in the control of 
intracellular events, are hydrolyzed and inactivated as second messengers by the cyclic nucleotide 
phosphodiesterases (PDE's). 
The presence of phosphodiesterase was first demonstrated by Sutherland and RaIl (1958). Butcher 
and Sutherland were able to partially purify the enzyme from bovine heart in 1967 and three years 
later in 1970, Kakiuchi and Yamazaki were able to show that rat brain phosphodiesterase could be 
inhibited by EGTA [ethyleneglycol-bis-(~-aminoethylether)-N,N,N',N',-tetraacetic acid]. Cheung 
(1970) noted a percipitous drop in activity relative to his starting product after he passed the 
enzyme through an anion exchange column in order to purify it and enable better characterization. 
He found this to be due to dissociation of an activator protein from the enzyme. In independent 
studies Kakiuchi et ai., (1970) also demonstrated the presence of an activator. Teo and Wang 
(1973) were able to show that the activation of PDE was dependent on the presence of both the 
activator and Ca2+. This activator protein has since been named calmodulin (Cheung, 1980). 
These phosphodiesterase enzymes have been extensively studied in the brain and other tissue, and 
numerous assays have been devised to monitor their activity. The most widely used of these assays 
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are radiometric and involve the separation of the hydrolyzed 5' - nucleotide phosphate product from 
the substrate. The separation of the hydrolyzed radioactive product has been achieved in a number 
of ways, including batch or column anion exchange resin (Thompson and Appleman, 1971; Lynch 
and Cheung, 1975), paper chromatography (Nakai and Brooker, 1975) and precipitation (Le Donne 
and Coffee, 1979). These assays are all sensitive, relatively inexpensive and easy to use. 
The batch method of Thompson and Appleman (1971) is popular because of its simplicity and 
economy of time. The method makes use of anionic exchange resin which presumably binds the 
unreacted cAMP (which carries a negative charge) but not the adenosine (which has no net charge). 
However Lynch and Cheung (1975) have shown that this method may underestimate the true 
cAMP-PDE activity, as the resin may sometimes npt bind all the unreacted substrate. They feel that 
the column methods under certain circumstances may produce the same error. 
The method of LeDonne and Coffee (1979) which employs a precipitation (ppt) technique, has been 
used in this laboratory and thin layer chomatography (TLC) method of Neuman (1983) was used 
for separation. 
4.1.1 Summary of Assay 
In this method cAMP and tritiated cAMP (tracer) are used as substrates. Pineal tissue homogenate 
is then added and the phosphodiesterase present in the homogenate hydrolyzes the cAMP substrate. 
The reaction is then terminated by the addition of trichloroacetic acid. An aliquot of the reaction 
mixture is spolled onto a TLC plate and the 5' AMP is then quantitated to be used as an indicator 
of PDE activity. 
4.2 
4.2.1 
4.2.1.1 
CYCLIC-AMP PDE DETERMINATION TECHNIQUE 
Material and Methods 
Chemicals, Drugs and Reagents 
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[8-3H] Adenosine 3',5'-cyclic phosphate, ammonium salt (21,2 Ci/mmol) was purchased from 
Amersham, England. Adenosine 3',5' - cyclic phosphate and Adenosine 5' -monophosphate were 
obtained from Boehringer Mannheim, Germany. TLC plates (Alugram Sil G/ UV 254 0.025 x 20 
x 20 cm) were obtained from Macherey-Nagel, West Germany. The solvents used for TLC and 
chemicals used in buffers were of analytical grade from commercial sources. 
4.2.1.2 Animals 
Male albino Wistar rats (200-280g.b.wt) were housed five per cage in a temperature controlled 
room under a fixed lighting cysle of LD12:12 (lights on 06hOO) with food and water ad libitum. 
The rats were sacrificed by neck fracture between 10h30 and llh30, to maintain uniformity with 
previous studies. 
4.2.1.3 Pineal Glands 
Pineal glands for cAMP-PDE determinations were swiftly removed as before [2.3.1.2] and placed 
in culture vessels containing 200 pI BGJb culture medium. Five pineal glands were transferred to 
each vessel. 
4.2.1.4 
4.2.1.4 
Assay of cAMP-PDE in Rat Pineal Glands 
(i) cAMP-PDE Assay 
Five pineal glands were exposed to vehicle (control glands) while the remaining five glands were 
stimulated with the drug. These groups were incubated together with 200ml BGJb culture medium 
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at 37°C. The pineals were then removed from the vessels and each pineal gland was transferred to 
its own homogenization tube, for the measurement of cAMP-PDE activity as described below. The 
scheme for the cAMP-PDE assay is summarized in Table 4.1. 
TABLE 4.1 Scheme for the cAMP - PDE assay (Neuman. 1983) 
Reaction vessel Blank 
Buffer 20)l1 30)l1 
cAMP (l)lM) lO)ll lO)ll 
[3H ] - cAMP lO)ll lO)ll 
Pineal homogenate lO)ll -
Incubate at 37°C Jor 30 minutes 
Add 30 Jl1 oj a 10% TCA 
Spot 10 Jl1 onto TLC plates 
The pineal glands were individually homogenized in lOOp! buffer (40pM Tris-HCl, pH8; 5pM Mg 
C12). A lOpl aliquot of pineal homogenate was rem'oved and transferred to a reaction tube. It was 
incubated at 37° with 1pM cAMP, 3 x105 cpm eH] cAMP and buffer (final volume 50P!). The 
reaction stopped after 30min by the addition of 30pl of 10% trichloroacetic acid (TCA) and the 
eHJ-5' -AMP formed was separated from the [3H] cAMP remaining on thin layer chromatography 
(TLC) plates, using a solvent system containing isopropyl alcohol, 25% water of NH40H and water 
(7:1:2). 
4.2.1.4 (ii) Thin Layer Chromatography 
10pl aliquots of each sample was spotted in duplicate 15mm from the bottom of the plates. and in 
the centre of 15mm wide channels inscribed on the silica gel TLC plates. The mobility of cAMP 
and 5'AMP was monitored routinely by spotting lOpI aHquots of standard solutions containing 
O.2mg/ml authentic cAMP or 5'-AMP, dissolved in distilled water, in adjacent channels near one 
end of the plate. Following development of the plates (± 2 hours), the plates were dried under a 
gentle stream of nitrogen, then placed in a oven at 60°C (lOmin) to dry the plates. 
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4.2.1.5 Quantitation 
Visualization of these markers was accomplished under short wave ultraviolet light. The 
radioactivity in the identified spots was determined by scraping off the spots into a scintillation vial 
containing 400pl O.OlM KOH (Beckman Information Brochure). 
After the KOH had solubilized the scrapings, 3ml of scintillation cocktail (Beckman Ready-Solv 
HP/b) was added to the vials. These were then shaken on a Griffith Flask shaker for 20 min. after 
which the vials were placed in a Beckman LS 2800 scintillation counter and each vial was counted 
for a total of 5 minutes. 
4.2.1.6 Data Analysis and Statistics 
The mean dpm's were determined for each sample. Blanks were run in exactly the same way except 
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that TCA was added to the tubes before tissue was included. Thompson et ai,. (1974) described 
several factors which could influence blank values. These authors suggest that the method of 
terminating the reaction by boiling for 2 minutes could possibly increase blanks in tritium based 
assays, apparently due to formation of tritiated water. Wells and Hardman (1977) suggest that the 
construction of the appropriate blanks is best achieved by the addition of the stopping mixture prior 
to the addition of tissue and they reported that this should equal blank values. 
Blank values, which were very low, were first subtracted from the results before these were finally 
expressed as nmol cAMP hydrolyzed/30 min/pineal gland. 
4.2.1.7 Statistical Analysis 
Cyclic-AMP PDE levels (the mean of triplicate determinations) for the assays are expressed as nmol 
cAMP hydrolyzed/30 min/pineal gland. The significance between those glands stimulated with drug 
and control glands was evaluated using the two-tailed Student's t-test. 
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4.2.2 Results and Discussion 
The radioactivity being applied to the TLC plates was checked to detennine if it was being 
recovered in order to validate the assay. In order to assess the recovery of cAMP from silica gel 
TLC plates in the assay system, sample tubes were made up containing the equivalent amounts of 
reaction mixture that they would have contained under assay conditions. The TCA was added first 
to inactivate any PDE in the pineal tissue homogenate used. Aliquots (10pl) were then removed 
from these sample tubes and applied to TLC plates, either before or after development, or directly 
to scintillation vials. The quantitation and counting procedures were then followed as described 
above I4.2.1.5]. 
The radioactivity remaining at the origin or at the 5' AMP region was negligible in the TCA blanks 
with the major radioactivity being recovered at the eH]-cAMP region, thus validating this assay. 
4.3 Experiment: TO DETERMINE THE EFFECT OF PHYSOSTIGMINE 
ON PDE ACTIVITY 
4.3.1 Introduction 
The relative rate of fonnation and degradation of the cyclic nucleotides detennine the steady state 
levels of these compounds. Robison et ai., (1971) proposed that inhibition of cAMP-PDE should 
potentiate the effect of honnones acting via cAMP and has often been used in attempts to 
demonstrate cAMP involvement in a honnone response (Wells and Kramer, 1981). Alternatively 
the opposite is true, that by demonstrating cAMP potentiation in the presence of the honnone is due 
to cAMP-PDE inhibition. The cAMP studies I3.3.3] showed that a cholinomimetic agent 
acetylcholine increased cAMP levels significantly. In this study the anticholinesterase physostigmine 
was used to investigate whether the drug has any effect on the cyclic AMP-PDE activity. 
4.3.2 
4.3.2.1 
Materials and Methods 
Materials 
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Physostigmine was purchased from Sigma Chemical Co., USA. Sources of all other materials were 
recorded in [4.2.1.1]. 
4.3.2.2 Animals 
Male Wi star rates (200-280g.b.wt) were used in this study. Their living environment has been 
described in [2.3.1.2]. The rats were sacrificed by neck fracture between lOh30 and Ilh30. This 
was at the same time as in other studies thus maintaining uniformity. 
4.3.2.3 Method 
After decapitation, pineals were swiftly removed aseptically as before in [2.3.1.2] and placed in 
culture vessels containing BGJb culture medium at 37°C in an atmosphere of 5%C02:95%02 
(carbogen). Five pineal glands were transferred to vessels containing vehicle in the case of the 
control, and a further five to vessels containing physostigmine (IO,sM) drug in the other. The 
vessels contained a final incubation volume of 200pl. After a 3 hour incubation period at 37°C the 
pineals were removed from the vessels and each transferred to its own homogenization tube 
containing "cAMP-PDE buffer". The cAMP-PDE activity was then assayed as described above 
[4.2.1.4]. The significance was evaluated using Student's t-test. 
4.3.3 Results 
Physostigmine caused a significant increase in PDE activity (p<O.05) when compared to the 
controls (Table 4.2 and Figure 4.1). 
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TABLE 4.2 Cyclic AMP-phosphodiesterase activity per rat pineal gland 
in the presence of vehicle or physostigmine (10-5M) {mean :t SEMi n=5 
glands per group. 
Treatment CAMP hydrolyzed 
(nmol/30min/pineal gland) 
Control 83,65 ± 23,27 
Physostigmine 129,85 ± 37 128* 
,. In comparison with respect to the vehicle control, p < *0.05 (Student's t-test). 
4.3.4 Discussion 
The anticholinesterase physostigmine caused an increase in phosphodiesterase activity (p<O.05). In 
parallel experiments, organ culture studies [2.7.3] showed an increase in aHT and not aMT. In 
cAMP studies [3.3.3] cholinomimetic agent acetylcholine caused a significant rise in cAMP levels. 
It is a well known finding that the rise in intracellular concentration of cAMP is coupled to a 
corresponding increase in its regular CAMP-phosphodiesterase (PDE) (Oleshansky and Neff, 1975). 
It may be thus speculated that an increase in cAMP occurs due to cholinergic agents with a 
concomitant rise in PDE activity levels. In so doing these drugs may possibly induce a rise in NAT 
activity and aHT levels. 
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Figure 4.1 Cyclic AMP - Phosphodiesterase activity per rat pineal gland in the presence of vehicle or 
physostigmine (lO-5M) (mean ± SEM; n=5 glands per group; p<*O.05 Student's t-test) 
5.1 Introduction 
CHAPTER 5 
N-ACETYLTRANSFERASE STUDIES 
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The honnone melatonin, isolated by Lerner et at., (1958) is produced in the pineal gland by 0-
methylation of N-acetylserotonin (Axelrod and Weissbach, 1960). The enzyme responsible for 0-
methylation in the pineal, hydroxyindole-o-methy~transferase, can only utilize serotonin one tenth 
as efficiently as it can N-acetylserotonin implying that N-acetylation preceeds O-methylation 
(Axelrod and Weissbach, 1960). Serotonin has shown to be N-acetylated to N-acetylserotonin in 
vivo (McIsaac and Page, 1959) and this reaction is catalyzed by an N-acetyltransferase enzyme 
(Weissbach et aI., 1960). 
Investigations carried out in rat pineal glands have shown that the release of noradrenaline from the 
nerve tenninals innervates the gland and regulates N-acetyltransferase activity (Klein et aI., 1981a; 
Moore and Klein, 1974; Klein and Moore, 1979; Brownstein and Axelrod, 1974). The release 
causes B receptor stimulation leading to an elevation of intracellualar cAMP (S~rada et ai., 1972; 
Deguchi and Axelrod, 1973). The elevated cAMP levels stimulates a series of protein 
phosphorylations (Morgan et at., 1988) which induces the activity of the arylalkylamine N-
acetyltransferase (NAT), the rate limiting enzyme in the conversion of serotonin to melatonin (Klein 
et at., 1981a). The 0<:- and /3-receptors playa crucial role in the mechanism by which NA controls 
cAMP. Sugden and Klein (1984) confinned the presence of o<:-receptors in the pineal gland. 
Noradrenaline has been found to regulate cAMP and cGMP through an unusual synergistic 
mechanism. Both cAMP and cGMP are increased through /3-adrenoceptor stimulation whilst 0<:-
adrenoceptor stimulation of the pineal gland alone produces no detectable change in the levels of 
these two nucleotides (Vanacek et at., 1986). 
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The a-adrenoceptor stimulation does however amplify the ~-adrenoceptor response by potentiating 
the accumulation of cAMP and cGMP (Klein et a!., 1983; Vanacek et ai., 1985; Klein, 1985). Beta-
adrenergic activity sufficient for the induction of NAT (Klein, 1978; Zatz, 1982) has been shown 
to be potentiated by a-adrenoreceptor stimulation (Klein et ai., 1983) although the effect is not as 
pronounced as that seen with cAMP levels (Illnerova et ai., 1983; Klein, 1985; Illnerova, 1985). 
Before the development of the very sensitive radioimmunoassays for melatonin the most common 
indication of pineal function and especially of melatonin production were the activities of NAT 
(Klein and Weller, 1970) and HIOMT (Wurtman et ai., 1963b). NAT was thought to be the rate 
limiting enzyme in melatonin formation (Klein and Weller, 1970; 1973) since it had been shown 
to best correlate with melatonin production (panke et al., 1978; Wilkinson et ai., 1977; Morton, 
1987). 
The accumulation of some evidence shows that NAT activity does not always mirror the production 
of melatonin. By subjecting rats to stress produces varied NAT results in comparison to melatonin 
(Seggie et ai., 1985; Vollrath and Welker, 1988). The pineal appears to modulate the body's 
response to stress via a mechanism involving the release of melatonin. 
Tannenbaum et ai., (1988) supported this by demonstrating decreased NAT levels in the presence 
of raised aMT. Kahn et ai., (1990) have demonstrated that gastric ulcers induced by cold stress are 
reduced in the presence of melatonin. 
5.1.1 Theory of the Assay 
Deguchi and Axelrod (1972a) have developed a radiochemical method of assaying serotonin N-
acetyltransferase and is based on the acetylation of tryptamine with radioactive acetyl coenzyme 
A by NAT to form radioactive N-acetyltryptamine. Tryptamine is used in place of the natural 
substrate 5-hydroxytryptamine as the enzyme can utilize it far more readily than 5-
hydroxytryptamine. The radioactive N-acetyltryptamine thus formed can be extracted into an 
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organic solvent and measured by liquid scintillometry. The use of this assay permits a rapid and 
sensitive evaluation of NAT activity and also enables a more accurate interpretation of any 
pharmacological effects on the enzyme (Deguchi and Axelrod, 1972a). 
In the sections that follow the method of Deguchi and Axelrod (1972a) with minor modifications, 
is described. 
S.2 
S.2.1 
S.2.1.1 
NAT ASSAY TECHNIQUE 
Materials and Methods 
Animals 
Adult male Wistar rats (200-250g) were used. The animals were maintained under normal 
laboratory conditions as detailed in [2.3.1.2]. Ilnerova (1975) showed NAT in rats to be insensitive 
to oestradiol treatment. Hence female albino Wistar rats may be used throughout the NAT studies 
as NAT, unlike HIOMT, has been shown not to be influenced by the various stages of the estrus 
cycle (Cardinali and Vacas, 1978). Male rats were however used to maintain uniformity with 
previous studies. 
The rats were sacrificed between lOh30 and llh30 by neck fracture. This was done to avoid 
possible interference with ~-receptor sensitivity changes. It is well known that the increase on NAT 
activity following adrenergic stimulation is dependent on the time of day (Romero and Axelrod, 
1974). The ~-receptors show down regulation after the full stimulation of the night, a rhythm in 
receptor density which is well documented (Reiter et al., 1985; Gonzalez Brito et aI., 1988; Santana 
et al., 1988). 
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5.2.1.2 Chemicals and Reagents 
Batches of tritiated acetyl coenzyme A (specific activity 3.9 Ci/mmol) were purchased, as required, 
from Amersham Laboratories (England); Tryptamine-HCl and l-isoprenaline-HCl from Sigma 
Chemical Co. (USA); and unlabelled acetyl coenzyme A from Boehringer Mannheim (Germany). 
All other chemicals and reagents were obtained from local commercial sources and were of 
analytical grade. 
5.2.1.3 NAT Assay Procedure 
The assay used is a modification of that originally described by Deguchi and Axelrod (1972a). 
Pineal glands were rapidly excised from rats as described previously I2.3.1.2]. Each pineal was 
individually placed in a small glass homogenizer containing 100).11 of ice-cold 50mM phosphate 
buffer (PH 6.S) and homogenized for 30 seconds (about 15 strokes). The reaction mixture contained 
20).11 homogenate which was removed and transferred to the bottom of corresponding separate cold 
microfuge tubes with 10).11 of the working solution. The working solution was made up of 5.6mM 
tryptamine, SOO).lM acetyl CoA and 40nCi eH] acetyl coenzyme A in a total volume of 10).11 per 
sample tube. 
All manipulations and additions up to this stage were performed on ice. Samples were then 
incubated for 45 minutes at 37°C on a waterbath and the reaction terminated by the addition of 
100).11 chilled O.2M borate buffer (pHIO.O). A blank containing no tissue, was also included in each 
series of incubations. Using a Pasteur pipette the reaction mixture was then transferred to a tube 
containing 1ml of the toluene: isoamyl alcohol (97:3). The tubes were sealed and shaken for 5 
minutes using a Griffith flask shaker. The emulsion formed as a result was dispersed by 
centrifugation in a microfuge for 30 seconds. Chilled borate buffer (100).11) was then added to each 
tube to wash out any contamination. Once again tubes were shaken for 5 minutes as before and 
centrifuged for 30 seconds. Aliquots of 500).11 were transferred from the organic phase to a plastic 
scintillation vial containing 3ml scintillation fluid (Ready-So1v HP/B Beckman, USA). 
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The radioactivity in each sample was quantitated using liquid scintillometry spectroscopy in a 
Beckman LS 2500 scintillation counter at an efficiency of 61.15 %. Counting efficiency, using 
computer-assisted analysis was determined by the external channel ratio method of quench 
correction. A correction factor was built into the quench correction program to allow for tritium 
decay. This enabled an accurate assessment of the label being quantitated. Radioactivity counts did 
not appear to fluctuate significantly after storing vials for up to two weeks. However, since 
scintillation fluid does evaporate from plastic vials with time, all samples were quantitated within 
24 hours of preparation. Blank values were subtracted from the assay values before expressing the 
results as picomoles eH]-N-acetyltryptamine formed/gland/hour (Deguchi and Axelrod, 1972a). 
5.2.1.4 In Vitro Studies 
For studies aimed at evaluating the effect of pharmacological manipulation, in vitro, on NAT 
activity, groups of 5 pineals were incubated in sterile 12mm diameter glass culture vessels 
containing 490}ll of the culture medium (BGJb Filton-Jackson modification), Gibco (Europe) 
[2.3.1.3]. The culture medium was placed in vessels of sterile 20ml glass vials during incubation. 
Drugs were added to the culture medium as 1000l aliquots. The tubes were sealed and incubated at 
37°C for a specified time period. Following incubation, the glands were removed, homogenized and 
the enzyme activity determined as described above. 
5.2.2 Results 
The linear relationship between the amount of eH]-N-acetyltryptamine formed and the incubation 
period in each assay is depicted in Figure 5.1 - the time course experiment. In all subsequent 
assays a 45 minute incubation period was used as it gave the greatest dpm counts. Blank values 
were obtained by incubation without enzyme. 
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Figure S.l Effect of incubation time on N-acetyltransferase (NAT) activity. 
Five pineal glands were collected and homogenized in SOmM phosphate buffer (PH 6.8). A 20pl aliquot 
of homogenate was used in the assay in a total volume of 3Op.1. Samples were incubated at 37°C for 
varying time periods. Each point represents the mean of duplicate determinations. 
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5.2.3 Discussion 
In the assay, the use of tryptamine and radioactive acetyl coenzyme A as substrates makes it 
possible to extract the enzymically formed N-acetyltryptamine into a nonpolar solvent which does 
not extract acetyl coenzyme A. Within the conditions described above, the assay proved to be linear 
with time and homogenate concentration. In addition, the assay affords the measurement of enzyme 
activity in a single rat pineal gland. 
5.3 Experiment: TO DETERMINE THE EFFECT OF PHYSOSTIGMINE 
ON NAT ACTIVITY IN RAT PINEAL GLANDS. 
5.3.1 Introduction 
The anticholinesterase agent physostigmine produced a significant rise in indole levels of N-
acety lserotonin in organ culture studies [2.7.4]. N -acety ltransferase (N AT) is the enzyme responsible 
for the conversion of serotonin to N-acetylserotonin. The aim of this investigation is to determine 
whether the cholinergic system acts through the enzyme NAT in order to cause a rise in N-
acetyl serotonin levels without influencing melatonin levels. The drug physostigmine, a 
anticholinesterase agent was used. 
5.3.2 Materials and Methods 
5.3.2.1 Materials 
I-Isoproterenol-HCI and physostigmine were purchased from the Sigma Chemical Co., USA. All 
other items are described in [5.2.1.2J. 
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5.3.2.2 Animals 
Adult male albino Wistar rats (200-250g.b.wt) were used in this study. Their environment is 
described in [2.3.1.2] and were housed five per cage in a temperature controlled room under a fixed 
lighting cycle of LD12:12 (lights on at 06hOO) with food and water ad libitum. The rats were 
sacrificed between lOh30 and 11h30. This maintained unifonnity with previous studies. 
5.3.2.3 Methods 
After the rats (n=15) were sacrificed their pineals were removed and transferred to sterile culture 
vessels containing BGJb culture medium. (Fitton-Jackson modification) at the required volume 
[5.2.1.4]. Five pineals were transferred to each of three incubation vessels containing BGJb culture 
medium. To one group of pineals isoproterenol (IO-5M) was added to the medium, to another 
physostigmine (IO-5M) and in the final group of pineals vehicle was added to give a final 
incubation volume of 500pl in each of the three vessels. The atmosphere in the vessels was 
saturated with carbogen (5%COz:95%O;' before the taps were finnly secured. The vials were placed 
in a Fonna Scientific a incubator and incubated in the dark at 37°C for 6 hours. After 6 hours the 
incubation was tenninated by removing the glands from the vessels and placing them in individual 
1ml glass homogenization tubes. They were assayed by the technique described in [5.2.1.3]. 
5.3.2.4 Data Analysis and Statistics 
Data are expressed as pmol N-acetyltransferase activity/pineal gland/hour, with each point 
representing the mean ± SEM for 5 glands. Statistical comparisons are made using the One-Way 
ANOVA followed by Neuman-Keuls Multiple Range test. 
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5.3.3 Results 
The results are represented in Table 5.1. Isoproterenol (l0-5M) caused the expected rise in NAT 
activity (p<O.02) whilst physostigmine did not cause NAT activity to rise significantly above basal 
levels. 
TABLE 5.1 N-acetyltransferase activity per rat pineal gland in the 
presence of vehicle or when stimulated with either isoproterenoll1 U5 M) 
or physostigmine 11 0-5M) [mean ± SEMi n=5 glands per group). 
Treatment N~acetyltryptamine formed 
(pmol/pineal/hour) 
Control 0,234 ± 0,070 
Isoproterenol 0,344 ± 0,046* 
physostigmine 0,266 ± 0,035 
In comparison with respect to vehicle control, p<*O,02 (One-Way ANOVA 
followed by Neuman-KeuIs Multiple Range test) 
5.3.4 Discussion 
Isoproterenol produced an increase in NAT as a result of adrenergic stimulation. NAT activation 
is dependent on the activation of adenylyl cyclase enzyme (Klein et aI., 1970; Klein et ai., 1978) 
leading to increased cAMP levels. These are controlled by p receptor stimulation which may be 
activated by the p receptor agonist isoproterenol, resulting in increased NAT activity. 
Physostigmine did not alter basal NAT activity suggesting that the cholinergic activated increase 
in the aHT did not occur due to the stimulation of the enzyme NAT. 
The cAMP assay studies [3.3.3] revealed that the rise in aHT and not aMT due to the presence of 
acetylcholine in the organ culture studies [2.7.3] was possibly caused by the activation of the 
adrenergic P receptors resulting in the conversion of ATP to cAMP. Also, the adrenergic system 
is known to act by increasing intracellular cAMP in the pineal which in turn activates NAT enzyme 
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activity. The above NAT results [5.3.3] however show that NAT activity was not increased in the 
presence of an anticholinesterase agent. The cAMP-PDE studies revealed a significant rise in 
cAMP-PDE enzyme activity in the presence of an anticholinesterase agent physostigmine. The rise 
in cAMP levels could possibly be speculated to cause a transient increase in NAT enzyme activity 
thus explaining the aHT rise and not aMT. 
The reasons for the acetylcholine inducing a rise in pineal cAMP without inducing a rise in pineal 
NAT activity remains unclear, but could however be related to a recent finding by Olivieri and 
Daya (1992) that raised intracellular calcium could reduce or inhibit pineal N AT activity. The 
synthesis of the pineal hormone melatonin, is regulated primarily by a classical B-adrenoceptor 
system, calcium playing a important role in this regulatory mechanism (Brown et al., 1989). During 
the synthesis of melatonin in the pineal gland, the enzyme NAT catalyzes the conversion of 
serotonin to N-acetylserotonin, the precursor of melatonin (Weissbach et at., 1960; Axelrod and 
Weissbach, 1961). The activity of the enzyme is presently used as an indicator of pineal activity 
(Rodriguez-Cabello et al., 1990). 
Exposure of rats to the light during the dark phase of diurnal light cycle induces a rapid decline in 
pineal NAT activity (Klein and Weller, 1972). Such a decline in NAT activity has also been 
observed during homogenization of stimulated pineal glands (Binkley et aI., 1976). Studies have 
shown that calcium channel blockers reduce the nocturnal rise in pineal activity (Zawilska and 
Nowak, 1991). Chelation of extracellular calcium results in a reduction of NAT activity due to a 
reduced B-adrenoceptor sensitivity as well as to reduce NAT protein synthesis (Zatz and Romero, 
1978). A recent study using the chelating agent ethyleneglycol-bis-N,N,N' ,N' ,-tetraacetic acid 
(EGT A) in homogenates of pineal from isoproterenol treated rats have shown that EGT A reduces 
the rate of deactivation of NAT (Rodriguez-Cabello et ai., 1990). 
Olivieri and Daya (1992) support the view that EGTA, a chelating agent, enhances NAT activity. 
In addition, the authors suggest that the addition of calcium at high concentrations to pineal 
homogenates reduces pineal NAT activity. It appears therefore that the concentration of calcium in 
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pinealocytes is important for the regulation of pineal NAT. Acetylcholine is known to trigger the 
inositol phosphate signalling system in the pineal gland. This signalling system is known to result 
in a elevation of diacylglycerol (DAG) as well as intracellular calcium providing a possible way 
by which acetylcholine induces a rise in pineal cAMP without inducing a rise in pineal NAT 
activity. 
CHAPTER 6 
HYDROXYINDOLE-O-METHYL TRANSFERASE (HIOMT) STUDIES 
6.1 Introduction 
6.1.1 Properties of HIOMT 
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Hydroxyindole-O-methyltransferase was first detected in bovine pineal glands by Axelrod and 
Weissbach (1960) and has since been found in the pineal glands of other mammals (Quay, 1966), 
birds, reptiles and amphibians (Quay, 1965). Until recently it was thought to be unique to the pineal 
gland but has since been found in the retina and harderian gland (Cardinali and Wurtman, 1972) 
and may occur in enterochromaffin cells (Raikhlin et at., 1975). Retinal hydroxyindole-O-
methyltransferase exhibits similar properties to the pineal enzymes while that from the harderian 
gland is notably different, showing a different spectrum of substrate specificities (Cardinali and 
Wurtman, 1972). 
HIOMT is capable of transferring the methyl group of S-adenosyl methionine to the hydroxy group 
of N-acetylserotonin. Axelrod and Weissbach (1961) showed that unlike catechol-O-
methyl transferase, this enzyme had no requirement for a metal. The optimum enzyme activity 
occurs between pH 7.5 and 8.3 and N-acetylserotonin proved to be the best substrate. Other 5-
hydroxyindo1eamines, serotonin and its N-methylated derivatives, as well as 5-hydroxyindole acetic 
acid are also O-methy1ated, but at a much reduced rate. 
Deguchi and Barchas (1971) showed that S-adenosyl-homocysteine, the product which results when 
S-adenosylmethionine donates its methyl group, is a potent inhibitor of HIOMT activity and binds 
to HIOMT with a higher affinity than S-adenosyl methionine. 
Cardinali and Wurtman (1972) demonstrated the presence of HIOMT in the rat pineal gland, retina 
and harderian gland. They found that Mg++ enhances HIOMT activity in the harderian gland but 
111 
does not affect HIOMT activity in the pineal and retina. These authors concluded that the pineal 
and retinal HIOMT enzymes were very similar but differed from that in the harderian gland in 
requirements for storage, pH optima and metal ions. 
Hydroxyindole-O-methyltransferase catalyses the fonnation of a variety of methoxyindoles including 
5-methoxytryptophan and 5-methoxytryptamine (Balemans et al., 1980), melatonin (Axelrod and 
Weissbach, 1960), 5-methoxytryptophol (McIsaac et ai., 1965) and 5-methoxyindole-3-acetic acid 
(Axelrod and Weissbach, 1961). It has been suggested that several such enzymes exist in the pineal 
(Cremer-Bartels, 1979), activity being regulated by pterins and pteridines (Cremer-Bartels, 1979; 
Balemans et aI., 1980). 
6.1.2 Effect of Light on HIOMT Rhythms 
There is a diurnal fluctuation in pineal HIOMT activity. HIOMT activity increases during the night 
and drops during the day (Axelrod et ai., 1965). The presence of light suppresses the activity of 
this enzyme (Wurtman et al., 1963a). The nocturnal rise of the enzyme is abolished by bilateral 
superior cervical ganglionectomy (Axelrod et al., 1965). 
Yochim and Wallen (1974) showed that although HIOMT activity rises and remains high in rats 
placed in continuous darkness (Wurtman and Axelrod, 1965), an estrus cycle pattern of HIOMT 
activity remains. The presence of such a rhythm in the dark suggests an endogenous aspect of the 
rhythm. They described the pattern of enzyme activity as the interaction of two component rhythms 
with slightly different periodicities whose characters are endogenous, synchronized with the estrus 
cycle, yet modified by light. 
Pevet et ai., (1980) found that the rat pineal HIOMT activity involved in the synthesis of melatonin 
is high at the end of the dark period and at the middle of the light period. The pineal HIOMT 
activity concerned with the production of 5-methoxytryptophol is only observed during the light 
period. Comparing the peaks, these authors conclude that the pineal produces more 5-
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methoxytryptophol than melatonin. They suggest that different HIOMT enzymes are involved in 
the synthesis of 5-methoxytryptophol and melatonin. Balemans et al., (1980) found that in rat 
pineals and harderian glands a larger amount of 5-methoxytryptophol than melatonin is synthesized, 
confirming the proposal by Pevet et aI., (1980). 
Jackson and Lovenberg (1971) speculate that the diurnal variation observed in the activity of 
HIOMT might be due to an association-dissociation phenomenon while Yang and Neff (1976) 
showed that the diurnal variation is due to an alteration of enzyme molecule numbers rather than 
a change in enzyme kinetics. 
Although studies have evaluated some kinetic parameters (Cardinali and Wurtman, 1972) and 
several groups have obtained pure enzyme (Jackson and Lovenberg, 1971; Kuwano et al., 1978) 
only one report has suggested a catalytic mechanism (Satake and Morton, 1979). This report 
proposed an ordered BiBi mechanism for the enzyme. 
6.1.3 Theory of the Assay 
The assay technique used for the determination of HIOMT activity was the one by Champney et 
al., (1984). The assay is based on the transfer of a radioactive e4C]-methyl group from the methyl 
donor, S-adenosyl-L-[methyl-14q methionine to the substrate, N-acetylserotonin to form radioactive 
melatonin (N-acetyl-5-[methoxy)4q tryptamine). In the pineal gland, HIOMT O-methylates N-
acetylserotonin to form melatonin. By adding radioactive S-adenosyl methionine to pineal 
homogenates incubated with N-acetylserotonin, radioactive melatonin is formed which can be 
extracted and measured by liquid scintillometry. The amount of radioactive melatonin formed can 
be used as an indication of HIOMT activity. 
In the sections that follow the method described by Champney et ai., (1984) with minor 
modifications, is used. 
6.2 
6.2.1 
6.2.1.1 
HIOMT ASSAY TECHNIQUE 
Materials and Methods 
Animals 
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Adult male Wistar rats (200-250g) were used: The animals were maintained under normal 
laboratory conditions as detailed in [2.3.1.2]. Wurtman et ai., (1963a) showed that rat pineal 
HIOMT activity varies during the estrus cycle and in light of this finding only male rats were used 
to maintain a uniformity with previous studies. The rats were sacrificed between lOh30 and 11h30 
by neck fracture, at the same time as the rats used in the organ culture studies. This was done to 
avoid possible interference with ~ receptor sensitivity changes. 
6.2.1.2 Chemicals and Reagents 
Radioactive S-adenosyl-L-[methyl-14C] methionine (Specific Activity 56mCi/mmol) was purchased 
as required from Amersham Laboratories (England). N-acetylserotonin and cold S-adenosyl 
methionine were purchased from Sigma Chemical' Co. (USA). All other chemicals and reagents 
were obtained from local commercial sources and were of analytical grade. 
6.2.1.3 HIOMT Assay Procedure 
Pineal glands were rapidly excised from rats aseptically as described previously [2.3.1.2]. Each 
pineal was placed in a small glass homogenizer containing 100pl of ice-cold 50mM sodium 
phosphate buffer (pH7.9) and homogenized for 30 seconds (about 15 strokes). The reaction mixture 
contained lOpl homogenate which was removed and transferred to the bottom of corresponding 
separate cold microfuge tubes together with 10pl of the working solution. The working solution 
contained 3mM N-acetylserotonin, 200mM sodium phosphate (pH7.9) buffer and e4C] SAM in a 
total volume of 10pl per sample tube. 
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All manipulations and additions up to this stage were performed on ice. Samples were then 
incubated for 30 minutes at 30°C on a waterbath and the reaction terminated by the addition of 
lOOpI chilled O.3M borate buffer (pHlO.O). A blank containing no tissue was also included in each 
series of incubations. 
Using a Pasteur pipette the reaction mixture was then transferred to a tube containing 1ml of the 
toluene: isoamyl alcohol (97:3). The tubes were sealed and shaken for 5 minutes using a Griffith 
flask shaker. The emulsion formed as a result was dispersed by centrifugation in a microfuge for 
30 seconds. Chilled borate buffer (100pl) was then added to each tube to wash out any 
contamination. Once again tubes were shaken for 5 minutes as before and centrifuged for 30 
seconds. Aliquots of 500pl of the organic phase were transferred to plastic scintillation vials 
containing 3ml scintillation fluid (Ready-Solv HP/B Beckman, USA). 
The radioactivity in each sample was quantitated using liquid scintillometry in a Beckman LS 2500 
scintillation counter at an efficiency of 61,15%. Counting efficiency, using computer-assisted 
analysis was determined by the external channel ratio method of quench correction. Blank values 
were subtracted from the assay values before expressing the results as picomoles e4C] melatonin 
formed/gland/hour (Champney et al., 1984). 
6.2.1.4 In Vitro Studies 
For studies aimed at evaluating the effect of pharmacological manipulation, in vitro, on HIOMT 
activity, groups of 5 pineals were incubated in' sterile 12mm diameter glass culture vessels 
containing 490pl of the culture medium (BGJb Fiuon-Jackson modification, Gibco (Europe) 
[2.3.1.3]. The culture medium was placed in vessels of sterile 20ml glass vials during incubation 
and prewarmed. Drugs were then added to the culture medium as 10pl aliquots. The tubes were 
sealed and incubated at 37°C for a specified time 'period. Following incubation, the glands were 
removed. homogenized and the enzyme activity determined as described above. 
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6.2.2 Results 
The HIOMT assay was carned out using a 45 minute incubation period. Blank values were obtained 
by incubating the tubes without the enzyme present. 
6.2.3 Discussion 
In the assay the use of radioactive S-adenosyl-methionine (SAM) and N -acetylserotonin as 
substrates makes it possible to extract the enzymically fonned melatonin (N-acetyl-5-[methoxy 14C] 
tryptamine) into a nonpolar solvent. The amounts of radioactive melatonin fonned gives an 
indication of the amount of HIOMT activity. This assay affords the measurement of enzyme activity 
in a single rat pineal gland. 
6.3 Experiment: TO DETERMINE THE EFFECT OF PHYSOSTIGMINE 
ON HIOMT ACTIVITY IN THE RAT PINEAL GLAND 
6.3.1 Introduction 
The anticholinesterase enzyme physostigmine produced a significant increase in N-acetylserotonin 
levels but not melatonin [2.8.3]. The N-acetyltransferase enzyme studies [5.3.3] showed that the rise 
in aHT was not caused by the stimulation of the enzyme NAT. The aim of this investigation is to 
detennine whether physostigmine inhibits enzyme HIOMT to reduce conversion of the high levels 
of aHT to aMT. 
6.3.2 Materials and Methods 
6.3.2.1 Materials 
Physostigmine was purchased from the Sigma Chemical Co., USA. All other chemicals and reagents 
are described in [6.2.1.2]. 
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6.3.2.2 Animals 
Adult male albino Wi star rats (200-250g.b.wt) were used in this study. The rats were housed five 
per cage in a temperature controlled room under a fixed lighting cycle of LD 12: 12 (lights on at 
06hOO) with food and water ad libitum. The rats were sacrificed between 1Oh30 and I1h30. This 
maintained uniformity with previous studies. 
6.3.2.3 Methods 
After the rats (n= 10) were sacrificed their pineals were removed and transferred to sterile culture 
vessels containing BGJb culture medium (Finon-Jackson modification) at the required volume 
[6.2.1.4]. Five pineals were added to both incubation vessels which contained BGJb culture medium. 
To one group of pineals physostigmine (IO-5M) was added and to the other vessel vehicle was 
added and acted as the control group. The final incubation volume in each vessel was 500)11. The 
atmosphere in the vessels was saturated with carbogen (5%COz:95%Oz) before the taps were firmly 
secured. The vials were placed in a Forma Scientific a incubator and incubated in the dark at 37°C 
for 6 hours. After 6 hours the incubation was terminated by removing the glands from the vessels 
and placing them in individual 1 ml glass homogenization tubes. They were assayed by the usual 
technique [6.2.1.3]. 
6.3.2.4 Data Analysis and Statistics 
Data are expressed as pmol hydroxyindole-O-methyltransferase activity/pineal gland/hour with each 
point representing the mean ±SEM for five pineal glands. Statistical comparisons were made using 
the Students t- test. 
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6.3.3 Ites~ts 
The HIOMT activity for the physostigmine stimulated group was not significantly different to the 
controls. The results are tabulated in Table 6.1. 
TABLE 6.1 Hydroxyindole-o-methyltransferase activity per rat pineal 
gland in the presence of vehicle. or when stimulated with 
physostigmine 11 0-5M) (mean:!: SEMi n=5 glands per group). 
Treatment melatonin formed 
pmol/pineal gland/hour 
Control 8,165 ± 0,553 
Physostigmine 9,695 ± 1,483* 
,. Not significant in comparison with respect to the vehicle control. 
6.3.4 Discussion 
The results show that physostigmine did not cause any significant changes in basal HlOMT activity. 
This indicates that physostigmine did not inhibit the enzyme HIOMT to reduce the conversion of 
the high levels of N-acetylserotonin induced by this drug, to melatonin. 
Hence the mechanism by which the cholinergic agonist acetylcholine and the anticholinesterase 
agent physostigmine is able to increase aHT levels and not aMT levels still remains to be 
elucidated. A number of possible mechanisms causing this phenomenon may be examined : 
(i) The occupation of the cell surface receptors by cholinergic molecules may be speculated 
to occur leading to a generation of intracellular second messengers ego cyclic nucleotide, 
Ca2+ and diacylglycerol (DAG) which act as allosteric effectors to activate a variety of 
protein kinases (Shenolikar, 1987). These secondary messengers may hold the answer as 
to how aHT levels are able to rise without an increase in aMT levels. 
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Oi) The neutral lipid diacylglycerol is nonnally absent from membranes. On receptor 
stimulation, it appears transiently and disappears within seconds due to its conversion back 
to inositol phospholipids and its degradation to arachidonic acid (AA) which in tum can 
generate other messengers ego the prostaglandins. The diacylglycerol fonnation resultant 
from phosphoinositol breakdown, following ex-adrenergic stimulation, and the subsequent 
effects on cyclic nucleotide (Sugden et al., 1985) and NAT activation (Zatz, 1985) have 
been adequately demonstrated in rats. The transient action of diacylglycerol may be a 
mechanism by which a transient increase in NAT activity occurred and by which levels of 
aRT rose wlthout causing a concomitant rise in aMi. 
(iii) Another mechanism which needs to be considered is the phosphoinositides. A compelling 
amount of evidence indicates that the ubiquitous inositol lipid signalling pathway plays a 
key role in neurotransmission and neuro-modulation (Exton, 1985). Laitinen et at., (1989b) 
suggest the presence of a functional acetylcholine receptor in the rat pineal which are 
coupled to the phosphoinositide signalling pathway. Although the muscarinic receptor 
density in rat pineals (Taylor et at., 1980) seems to be only a fraction of that reported for 
oc-adrenoreceptors in the gland (Sugden and Klein, 1985), the phosphoinositide response 
for submillimolar concentrations of both muscarinic and adrenergic agonists were very 
similar (Laitinen et al., 1989b). The results of the study done by Laitinen et al., (1989b) 
suggest that acetylcholine could modulate pineal function through the stimulation of 
phosphoinositide turnover. This signalling pathway may in some way influence aHT levels 
to rise without aMT being affected. 
(iv) It has been reported that four different genes code for muscarinic receptors (Kerslavage et 
aI., 1987). Studies on second messenger coupling of muscarinic receptors sUbtypes (M]-M4) 
suggest that the expression of rat muscarinic M] and human M1 and M4 receptor genes in 
cells lacking endogenous muscarinic receptors can lead to a complete appearance of the 
phosphoinositide (PI) signalling pathway and that the magnitude of the signal produced is 
proportional to the level of gene expression for these receptors (Dudley et at., 1988; Peralta 
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et ai., 1988). Hence muscarinic gene activation may also be in some way linked to the N-
acetyl serotonin levels rising without a rise in melatonin levels. 
(v) Cyclic-GMP is a secondary messenger whose concentration is regulated in a manner 
somewhat similar to cAMP (Vanacek et al., 1985). A fascinating feature of the pineal gland 
is that there are reciprocal changes in the magnitudes of cAMP and cGMP responses 
produced by changes in chronic neural stimulation (Deguchi and Axelrod, 1973; Klein et 
al., 1981b). Following long periods of stimulus deprivation, produced by keeping animals 
in constant lighting or denervating the pineal gland, the cAMP response increases two-fold, 
an example of denervation supersensitivity. This is similar to what is generally seen in 
neural and hormonal regulation. In contrast the pineal cGMP response exhibits the opposite, 
a denervation subsensitivity . These effects of a supersensitive cAMP response and a 
subsensitive cGMP response are termed "see-saw" signal processing. The importance of this 
has not been established, but it may have important implications because it shifts the pineal 
gland between a mono- and a bi-cyclic nucleotide second messenger system. Assuming that 
each regulates different processes, one can imagine that the two cyclic nucleotides might 
be responsible for turning "off' and "on" different hormone systems eg while cAMP 
controls aMT production, cGMP might regulate another hormone. Hence cGMP may be 
speculated to have some influence on aHT and a closer examination of this secondary 
messenger needs to be carried out. 
(vi) Prostaglandin stimulation of NAT may rcpresent another mechanism by which the pineal 
is able to regulate its aHT and aMT production. Cardinali and Vacas (1987) have shown 
that prostaglandin E (in vitro) affects pineal NAT activity. The prostaglandins could hence 
also provide a possible mechanism by which increased aHT levels could be obtained 
without a rise in aMT levels. 
(vii) Stress and the release of catecholamines from synaptic nerve endings and adrenal medulla 
could influence the rise in NAT activity and cause a increase in aHT levels. Vaughan et 
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aI., (1978) found NAT activity to be sensitive to stressful stimuli and provides a possible 
way by which N-acetylserotonin levels are increased. 
(viii) The rise may also be speculated to be caused by non-cholinergic agents. NAT activity is 
very sensitive to drug manipulations which affect beta-receptor adenylate cyclase coupled 
regulating mechanisms. Agents such as isoproterenol, pargyline (monoamine oxidase 
enzyme inhibitor), cocaine (noradrenaline reuptake blocker) have all been found to affect 
NAT activity (Deguchi and Axelrod, 1972b). This provides another mechanism by which 
aHT levels could be influenced. 
(ix) The reasons for actylcholine inducing a rise in pineal cAMP without inducing a rise in 
pineal NAT activity remains unclear, but could however be related to a recent finding by 
Olivieri and Daya (1992) that raised intracellular calcium levels could reduce or inhibit 
pineal NAT activity. Acetylcholine is known to trigger the inositol phosphate signalling 
system in the pineal. The signalling system is known to result in a elevation of 
diacylgycerol (DAG) as well as intracellular calcium, and hence could play a role in 
influencing the rise in aHT. 
The physiological significance of the rise in aHT by acetylcholine without influencing aMT levels 
remains to be elucidated and the mechanism by which it occurs needs to be researched further. 
7.1 Introduction 
CHAPTER 7 
ACETYLCHOLINESTERASE STUDIES 
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Acetylcholinesterase is the enzyme which breaks down and inactivates the neurotransmitter 
acetylcholine. Hence, the presence of acetylcholinesterase (AChE) is one indicator of the neural 
nature of a tissue (Cooper et al., 1982). This however, cannot be the sole indicator and additional 
evidence is necessary for exceptions to this generality are common. The study of Manocha (1970) 
demonstrated the complexity of the distribution of AchE (also called true or specific cholinesterase) 
and nonspecific cholinesterase (also called pseudo- or butyrylcholinesterase) in neural tissue. 
When considering the pineal gland, AChE has been shown in a number of non mammalian animals, 
where pineal neurons are present and stain for AchE. Examples of these are anurans (Wake et al., 
1974), goldfish (Wake, 1973), rainbow trout (Korf, 1974), eel (Matsuura and Herwig, 1981) and 
birds (Ueck and Kobayashi, 1972). In mammals, AchE is also present in the pineal gland in some 
species. The enzyme in the bovine pineal was detectable biochemically (23pM/g/hr, LaBella and 
Shin, 1968). Rodriguez De Lores Amaiz and Pellegrino De Iraldi (1972) estimated that the enzyme 
was equally distributed between pinealocytes and nerve fibres, since superior cervical 
ganglionectomy was followed by a 50% decrease of enzyme activity (Pellegrino De Iraldi and 
Rodriguez De Lores Amaiz, 1972). 
Histochemically the enzyme was regularly demonstrated in intrapineal sympathetic nerve fibres 
(Eriinko et aI., 1970; Trueman and Herbert, 1970a; Machado and Lemos, 1971). A mild to moderate 
reaction showed in the pinealocytes of the squirrel monkey (Manocha, 1970). 
A few researchers have found however that the pinealocytes of rats (Arstila, 1967) and ferrets 
(Trueman and Herbert, 1970a) are negative for AChE. Also, Vollrath (1981) citing unpublished 
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work by Kohl, reported that guinea pig pinealocytes lacked AChE activity, even though the nerve 
fibres tested positive. These studies were perfonned using light microscopy. Luo et ai., (1990) 
recently discovered through the ultrastructural localization of AchE in the guinea pig pineal gland 
that the AChE-positive pinealocytes synthesize AChE. The AChE reaction product was also seen 
in the intracellular space between pinealocyte processes. 
Acetylcholinesterase has been reported to possess peptidase activity and can hydrolyze both 
substance P (Chubb et at., 1980) and leu- and metenkephalin (Chubb et at., 1982). Substance P was 
revealed in the pineal glano with radioimmunoassay studies (Po weI et at., 1977), and substance? 
fibres were also found in the pineal organ, pineal stalk and deep pineal glands (Ronnekleiv and 
Kelly, 1984). However it is not known if the pineal AchE hydrolyzes the pineal substance P. 
Luo et ai., (1990) recently provided evidence through the ultrastructural localization of AChE in 
the guinea pig pineal gland that the AChE-positive pinealocytes synthesize AChE. The AChE 
reaction product was also seen in the intracellular space between pinealocyte processes, confinning 
the enzyme's presence in the pineal gland. 
7.1.1 Theory of the Assay 
The principle role of AChE is believed to be the tennination of nerve impulse transmission by 
hydrolysis of the neurotransmitter acetylcholine. The basis of the assay is the observation, by 
spectrophotometry, of a change in colour and hence absorption when the substrate acetylthiocholine 
is enzymatically broken down by acetylcholinesterase to acetate and thiocholine. 
7.2 
7.2.1 
7.2.1.1 
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ACETYLCHOLINESTERASE DETERMINATION TECHNIQUE 
Materials and Methods 
Chemicals, Drugs and Reagents 
Acetylthiocholine chloride, acetylcholine chloride, reserpine and 5,5 dithiobis-(2-nitrobenzoic acid) 
(DTNB) were purchased from the Sigma Chemical Co., USA. All other inorganic and buffer 
chemicals were of reagent grade. 
7.2.1.2 Animals 
Male rats of the Wistar strain weighing 200-250g were purchased from the South African Institute 
for Medical Research and housed five per cage under a diumallighting cycle ofLD12:12 with food 
and water ad libitum for at least two weeks prior to the experiment. The animals were maintained 
and sacrificed as previously described in 12.3.1.2]. 
7.2.1.3 Preparation of Rat Brain and Pineal Glands 
After removal of the rat brain cerebral cortex and pineal gland they were each individually 
homogenized. The brains were homogenized in 3ml and the pineals in 150pl of a O.lM phosphate 
buffer, pH7. To this Triton X-IOO was added, 3ml for brain tissue and 150pl for pineal tissue. The 
mixture was then centrifuged at 3000 x g for 15 minutes and 50pl aliquots were assayed for AChE. 
7.2.1.4 The Acetylcholinesterase Assay 
Hydrolysis of acetylthiocholine by acetylcholinesterase was recorded at 410nm at room temperature 
in accordance with the method described by Ellman et al., (1961). The assay mixture (3.14ml) 
contained phosphate buffer (O.lM, pH7) , buffered Ellman's reagent (DTNB 10 mM), NaHC03 
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(17.S5mM, pH7) and acety1thiocholine chloride (0.2 mM). Aliquots were made up to 3. 12m1 with 
phosphate buffer (pHS) and the reaction was initiated by the addition of 5Op1 pineal or brain 
supernatant as described above [7.2.1.3]. The enzyme concentration was determined using an 
absorption coefficient (Alcm) of 16.1 at 2S0nm and a Mr 260 000 (Silman, 1976). The protein 
concentration of the rat brain was determined according to a procedure developed by Lowry et al., 
(1951) using bovine serum albumin as a standard. A typical protein calibration curve as well as the 
scheme of the protein assay may be found in [3.2.1.4]. 
7.2.2 Results 
Acetylcholinesterase activity was detected in both the rat brain cerebral cortex and pineal glands 
confirming the sensitivity of the assay method. The results are shown in Table 7.1. 
TABLE 7.1 Acetylcholinesterase activity measured in the rat brain 
and pineal gland. 
Acetylcholinesterase activity 
Brain 0,978 ± 0, 416 ~mol min-1/mg protein 
Pineal Gland 0,079 ± 0,050 ~mol min-1/gland 
7.2.3 Discussion 
The results show that AChE activity is detectable in both the rat brain and pineal glands. This 
supports the findings of Luo et al., (1990). These authors carried out ultrastmctura110calization 
studies in the pineal glands of guinea pigs and located AChE-positive pinealocytes near blood 
vessels which were located and distributed in small groups. The method by Ellman et aI., (1961) 
was thus sensitive enough to detect acetylcholinesterase activity in the pineal glands of rats. 
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7.3 Experiment: TO DETERMINE THE EFFECT OF RESERPINE ON 
THE AChE DIURNAL RHYTHM IN RAT PINEAL GLANDS 
7.3.1 Introduction 
The purpose of this experiment was to detennine whether the acetylcholinesterase enzyme activity 
changes over a 24 hour period and to investigate the effect of reserpine on enzyme activity. 
7.3.2 Materials and Methods 
7.3.2.1 Materials 
Reserpine was purchased from the Sigma Chemical Co., USA. Sources of other materials are 
described in [7.2.1.1]. 
7.3.2.2 Animals 
Twenty adult male Wi star rats (200-250g.b.wt) were used for this study. They were housed as 
described in [2.3.1.2]. Ten animals were injected with reserpine (5mg.kg-1) one day prior to being 
killed. The remaining ten animals received saline at the same time and served as the controls. For 
the day time study five reserpine-treated and five saline-treated rats were killed by neck fracture 
at between lOh30 and IlhOO and the brain and pineals were rapidly removed. For the night time 
study, five reserpine-treated and five saline-treated animals were killed at OlhOO by neck fracture 
and pineals were rapidly removed [2.3.1.2]. The procedure for the acetylcholinesterase assay was 
carried out in accordance with the method described by Ellman et ai., (1961) [7.2.1.4], Significance 
was evaluated using Student's t-test. 
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7.3.3 Ftes~ts 
As shown in Table 7.2 acetylcholinesterase was detected in the rat pineal glands. There was a 
diurnal variation in acetylcholinesterase activity with lower activity at night and higher activity 
during the day. Reserpine treatment did not alter this diurnal rhythm, nor did it change the activity 
of the enzyme significantly. 
TABLE 7.2 Acetylcholinesterase activity (umol.min-1/glandJ during the 
day and night and the effect qf reserpine. 
Treatment Day Night 
Controls 0,079 ± 0,05 * 0,035 ± 0,02 
Reserpine 0,081 ± 0,02 * 0,059 ± 0,02 
'" As compared with night-time, p <*0.05 (Student's t-test) 
Acetylcholinesterase activity was measured in the brain cerebral cortex and no diurnal variation was 
detected in the activity of this enzyme in brain tissue. 
7.3.4 Discussion 
Although a cholinergic innervation of the pineal gland has not been clearly demonstrated, a number 
of studies have demonstrated the presence of cholinergic markers such as ChAT (Rodriquez De 
Lores Arnaiz and Pellegrino De Iraldi, 1972), muscarinic receptors (Taylor et ai., 1980) and AChE 
(Moller and Korf, 1983; Romijn, 1973) in the pineal. Moller and Korf (1983) were the first to 
demonstrate pineal nerve terminals containing vesicles which stained for acetylcholinesterase. 
Although the presence of the enzyme in the pineal does not necessarily imply that the pineal gland 
has a cholinergic innervation, it does suggest that acetylcholine plays a role in pineal function. 
The results of this study show that using the method described by Ellman et al., (1961) it was 
possible to detect AChE activity in the rat pineal gland. In addition, the activity follows a diurnal 
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rhythm, with higher activity during the day and lower activity at night. The possibility of this being 
under the control of the sympathetic nervous system was refuted by using catecholamine depletor, 
reserpine. Reserpine treatment did not alter the diurnal rhythm in the activity of the enzyme, neither 
did it change the activity significantly. These results support the view that disruption of the 
sympathetic innervation of the pineal gland does not interfere with cholinergic components in the 
pineal gland (Romijn, 1973; Taylor, 1980). Basinka et at., (1973) have established that functional 
muscarinic receptors associated with acetylcholine-induced increases in the turnover of 
phosphatidylinositol occur in the pineal gland. Whether acetylcholinesterase is present in the pineal 
to regulate the level of acetylcholine interacting with the muscarinic receptors in the gland remains 
to be established. 
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CHAPTER 8 
CHOLINE ACETYL TRANSFERASE STUDIES 
8.1 Introduction 
The enzyme acetyl-CoA : choline O-acetyltransferase (ChAT) catalyses the synthesis of the 
neurotransmitter acetylcholine from acetyl CoA and choline. According to its important role in the 
function of the nelVOUS system, considerable effort has been invested to develop sensitive, quick 
and accurate procedures for assaying this enzyme. 
Studies with this enzyme choline acetyltransferase were limited by the availability of the bioassays 
described by Chang and Gaddum (1933) and the much less sensitive method of Hestrin (1949). 
Shuberth (1963, 1966) developed a radiochemical assay for the enzyme, but the method required 
an acetyl CoA generating system since it did not distinguish acetyl CoA from acetylcholine. 
Selective precipitation methods were developed by McCaman and Hunt (1965) and Alpert et ai., 
(1966) in which ACh is precipitated as the reineckate, and by Fonnum (1966) in which 
tetraphenylborate salt is formed. These precipitation methods are specific and their sensitivity is 
limited only by the available specific activity of the substrate, but the tedium of washing and 
centrifuging the precipitated product remains. A gas chromatographic method by Stavinoha and 
Ryan (1965) is cumbersome for use in enzyme purification studies. 
Schrier and Shuster (1967) developed an assay method for choline acetyltransferase which is rapid 
and precise taking advantage of the fact that the enzyme transfers an acetyl moiety from an anionic 
substrate acetyl CoA, to a cationic substrate choline, resulting in a cationic product acetylcholine. 
The two classes of ions can be separated by use of an anion exchange resin. This method was found 
however, unable to separate acetylcholine from acetylcamitine and produces an artificially high 
value for the activity of choline acetyltransferase (White and Wu, 1973; Hamprecht and Amano, 
1974). 
129 
Fonnum (1969) developed a radiochemical assay for choline acetyltransferase based on 
reproducible, rapid and specific procedures for isolating acetylcholine from the incubation mixture. 
This was achieved by isolating labelled ACh by liquid cation exchange using sodium 
tetraphenylboron (Kalignost) in ethyl butyl ketone. Labelled ACh can be determined by liquid 
scintillation counting at high efficiency in the biphasic aqueous : toluene scintillation solution 
mixture. 
8.1.1 Theory of the Assay 
The method is based on the observation that choline esters and sodium tetraphenylboron (Kalignost) 
form complexes that are insoluble in water but soluble in organic solvents such as nitrates, higher 
ketones and benzyl alcohol. The extraction procedure is an example ofliquid cation exchange where 
tetraphenylboron is the cation exchange group. The proportion of choline esters extracted depends 
on the type and total amount of cation in the aqueous phase and the amount of sodium 
tetraphenylboron in the organic solvent. The proportion of choline esters extracted is independent 
of the choline ester concentration, the pH between 3 and 8, and the relative volumes of the two 
phases. The affinity of sodium tetraphenylboron for choline esters increases with an increase in the 
size of the acyl group. The choline esters extracted can be released into an aqueous solution by 
treatment with strong acid, silver salts and anion exchange resins. This procedure by Fonnum 
extracts acetylcholine selectively CRossier, 1977). 
8.2 
8.2.1 
8.2.1.1 
ChAT ASSAY TECHNIQUE 
Materials and Methods 
Chemicals, Drugs and Reagents 
Tritium-labelled acetyl coenzyme A (specific activity 3,9Ci/mmol) was obtained from Amersham 
Laboratories, England. Acetyl coenzyme A (acetyl CoA), physostigmine (eserine) and sodium 
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tetraphenylboron (Kalignost) were purchased from Sigma Chemical Co., USA. Acetonitrile was 
obtained from Saarchem Pty Ltd (South Africa) and butyronitrile from Merck (Germany). All other 
chemicals were of the purest analytical grade available. 
8.2.1.2 Animals 
Adult male Wi star rats (200-250g) were used. The animals were maintained under normal 
laboratory conditions as detailed in [2.3.1.2]. The rats were sacrificed between lOh30 and llh30 
maintaining the uniformity with previous studies. 
8.2.1.3 Preparation of Tissue Extraction 
Rat pineal glands were dissected from freshly obtained brains by the procedure described in 
[2.3.1.2]. The tissues were homogenized with a glass homogenizer in 5-10 volumes of ice-cold 
sodium phosphate buffer (50mM, pH7.4) containing ImM EDT A (5Opl/pineal). The homogenates 
were then centrifuged at 900 x g for 10 minutes at 4°C in a refridgerated centrifuge. To obtain full 
enzymatic activity 1% (v/v) Triton X-lOO was added to each supernatant (5J..ll) (Fonnum, 1966). 
Solutions were kept on ice for 15 minutes with occasional shaking. The control blank groups 
consisted of heat inactivated enzymes. 
8.2.1.4 The Choline Acetyltransferase Assay 
The activity of choline acetyltransferase was assayed by a technique which measures the transfer 
of eH] acetyl moiety from eH] acetyl CoA to choline to yield eH] acetylcholine (Fonnum 1969, 
1975). The resulting eH] acetylcholine was then isolated from aqueous solution by applying liquid 
cation exchange extraction procedure and by using Kalignost as an organic solvent. 
The incubation mixtures contained (final concentrations) lOmM choline chloride, 300 mM sodium 
chlO1ide, lOmM EDTA, 50mM sodium phosphate buffer (pH7.4), O.lmM eserine, eHJ acetyl CoA 
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and 0.5mM unlabelled acetyl CoA to give a final concentration of 0.5mM. Aliquots of lOp! 
incubation mixtures were transferred to test tubes which already contained lOpl of the enzyme 
solution. In all studies protein concentrations ranging between 2.5-3.Omglml were used. Reaction 
mixtures were incubated at 37°C for 15 minutes and terminated by adding sequentially and 
immediately 2.5ml of a lOmM sodium phosphate buffer (pH7.4) and Iml butyronitrile containing 
15mg Kalignost. After shaking (vortexing) for 10 seconds and centrifuging the reaction mixtures, 
aliquots of 0.5ml of organic layers were transferred to scintillation vials containing 3ml of toluene 
fluor and Iml acetonitrile. The radioactivity was then counted by liquid scintillation spectrometry 
at 61,12% efficiency. The activity of choline acetyltransferase was expressed as nmol [3H] 
acetylcholine formed fmg protein/hour. 
8.2.1.5 Kinetic Studies 
In order to carry out kinetic studies, the final concentrations of choline were varied from 20, 10, 
5,2.5, 1.25, to 1.0mM while keeping the concentration of acetyl CoA at a constant level of 0.5mM. 
Kinetic studies were also carrried out on melatonin stimulated brain tissue and the results are 
summarised in Figure 8.1. 
The present recovery of the newly synthesized eH] acetylcholine using the Kalignost butyronitrile 
extraction procedure was 98% as judged by assessing the radioactivity of known quantities of [3H] 
acetylcholine determined directly and following extraction procedures. 
8.2.1.6 Protein Determination 
The protein concentration of solutions were determined according to a technique developed by 
Lowry et ai., (1951) using bovine serum albumin as a standard. A typical protein calibration curve 
in these experiments as well as the scheme for the determination of protein by the method of Lowry 
et aI., (1951) may be found in [3.2.1.4]. 
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8.2.2 Results 
The ChAT assay by Fonnum (1976) was sensitive enough to detect ChAT enzyme activity in the 
rat brain cerebral cortex. The kinetic studies revealed K", value of 312.5 ± 44.05 pM and a Vmax 
value of 0.209 ± 0.014 nmol/mg protein/hour for melatonin treated brains and for the control, K", 
was 196 ± 23.91 pM and Vmax was 0.172 ± 0.0034 nmo1!mg protein/hour. 
8.2.3 Discussion 
Cholinergic neurons are distributed widely in the autonomic nervous system. For example, the 
preganglionic neurons of both sympathetic and parasympathetic nervous systems are cholinergic. 
Furthermore. the postganglionic parasympathetic neurons are mainly cholinergic. In addition, while 
the majority of postganglionic sympathetic fibers are adrenergic, the fibers supplying the sweat 
glands, vessels of the skeletal muscles in some species, and vessels of tongue muscles are all 
cholinergic in nature (Dale, 1937; Gabella, 1976). The development and use of 
immunohistochemical methods for measuring both cholinesterase and choline acetyltransferase have 
provided excellent tools for the localization of cholinergic neurons in various areas of CNS (Butcher 
and Woolf, 1984; Nitecka and Frotscher, 1989). 
The ChAT assay by Fonnum (1975) is a rapid, specific and sensitive procedure based on the direct 
extraction of synthesized ACh into the scintillation mixture. There is no interference by AChE 
resistant acetylation products formed in liver and heart tissues, such as acetylcamitine. This is 
apparently a serious problem for several other published ChAT assay methods. 
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8.3 Experiment: TO DETERMINE THE EFFECT OF PHYSOSTIGMINE 
AND MELATONIN ON ChAT ACTIVITY IN THE RAT BRAIN 
CEREBRAL CORTEX 
8.3.1 Introduction 
In recent studies Phansuwan-Pujito et ai., (1989) and Govitrapong et ai., (1989b) have identified 
muscarinic cholinergic receptors in the bovine pineal gland. They proceeded to measure the activity 
of choline acetyltransferase, determining its kinetic properties and thus substantiating the existence 
of cholinergic fibers in the bovine pineal gland. 
In the present study investigations were carried out into whether it was possible to detect choline 
acetyltransferase activity in the rat brain cerebral cortex and pineal gland as well as determining 
whether melatonin influences the production of acetylcholine in a significant manner, in these 
organs. 
8.3.2 Materials and Methods 
8.3.2.1 Materials 
Melatonin was obtained from Sigma Chemical Co., USA. All other chemicals and reagents used 
are as described in [S.2.1.1]. 
8.3.2.2 Methods 
In order to detennine the effect of melatonin on acetylcholine transferase enzyme activity a 1O-5M 
solution of melatonin was prepared and added to the incubation mixture. The procedure for the 
choline acetyltransferase assay was as described in [S.2.1.4]. The significance was evaluated using 
Student's t-test. 
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8.3.3 Results 
ChAT activity in the rat brain cerebral cortex was found to increase significantly in the presence 
of melatonin (Table 8.1). ChAT activity was unable to be detected in the pineal gland. 
TABLE 8.1 
Treatment 
Control 
Melatonin 
The effect of melatonin on ChAT activity in the rat brain 
cerebral cortex. . 
ChAT activity 
4.202 ± 0.664 
9.516 ± 1.817 * 
In comparison with respect to vehicle control p<*O,OOOl (Student's t-test). 
CMT activity was expressed as nmol PH] acetylcholine formed/mg 
protein/ hour. 
8.3.4 Discussion 
Acetylcholine is generally accepted as an important neurotransmitter in the peripheral and central 
cholinergic synapses (Tucek, 1979). It is synthesized by the reversible transfer of an acetyl group 
from acetyl CoA to choline, catalyzed by the enzyme choline acetyltransferase which was 
discovered initially in 1943 by Nachmansohn and Machado. 
Studies by Tucek (1985) have verified that there exists a direct relationship between the relative 
specific activity of the enzyme and the density of cholinergic fibers in different regions of the CNS. 
Studies by Govitrapong et al., (1989a) have identified in the bovine pineal gland, muscarinic 
cholinergic receptors with Bmax values of 69.75 ± 20.91 fmol/mg protein. The low density of 
cholinergic fibers in the bovine gland is indeed consistent with the low activity of choline 
acetyltransferase as being reported in this study of rat brain and pineal gland. Furthennore it is also 
in keeping with the low density of other characterized receptors for amino acids, biogenic amines 
and peptides in the pineal gland (Ebadi and Govitrapong, 1986 a and b; Ebadi et ai., 1989). 
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Melatonin was found to cause an increase in brain ChAT activity (p<O.OOOl) suggesting that it 
could in some way enhance cholinergic transmission in the brain. Pineal ChAT activity was unable 
to be detected suggesting that the enzyme was either not present or that its concentration was too 
low to be detected by the assay technique used. 
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CHAPTER 9 
MUSCARINIC RECEPTOR eH]QNB BINDING STUDIES 
9.1 Introduction 
Receptor binding studies have become commonplace among many researchers, particularly 
neuroscientists. Indeed its advent has led to a subsequent exponential growth in the volume of 
publications and our knowledge of neurotransmission and receptor interaction. 
Identification of neurotransmitter receptor sites by chemical measurements of direct binding has 
been reported for nicotinic cholinergic receptors of invertebrate electric organs (Changeux et ai., 
1970; Eldefrawi et al., 1971; Klett et al., 1973; Miledi et ai., 1971; O'Brien and Gilmour, 1969; 
Raftery et ai., 1971), mammalian neuromuscular junction (Berg et ai., 1972; Fambrough and 
Hartzell, 1972; Miledi and Potter, 1971) and central nervous system (Bosman, 1972; De Robertis, 
1971; De Robertis et ai., 1969; Eldefrawi and O'Brien, 1970) and for the glycerine receptor in the 
mammalian central nervous system (Young and Snyder, 1973). Attempts to study the muscarinic 
cholinergic receptor biochemically have involved measuring the binding of atropine to the guinea 
pig intestine (Paton and Rang, 1965; Rang, 1967) and subcellular fractions of the rat brain (Farrow 
and O'Brien, 1973). 
A number of studies have demonstrated the presence of high affinity binding sites for radiolabelled 
muscarinic antagonists in subcellular fractions from brain and smooth muscle and in intact tissues. 
A major part of such binding satisfies criteria which suggest that it occurs specifically to muscarinic 
receptors (Hulme et ai., 1978). The specific binding of eH] QNB to homogenates of rat brain has 
many characteristics which might be expected of interactions with muscarinic cholinergic receptors 
in the brain. Displacement of [3H] QNB binding is greatest with muscarinic antagonists and the 
relative affinity of muscarinic cholinergic agonists tend to parallel their pharmacological potency 
(Yamamura and Snyder, 1972). By contrast nicotinic and non-cholinergic drugs have much less 
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affinity for these binding sites. The extremely high affinity in the nanomolar range of the 
muscarinic antagonists for QNB binding sites is quite similar to their molar affinity for muscarinic 
receptors as demonstrated in smooth muscle. Atropine can interact with the specific choline uptake 
system of cholinergic neurons in the brain but only at concentrations several orders of magnitude 
greater than its affinity for QNB binding sites (Yamamura and Snyder, 1972). 
Muscarinic antagonists have negligible affinity for choline acetyltransferase, cholinesterase or 
acetylcholine storage sites. Thus the selectively high affinity of muscarinic anticholinergic drugs 
for muscarinic receptors and for QNB binding sites strongly favours the identity of the binding sUes 
with muscarinic cholinergic receptors in the brain. 
9.1.1 Methods for Receptor Binding 
For many years neuroscientists from many disciplines have been investigating the properties of 
neurotransmitter receptors. In order to do so indirect methods such as observing electrical, 
behavioural and biochemical changes after systematic administration of drugs have been used. 
This type of methodology, while substantiating the existence of receptors for drugs and endogenous 
compounds, cannot reliably reveal the direct interaction between the ligand in question and the 
receptor nor determine the absolute amount of receptors in a tissue. 
The radioreceptor assay is a method that avoids the major problems associated with the indirect 
methods. With the use of a radioactive ligand one can monitor the direct interaction of this 
substance with a receptor. The subsequent biological events are not monitored and cannot interfere 
with the observed receptor-ligand interaction. Thus direct observations of the ligand-receptor 
interaction are possible. Because only the binding of the ligand to the receptor is being monitored, 
the stability of the receptor and the ligand is all that is essential for a successful assay. Intact 
cellular structure and composition are not necessary as long as the receptor retains its native ability 
to interact potently with drugs and neurotransmitters. Tissue preparations, such as homogenization 
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that destroy the integrity of complex biological tissues do not necessarily destroy the binding 
properties of receptors. 
9.1.2 Theory of the Assay 
The equilibrium between the drug and the receptor is based on the dissociation and association 
rates. Experimentally it is extremely difficult to measure association rates directly as high affinity 
drugs have very rapid rates of association. Dissociation rates can be measured by allowing the 
tritiated drug to equilibrate with the receptor and then instituting a procedure that prevents 
reassociation of the radioactive drug onto the receptor after it has dissociated. The easiest and most 
satisfactory method is the addition of a large excess of nonradioactive competing drug to the 
equilibrated tritiated drug-membrane solution. As radioactive drug dissociates from the receptor, 
nonradioactive drug occupies the receptor. The rate of reduction of specific binding over time after 
addition of nonradioactive drugs is directly related to the dissociation rate of the radioactive drug 
from the receptor. 
9.2 
9.2.1 
9.2.1.1 
MUSCARINIC RECEPTOR [3H] QNB BINDING ASSAY 
Materials and Methods 
Chemicals, Drugs and Reagents 
Tritium labelled L-quinuclidinyl [pheny14-3H]-benzilate (eHJ QNB)(specific activity 50 Ci/mmol) 
was purchased from Amersham Corporation, England. Atropine was obtained from Sigma Chemical 
Co. (St Louis, USA). All other drugs and chemicals used were of the purest grade available and 
all solutions were prepared fresh. 
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9.2.1.2 Animals 
Male Wistar rats (220-250g.b.wt) were housed five per cage in a temperature controlled room under 
a fixed lighting cycle ofLD12:12 (lights on 06hOO) with food and water ad libitum [2.3.1.2]. The 
rats were sacrificed between 10h30 and 11h30. This maintained uniformity with previous studies. 
9.2.1.3 Preparation of Tissues 
Brain cerebral cortex tissues were obtained fresh from the male Wi star rats. 1-2g of tissue were 
homogenized in 20 vol ofice-cold Tris Buffer, pH7.4. The homogenates were centrifuged at 20 000 
rpm for 60 minutes at 4°C in a refridgerated centrifuge (HITACHI SCR 20 B). The supernatant was 
discarded and the pellets were resuspended in 20 volumes of ice-cold Tris buffer pH7.4 and then 
rehomogenized to get a smooth suspension. The crude pineal membrane preparations were stored 
at -20°C and used within one week. 
9.2.1.4 Radiogland Binding Assay 
A scheme for the muscarinic receptor CH]QNB binding assay is presented in Table 9.1. All binding 
assays were carried out using sufficient membrane preparations to provide a protein concentration 
of 1mg/ml. The protein concentration of solutions was determined according to the method of 
Lowry et al., (1951) using bovine serum albumin as a standard. A typical protein standard curve 
as well as the scheme of the protein assay may be found in [3.2.1.4]. Radioligand receptor binding 
assays were carried out by the addition of 400pl aliquots of membrane suspension (lmg protein/ml) 
to the glass tubes containing 80pl Tris buffer or appropriate drug atropine (10-5M) in buffer. The 
reactions were started by adding 20pl of the eH]QNB to give a final concentration of 5.0nM. 
Relevant dilutions were made to give eight concentrations of 3H( -) QNB ranging from 0.25nM -
5.0nM. The assays were performed at 25°C for 100 minutes. The binding reactions were terminated 
by filtering the incubation media through Whatman GF-C filter paper under vacuum. 
Table 9.1 Scheme for the fHlQNB binding assay tyamamura and 
Snyder. 1972) 
A. TOTAL BINDING 
[3H] QNB 
Concentration 0.25 0.5 1.0 1.5 2.0 3.0 4.0 
(nM) 
Protein 400 400 400 400 400 400 400 
(Ill) 
Tris buffer 80 80 80 80 80 80 80 
(Ill) 
[3H] QNB 1 2 4 6 8 12 16 
(Ill) 
Tris buffer 19 18 16 14 12 8 4 
(Ill) 
Total Vol (Ill) 500 500 500 500 500 500 500 
B. NON SPECIFIC BINDING 
[3H] QNB 
concentration 0.25 0.5 1.0 1.5 2.0 3.0 4.0 
(nM) 
Protein 400 400 400 400 400 400 400 
(Ill) 
Tris buffer 60 60 60 60 60 60 60 
(Ill) 
[3H] QNB 1 2 4 6 8 12 16 
(Ill) 
Tris buffer 19 18 16 14 12 8 4 
(Ill) 
Atropine 20 20 20 20 20 20 20 
(Ill) 
Total vol (Ill) 500 500 500 500 500 500 500 
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The nonspecific ligand binding was assessed in the presence of the drug. Subsequently each filter 
was washed three times with 3ml ice-cold Tris buffer (pH7.4). Receptor-bound radioactivity which 
was trapped on the filters was counted by liquid scintillation spectrometry in 3ml scintillation 
cocktail Beckman Ready-Solv ™ MP mUltipurpose premixed liquid scintillation solution. The protein 
concentration of the rat brain cerebral cortex was determined according to a procedure developed 
by Lowry et al., (1951) using bovine serum albumin as a standard [3.2.1.4]. 
9.2.1.5 Analysis of Data 
Saturation curves were initially analysed by the method of Scatchard (1949). All experiments were 
replicated a minimum of four times in each individual condition (Figure 9.1). A time course profile 
was also carried out and the results are summarised in Figure 9.2. An example of a Scatchard 
analysis plot of [3H]QNB binding to rat brain membranes may be found in Figure 9.3 and from 
which Kd and Bmax values were determined. 
9.2.2 Results 
The kinetics of 3H(_) QNB binding to rat brain membranes showed that [3H]QNB associated with 
its binding sites slowly at 25°C reaching equilibrium by 60 minutes and remaining constant for 
more than one and a half hours (Figure 9.1). The time course profile of specific 3H( -)QNB binding 
to rat brain membranes is shown in Figure 9.2. The membrane suspension containing 1mg 
protein/ml was incubated at 25°C in the presence or absence of WpM atropine. The reactions were 
started by the addition of 0.85nM 3H( -) QNB and incubated from 0 to 90 minutes at 25°C. The 
reactions were terminated by filtration as described in [9.2.1.4]. 
9.2.2.1 Ligand Saturation Studies 
The binding of 3H(_) QNB ranging from 0.25nM-5.0nM along with WpM atropine to account for 
the nonspecific equilibrium dissociation constant (Kd) and the receptor density (Bmax) was 
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Figure 9.1 Saturation curve of eH]QNB binding to rat brain membranes, which was carried out using 
eight concentrations of eH]QNB, ranging from 0.25-5.0 nM. The plots that have been obtained from four 
determinations represent the specific binding of [3H]QNB, ie the difference between total and non specific 
binding. 
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Figure 9.2 Time course of specific [3H]QNB binding to the rat brain membranes. Membrane suspension 
containing lmg protein/ml were incubated at 25°C in the presence or absence of 1O-5M atropine. The 
reactions were started by the addition of 0.85nM [3H]QNB and incubated from 0 to 90 min at 25°C. The 
reactions were terminated by filtration as described in [9.2.1]. Each point represents the mean of duplicate 
determinations. 
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Figure 9.3 An example of a Scatchard analysis plot of [3H]QNB binding to rat brain membranes, which 
was carried out using eight concentrations of eHJQNB, ranging from 0.25-5.0 nM. Each point represents 
the mean triplicate determinations. 
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detennined. The Kd values for 3H( -) QNB in the saturation studies from four individual experiments 
were 2.33 x 1O-'M whilst Bmax values were 1091.85 finol/mg protein. The saturation curve 
(Figure 9.1) gives an indication of the concentration range we will be working in. The plateau 
indicates the saturation zone where receptor sites are being saturated. 
9.2.3 Discussion 
The eH]-3-quinuclidinyl benzilate (eH] QNB) has been used successfully to isolate muscarinic 
receptor sites in the brain since its initial introduction by Yamamura and Snyder (1974b) as well 
as in the heart (Fields et aI., 1978; Ehlert et aI., 1983; Watson et ai., 1986). Pirenzepine (eH] PZ) 
was also used as a selective muscarinic antagonist and it was with this ligand that the concept of 
muscarinic receptor SUbtypes was first postulated (Hammer et al., 1980; Luthin and Wolfe, 1984). 
These and other studies (Giraldo et al., 1988) revealed the presence of three distinct receptor 
subtypes in human tissues designated Ml, M2 and M3 which have been found in neurons, heart 
and glands respectively. eH] QNB was employed as a simple, sensitive and specific label to 
quantify specific muscarinic cholinergic receptor binding in the rat brain (Yamamura and Snyder, 
1972). 
9.3 Experiment: TO DETERMINE THE EFFECT OF MELATONIN ON 
RAT BRAIN CEREBRAL CORTEX CHOLINERGIC RECEPTOR 
NUMBER AND AFFINITY. 
9.3.1 Introduction 
Quinuclidinyl benzilate is a potent muscarinic antagonist in the central nervous system (Albanus, 
1970; Meyerhoffer, 1972) and peripheral nervous system (Becker, 1964). Govitrapong et ai., 
(1989b) used quinuclidinyl benzilate as a ligand in binding studies when identifying and 
characterizing the muscarinic cholinergic receptors in bovine pineal glands. The purpose of this 
experiment was to investigate the effects of melatonin on rat brain cerebral cortex cholinergic 
receptor number and affinity using eH] QNB as a ligand in receptor binding studies. 
9.3.2 
9.3.2.1 
Materials and Methods 
Materials 
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Acetylcholine chloride was purchased from Sigma Chemical Co., USA. All other drugs and reagents 
used were as described in [9.2.1.1] and all solutions were prepared fresh prior to use. 
9.3.2.2 Animals 
Male Wistar rats weighing between 200-2S0g were treated with melatonin by injecting them 
subcutaneously with melatonin (Smg/kg) daily at IlhOO for 2 weeks. Rats were then sacrificed 14 
days after first treating them and the brains were removed as described in [9.2.1.2]. 
9.3.2.3 eH] QNB Radioligand Binding Assay 
All binding assays were carried out using sufficient brain cerebral cortex membrane preparations 
to provide a protein concentration of Img/m1. The assay procedure was carried out as in [9.2.1.3]. 
Significance was evaluated using Student's t-test. 
9.3.3 Results 
The results of the investigation were obtained from Scatchard plots. The Kd values for eH] QNB 
obtained from four individual experiments were 2.0S7 ± 0.076nM for the melatonin-treated brains 
and 1.10 ± 0.120nM for the controls. The Bmax values for the eH] QNB were 2614 ± 14S.60nM 
for the melatonin-treated brains and 1720 ± 91.65nM for the control as shown in Table 9.2. 
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TABLE 9.2 The effect of melatonin on fHlQNB muscarinic cholinergic 
receptor site affinity as well as receptor site availability for binding 
(mean:!: SEMi Kd and Bmax values obtained from Scatchard plots of 
four individual experiments) 
Treatment Mean Kd (nM) Mean Bmax 
(fmol/mg protein) 
Control 1,10 ± 0,120 1720 ± 91,65 
Melatonin 2,06 ± 0,076 * 2614 ± 145,60 ** 
In comparison with respect to vehicle control p<*O, 0005; ** 0,005 (Student's t-
test) 
9.3.4 Discussion 
In this study Scatchard plots indicate a higher mean Kd value for the brain cerebral cortex from 
melatonin-treated rats in comparison to the controls (p<O.0005) suggesting that melatonin increases 
the affinity of acetylcholine for its receptors. The Bmax values for the melatonin-treated brains also 
rose significantly in comparison to control brains (p<O.005) indicating an increase in receptor 
availability. Hence it may be suggested that melatonin increases acetylcholine receptor availability. 
These results show that melatonin may enhance cholinergic transmission in the brain cerebral 
cortex. There is a possibility that melatonin increases Bmax of available receptors by increasing 
gene expression for receptor production. Bonner et ai., (1987) discovered complementary DNA for 
three different muscarinic cholinergic receptors isolated from a rat cerebral cortex library. Analysis 
of human and rat genomic clones indicate that there are at least four functional muscarinic receptor 
genes and this gene family provides a new basis for evaluating the diversity of muscarinic 
mechanisms in the nervous system (Bonner, 1987). 
CHAPTER 1 
CHAPTER 10 
SUMMARY OF RESULTS 
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Armstrong et al., (1982) suggests that the functioning of the pineal gland must be at a higher level 
of integration since "considering the multitude of biochemical, physiological, endocrinological and 
behaviourial changes attributable to the pineal, it is unlikely to have so many specific functions". 
This suggestion coupled with others, such as the proposals that the pineal gland acts as a 'regulator 
of regulators' (Reiter and Hester, 1966) and that melatonin acts as a 'central inhibitory modulator', 
'neuro-endocrine transducer' or 'biological clock' (Datta and King, 1980) supports this hypothesis 
proposed by Armstrong et al., (1982), that the pineal is a 'synchronizer of regulators' with 
environmental lighting acting as the main zeitgeber (entraining agent or synchronizer). 
The pineal is ideally placed anatomically to collect, integrate and compare information from both 
extracranial sources and intracranial sites. The regulatory function of the pineal gland on the body 
as a whole (including the brain) appears to be by melatonin release (although other pineal secretions 
and peptidase may also be involved). Studies which have examined the pineal indole metabolism 
on adrenergic regulation of melatonin production, N-acetyl transferase activity and cAMP showed 
that noradrenaline affected this biosynthetic pathway and is mainly mediated by B-adrenergic 
receptors. Govitrapong and coworkers (1989b) have recently determined the presence of cholinergic 
receptor sites in the pineal gland although the physiological role of these receptors are not well 
characterized. Literature published on the pineal gland in recent years, as well as a background 
survey of the autonomic nervous system and the role and functioning of the cholinergic system in 
the pineal gland has been reviewed in this chapter. This has been done in order to put into 
perspective the full implications of this investigation into cholinergic interactions as well as in 
determining the role of cholinergic muscarinic receptors in the pineal gland. 
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CHAPTER 2 
The organ culture studies show that carbachol induces a rise in the indole, N-acetylserotonin (aHT) 
without altering melatonin (aMT) levels. Carbachol did not affect the adrenergic system with 
reference to aMT. Acetylcholine, a general agonist of both muscarinic and nicotinic receptors also 
induced a rise in aHT levels without altering aMT levels. The ganglion blocking agent 
hexamethonium did not alter the acetylcholine induced rise in aHT levels suggesting that the aHT 
increase is not induced via the nicotinic receptors. The rise in aHT and not aMT may be speculated 
to occur through the muscarinic receptors. This was further confirmed by using the anti muscarinic 
agent atropine in organ culture studies. Atropine blocked the aHT rise induced by acetylcholine 
implying that the cholinergic system acts on the pineal muscarinic receptor. The anticholinesterase 
drug neostigmine was found not to influence the pineal indoles in any significant manner although 
a related anticholinesterase agent physostigmine caused aHT levels to rise, again without altering 
aMT. Although both drugs are anticholinesterase agents neostigmine possesses a quaternary 
nitrogen which limits its passage into the CNS. Physostigmine on the other hand is lipid soluble, 
possessing a tertiary amine and is hence able to pass through the blood brain barrier and influence 
central cholinergic receptor sites. These results from organ culture studies further confirms the 
presence of muscarinic cholinergic receptors in the pineal gland, suggesting that cholinergic agents 
may play a role in regulating indoleamine synthesis in the pineal gland. 
CHAPTER 3 
Cyclic-AMP studies revealed that the presence of acetylcholine caused a significant increase in 
cAMP levels (p<O.OOOl) in the pineal gland and did not alter the isoproterenol-induced rise in 
cAMP levels in the gland (p<O.OOOl). Hence, the cholinomimetic agent acetylcholine influences 
the sympathetic pathway in a significant manner with regard to cAMP. 
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CHAPTER 4 
The cAMP-phosphodiesterase studies showed that physostigmine, an anticholinesterase agent, causes 
a significant increase in cAMP-phosphodiesterase enzyme activity (p<O.05). The cAMP-
phosphodiesterase activity increased in the presence of an anticholinesterase agent with a 
simultaneous rise in cAMP levels. 
CHAPTER 5 
The NAT enzyme assay studies showed that physostigmine does not alter basal NAT enzyme 
activity significantly suggesting that the cholinergic activated increase in aHT did not occur due to 
the stimulation of the enzyme NAT. 
CHAPTER 6 
The HIOMT enzyme assay studies revealed that physostigmine did not cause a significant change 
in basal HIOMT activity. Physostigmine thus does not inhibit the enzyme HIOMT to reduce the 
conversion of N-acetylserotonin to melatonin. The mechanism by which the cholinergic agonist 
acetylcholine and anticholinesterase agent physostigmine are able to increase aHT levels and not 
aMT levels still remains to be elucidated. The reasons for acetylcholine inducing a rise in pineal 
cAMP without inducing a rise in pineal NAT activiiy remains unclear bUl could however be related 
to a recent finding that raised intracellular calcium levels reduce or inhibit pineal NAT activity. 
Acetylcholine is known to trigger the inositol phosphate signalling pathway system in the pineal 
reSUlting in a elevation of diacylglycerol (DAG) as well as intracellular calcium. 
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CHAPTER 7 
Acetylcholinesterase enzyme studies reveal that the enzyme acetylcholinesterase undergoes a diurnal 
rhythm with a higher activity during the day and lower at night. The possiblity of this rhythm 
being under the control of sympathetic nervous system was refuted using the catecholamine 
depleting agent reserpine. Reserpine did not alter the diurnal rhythm of the acetylcholinesterase 
enzyme activity. Whether the acetylcholinesterase enzyme is present in the pineal to regulate the 
levels of acetylcholine interacting with the muscarinic receptors in the gland also remains to be 
elucidated. 
CHAPTER 8 
Choline acetyltransferase enzyme activity was detected in rat brain tissue but not in the rat pineal 
gland. Melatonin was found to increase CIlA T. enzyme activity in the brain cerebral cortex 
suggesting that it somehow enhances cholinergic activity there. A series of kinetic studies were 
carried out in brain tissue using melatonin. 
CHAPTER 9 
The muscarinic binding studies using [3H]QNB were carried out on rat brain cerebral cortex and 
a saturation curve as well as a time trial were carried out. Scatchard plots produced the required 
Kd and Bmax values. The Kd results indicated that melatonin causes an increase in affinity of 
acetylcholine for its receptors whilst Bmax results suggest melatonin causes an increase in 
cholinergic receptor number in the brain. Melatonin may thus be speculated to enhance cholinergic 
receptor affinity and receptor number in the brain cerebral cortex of rats. 
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CHAPTER 11 
CONCLUSION 
The existence of muscarinic cholinergic receptors sites in the pineal gland have been identified and 
characterized. Stimulation of these muscarinic cholinergic receptor sites, using a 
parasympathomimetic agent carbachol, caused a rise in aHT levels leaving aMT levels unaltered. 
Further, organ culture studies using cholinergic agonists, ganglion blocking drugs, anti-muscarinic 
and anticholinesterase agents confirmed the presence of a cholinergic innervation in the pineal. The 
rise in aHT induced by acetylcholine and physostigmine was investigated and the results from 
studies using these two cholinergic agents show that pineal cAMP as well as cAMP-PDE levels rose 
without a concommitant increase in NAT. The reason for this is unclear, but it could be related to 
intracellular calcium levels causing a reduction or inhibition of pineal NAT activity. The rise in 
aHT was found however, not to be due to a reduction in the conversion of aHT to aMT by 
inhibiting the enzyme HIOMT. The mechanism by which aHT increases and not aMT still remains 
to be elucidated. Possible avenues which need to be investigated in order to shed more light on 
this mechanism are: 
(i) 
(ii) 
(iii) 
The intracellular secondary messenger diacylglycerol, which appears transiently and 
then disappears within seconds due to its conversion back to the inositol 
phospholipid and its degradation to arachidonic acid which in tum can generate 
other messengers. 
the phosphoinositides which participate in the inositol lipid signalling pathway. 
the secondary messenger cGMP which is regulated in a similar manner to cAMP. 
(iv) 
(v) 
(vi) 
(vii) 
(viii) 
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the possibility of muscarinic receptor gene activation which could cause the 
appearance of the phosphoinositidc signalling pathway and result in levels of aHT 
rising. 
the role of prostaglandins in the stimulation of NAT. 
stress and the release of catecholamines from synaptic nerve endings and adrenal 
medulla which could influence the rise of NAT and cause aHT levels to rise. 
the possibility of non cholinergic agents influencing NAT activity. 
the role that intracellular calcium levels play in reducing or inhibiting NAT 
activity. Acetylcholine is known to trigger the inositol phosphate signalling 
pathway system in the pineal which results in a elevation of diacylglycerol as well 
as intracellular calcium and could playa role in causing a rise in aHT levels. 
Acetylcholinesterase, the enzyme which inactivates the neurotransmitter acetylcholine by breaking 
it down to choline and acetate, undergoes a diurnal rhythm in the pineal gland. The activity of this 
enzyme is higher during the day and lower at night. This diurnal rhythm is not under the control 
of the sympathetic nervous system. Further work needs to be done in determining whether the 
acetylcholinesterase enzyme is present in the pineal to regulatc levcls of acetylcholine intcracting 
with muscarinic receptors or not. 
The enzyme cholinc acetyltransferasc catalyses the synthcsis of thc ncurotransmitter acetylcholine 
from acetyl CoA and choline. This enzyme was not mcasured in thc pineal gland although activity 
was detected in brain cerebral cortex tissuc. Melatonin was found to incrcasc ChAT activity in brain 
cerebral cortex suggesting that it somehow enhances cholincrgic activity in this tissue. Muscarinic 
receptor binding studies were carried out on brain cerebral cortcx tissue of rats and the results show 
that melatonin enhances receptor affinity and numbers therc. 
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Pineal research is a dynamic and exciting field of study in the neurosciences as new discoveries 
shed more and more light on this unique gland. In investigating the role of cholinergic muscarinic 
receptors as well as cholinergic interactions in the pineal gland more facts have been added to the 
pool of existing information on this gland. This is just the tip of the iceberg however, and more 
avenues of research need to be pursued in order to fully understand the full functioning and 
mechanism of the cholinergic system as well as the role that these muscarinic receptors play in the 
pineal gland. 
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